Cochrane Library

Cochrane Database of Systematic Reviews

Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction (Review)

O'Byrne L, Webster KE, MacKeith S, Philpott C, Hopkins C, Burton MJ

O'Byrne L, Webster KE, MacKeith S, Philpott C, Hopkins C, Burton MJ.
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
Cochrane Database of Systematic Reviews 2022, Issue 9. Art. No.: CD013876.
DOI: 10.1002/14651858.CD013876.pub3.

www.cochranelibrary.com

WILEY

TABLE OF CONTENTS

[Intervention Review]

Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction

Lisa O'Byrne[1], Katie E Webster[2], Samuel MacKeith[3], Carl Philpott[4], Claire Hopkins[5], Martin J Burton[6]

[1]Department of Otolaryngology Head and Neck Surgery, St Vincent's University Hospital, Dublin 4, Ireland. [2]Cochrane ENT, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. [3]Oxford University Hospitals NHS Foundation Trust, Oxford, UK. [4]Department of Medicine, Norwich Medical School, University of East Anglia, Norwich, UK. [5]ENT Department, Guy's Hospital, London, UK. [6]Cochrane UK, Oxford, UK

Contact: Katie E Webster, katie.webster@nds.ox.ac.uk.

Editorial group: Cochrane ENT Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 9, 2022.

Citation: O'Byrne L, Webster KE, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction. *Cochrane Database of Systematic Reviews* 2022, Issue 9. Art. No.: CD013876. DOI: 10.1002/14651858.CD013876.pub3.

ABSTRACT

Background

Olfactory dysfunction is a common consequence of COVID-19 infection and persistent symptoms can have a profound impact on quality of life. At present there is little guidance on how best to treat this condition. A variety of interventions have been suggested to promote recovery, including medication and olfactory training. However, it is uncertain whether any intervention is of benefit. This is an update of the 2021 review with one additional study added.

Objectives

1) To evaluate the benefits and harms of any intervention versus no treatment for people with persisting olfactory dysfunction due to COVID-19 infection.

2) To keep the evidence up-to-date, using a living systematic review approach.

Search methods

The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the latest search was 20 October 2021.

Selection criteria

We included randomised controlled trials (RCTs) in people with COVID-19 related olfactory disturbance that had persisted for at least four weeks. We included any intervention compared to no treatment or placebo.

Data collection and analysis

We used standard Cochrane methods. Our primary outcomes were the recovery of sense of smell, disease-related quality of life and serious adverse effects. Secondary outcomes were the change in sense of smell, general quality of life, prevalence of parosmia and other adverse effects (including nosebleeds/bloody discharge). We used GRADE to assess the certainty of the evidence for each outcome.

Main results

We included two studies with 30 participants. The studies evaluated the following interventions: systemic corticosteroids plus intranasal corticosteroid/mucolytic/decongestant and palmitoylethanolamide plus luteolin.

Systemic corticosteroids plus intranasal corticosteroid/mucolytic/decongestant compared to no intervention

We included a single RCT with 18 participants who had anosmia for at least 30 days following COVID-19 infection. Participants received a 15-day course of oral corticosteroids combined with nasal irrigation (consisting of an intranasal corticosteroid/mucolytic/decongestant solution) or no intervention. Psychophysical testing was used to assess olfactory function at 40 days. This is a single, small study and for all outcomes the certainty of evidence was very low. We are unable to draw meaningful conclusions from the numerical results.

Palmitoylethanolamide plus luteolin compared to no intervention

We included a single RCT with 12 participants who had anosmia or hyposmia for at least 90 days following COVID-19 infection. Participants received a 30-day course of palmitoylethanolamide and luteolin or no intervention. Psychophysical testing was used to assess olfactory function at 30 days. This is a single, small study and for all outcomes the certainty of evidence was very low. We are unable to draw meaningful conclusions from the numerical results.

Authors' conclusions

There is very limited evidence available on the efficacy and harms of treatments for persistent olfactory dysfunction following COVID-19 infection. However, we have identified a number of ongoing trials in this area. As this is a living systematic review we will update the data regularly, as new results become available.

PLAIN LANGUAGE SUMMARY

Interventions for the treatment of persistent smell disorders (olfactory dysfunction) after COVID-19 infection

Why this is important

The sense of smell is critical to one's enjoyment of odours and tastes, and is important for safety. During the COVID-19 pandemic there has been an increasing focus on change in sense of smell as one of the early symptoms associated with infection. This can be a reduction, change or complete loss of the sense of smell. For most people this is temporary, however for some this lasts weeks or even months. If a person has lost their sense of smell for a long time (over four weeks after having COVID-19), we do not know if there are any treatments that might help it to recover.

How we identified and assessed the evidence

We searched the medical literature, identifying relevant studies and summarising the results. We assessed the quality of the studies as well as the certainty of the evidence. Factors influencing this included the size of the studies, the methods used to perform them and how results were reported by researchers. Based on this, we classed the evidence as being of very low, low, moderate or high certainty.

What we found

We found two small studies to include in the review, including a total of 30 people. All participants had problems with their sense of smell that had lasted for at least four weeks, and started after a COVID-19 infection. Problems with the sense of smell were identified using special smell identification tests carried out by the research team. The patients were randomly divided into two groups: those who would receive treatment and those who would not.

The treatment in one study was a course of corticosteroid tablets ('systemic') and nasal irrigation (with a wash consisting of a mix of corticosteroids, decongestant and an agent that breaks down mucus). The second study used a course of a supplement known as palmitoylethanolamide and luteolin.

Systemic corticosteroids and nasal irrigation (intranasal corticosteroids/decongestant/mucolytic) compared to no treatment

We do not know whether corticosteroid tablets with nasal irrigation is better or worse than no treatment at:

- restoring the sense of smell back to normal after 40 days;
- changing the sense of smell after 40 days;
- causing any unwanted side effects.

This is because the evidence that we found was of very low certainty, mainly due to the fact that only one study was identified and it included a small number of patients.

Palmitoylethanolamide and luteolin compared to no treatment

We do not know whether palmitoylethanolamide and luteolin is better or worse than no treatment at:

- restoring the sense of smell back to normal after 30 days;
- changing the sense of smell after 30 days;
- causing any unwanted side effects.

This is because the evidence that we found was of very low certainty, mainly due to the fact that only one study was identified and it included a small number of patients.

We did find a number of other studies that are being carried out, but no results from these studies are yet available to be included in this review.

What this means

It is unclear whether using corticosteroids with nasal irrigation, or using a palmitoylethanolamide and luteolin supplement, might treat problems with the sense of smell after COVID-19, or whether these treatments can potentially cause harm.

Other treatments are under investigation. This review is a 'living systematic review', meaning that we will keep checking for new studies that might be relevant, and the review will be continually updated when any extra results are available.

How up-to-date is this review?

The evidence in this Cochrane Review is current to October 2021.

Summary of findings 1. Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant compared to no intervention for persistent post-COVID-19 olfactory dysfunction

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant compared to no intervention for persistent post-COVID-19 olfactory dysfunction

Patient or population: adults with olfactory dysfunction for ≥ 4 weeks following COVID-19 infection
Setting: 2 hospitals in Italy
Intervention: systemic corticosteroids plus intranasal steroid/mucolytic/decongestant
Comparison: no intervention

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	№ of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with no intervention	Risk with systemic corticosteroids plus intranasal steroid/mucolytic/decongestant				
Psychophysical testing for recovery of sense of smell Assessed with: CCCRC test score (range 0 to 100, normal olfactory function classed as a score of 90 or 100) Follow-up: 1 to 3 months	Study event rate^ 0/9	5/9	RR 11.00 (0.70 to 173.66)	18 (1 RCT)	⊕⊖⊖⊖ **very low**[1,2]	—
Disease-related quality of life	No studies reported on this outcome.					
Serious adverse events Follow-up: 1 to 3 months	Study event rate^ No events were reported for either group.		Not estimable	18 (1 RCT)	⊕⊖⊖⊖ **very low**[1,3]	—
Psychophysical testing for change in sense of smell Assessed with: CCCRC psychophysical testing (range 0 to 100) Follow-up: 1 to 3 months	This study reported a median improvement in CCCRC score of +60 (IQR 40) in the group receiving systemic steroids and nasal irrigation compared to a median improvement of +30 (IQR 25) in the control group (P = 0.024).		Not estimable	18 (1 RCT)	⊕⊖⊖⊖ **very low**[1,4]	—

Generic quality of life	No studies reported on this outcome.				
Presence of parosmia	No studies reported on this outcome.				
Other adverse outcomes Follow-up: 1 to 3 months	Study event rate^ No events were reported for either group.	Not estimable	18 (1 RCT)	⊕⊖⊖⊖ **very low**[1,3]	—

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).
^We present the study event rate as there were no events in the comparator group for this study.
CCCRC: Connecticut Chemosensory Clinical Research Center; **CI:** confidence interval; **IQR:** interquartile range; **RCT:** randomised controlled trial; **RR:** risk ratio

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

[1]Serious risk of performance bias due to a lack of blinding to treatment allocation.
[2]Very serious imprecision as the sample size does not reach the optimal information size (considered to be 400 participants) and the 95% CI is consistent with the possibility of important benefit or harm.
[3]Very serious imprecision as the sample size does not reach the optimal information size (considered to be 400 participants) and no estimate of effect could be determined, due to the lack of events in either group.
[4]Very serious imprecision as the sample size does not reach the optimal information size (considered to be 400 participants) and no estimate of effect could be determined (data presented as median and IQR).

Summary of findings 2. Palmitoylethanolamide and luteolin compared to no intervention for the treatment of persistent post-COVID-19 olfactory dysfunction

Palmitoylethanolamide and luteolin compared to no intervention for the treatment of persistent post-COVID-19 olfactory dysfunction

Patient or population: adults with olfactory dysfunction for ≥ 4 weeks following COVID-19 infection
Setting: single hospital in Italy
Intervention: palmitoylethanolamide and luteolin
Comparison: no intervention

Outcomes	Anticipated absolute effects* (95% CI)	Relative effect (95% CI)	№ of participants (studies)	Certainty of the evidence (GRADE)	Comments

	Risk with no intervention	Risk with palmitoylethanolamid and luteolin				
Recovery of sense of smell (as assessed with psychophysical testing) Assessed with: Sniffin' Sticks, score of ≥ 31 (range 0 to 48) Follow-up: 1 to 3 months	Study population 600 per 1000	144 per 1000 (18 to 1000)	RR 0.24 (0.03 to 1.67)	12 (1 RCT)	⊕⊖⊖⊖ **very low**[1,2]	There was considerable baseline imbalance in this study, with participants in the intervention group having worse scores at the start of the study than those in the control group.
Disease-related quality of life	No studies reported on this outcome.					
Serious adverse events Follow-up: 1 to 3 months	No events were reported for either group.		Not estimable	12 (1 RCT)	⊕⊖⊖⊖ **very low**[1,3]	
Change in sense of smell (as assessed with psychophysical testing) at 1 to 3 months Assessed with: Sniffin' Sticks, change from baseline (range 0 to 48) Follow-up: 1 to 3 months	The mean change in sense of smell (as assessed with psychophysical testing) at 1 to 3 months was 2.3 points.	MD 2.2 higher (4.4 lower to 8.8 higher)	—	12 (1 RCT)	⊕⊖⊖⊖ **very low**[1,4]	The minimally important difference on the Sniffin' Sticks score is considered to be a change of 5.5 points (Gudziol 2006).
Generic quality of life	No studies reported on this outcome.					
Presence of parosmia	No studies reported on this outcome.					
Other adverse outcomes Follow-up: 1 to 3 months	No events were reported for either group.		Not estimable	12 (1 RCT)	⊕⊖⊖⊖ **very low**[1,3]	

*__The risk in the intervention group__ (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **MD:** mean difference; **RCT:** randomised controlled trial; **RR:** risk ratio

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

---

[1]Serious risk of performance bias due to lack of blinding. Additional risk of bias due to baseline imbalance in the study.
[2]Sample size fails to meet optimal information size (taken as 400 participants, as a rule of thumb), and 95% confidence interval is consistent with both a potential benefit and potential harm of the intervention.
[3]Very serious imprecision as the sample size does not reach the optimal information size (considered to be 400 participants) and no estimate of effect could be determined, due to the lack of events in either group.
[4]Sample size fails to meet optimal information size (taken as 400 participants, as a rule of thumb) and 95% confidence interval is consistent with a potentially beneficial effect (exceeding the minimally important difference of 5.5 points) or a trivial difference.

BACKGROUND

Description of the condition

Loss of olfactory function (the sense of smell) emerged as a marker of COVID-19 infection in March 2020 (Hopkins 2020a). Since that time, it has become established that this is a cardinal symptom of COVID-19 infection (Menni 2020), with a high predictive value (Gerkin 2020). This usually takes the form of complete or partial loss of olfactory function (anosmia and hyposmia respectively) (Lechien 2020).

Olfactory dysfunction, through loss (quantitative changes) or distortion (qualitative changes) of smell, is a debilitating condition with a variety of causes and has a major impact on quality of life (Croy 2014; Erskine 2020; Philpott 2014). It also has safety implications, through the inability to detect odours that may signal danger (such as smoke, gas or spoilt food). Through its intimate relationship with the sense of taste, the disturbance of olfactory function can also hamper the ability to enjoy food.

Post-infectious olfactory dysfunction (PIOD) is one of the most common causes of olfactory dysfunction, representing up to 20% of all cases in specialist olfactory clinics (Cain 1988; Damm 2004; Seiden 2001). Many viruses have been implicated in PIOD, including the coronavirus family. However, the prominence of SARS-CoV-2 (which causes COVID-19) as a causative agent has been notable, and can perhaps be attributed to the spotlight created by it being the cause of a pandemic.

Accurate estimates of the prevalence of olfactory dysfunction resulting from COVID-19 are difficult to obtain, and may vary according to the clinical presentation of the disease (which ranges from mild, or relatively asymptomatic, to serious complications requiring intensive care). A recent systematic review identified an overall prevalence of smell loss of 43%, however the authors noted high variation between the estimates from different studies (von Bartheld 2020). Another systematic review showed a prevalence of 62% across the range of studies included (Rocke 2020). A large European cohort, which included hospitalised individuals with mild-moderate symptoms, as well as individuals who did not require hospital treatment, reported the prevalence of olfactory dysfunction to be 85.6% (Lechien 2020). The majority of individuals included in this study reported anosmia, with a minority reporting hyposmia (20.4%).

The incidence of anosmia or olfactory dysfunction related to COVID-19 appears to vary across the world, with studies from the USA and Europe typically demonstrating much higher incidence than those from Asia (Meng 2020; von Bartheld 2020). A study from Wuhan, China, reported abnormalities of olfactory function in only 5.1% of their cohort (214 patients, with both severe and mild forms of the disease) (Mao 2020). It is not clear why this may be. Gender and age have also been suggested as possible effect modifiers, with some reviews suggesting preponderance in females (Meng 2020), and others suggesting an increased incidence in younger age groups (Fuccillo 2020).

The incidence of olfactory dysfunction may also vary depending on the method used to diagnose it. Studies that used self-reported symptoms of loss of smell identified a lower prevalence than those that utilised some form of objective assessment (von Bartheld 2020). It is well recognised that, for healthy individuals, self-rating of the sense of smell may correlate poorly with scores achieved on psychophysical testing (Landis 2003; Lötsch 2019). Correlation is better for those who report olfactory dysfunction (particularly anosmia), but on an individual level there is still considerable variation between the severity of the reported loss, and that identified with psychophysical tests (Welge-Luessen 2005). With larger numbers reporting COVID-19 symptoms in general, the data collected by the COVID tracker app is more likely to reflect the prevalence of olfactory dysfunction in the non-hospitalised population (Menni 2020).

A further complication in obtaining accurate estimates of prevalence is the variety of data sources that are available. Studies conducted in a hospitalised population may present very different estimates to those where data are gathered from internet-based surveys. This may reflect genuine differences in the presence of olfactory dysfunction in these varied populations, different methods of ascertaining olfactory function, or potentially a different preponderance to report symptoms. Internet-based surveys may have a greater propensity for responder bias than other cross-sectional studies - those who have symptoms may be more likely to participate or complete the required data, resulting in inflated estimates of prevalence. However, some prospective series have also identified a high prevalence of olfactory dysfunction (Spinato 2020).

Other symptoms of olfactory dysfunction include phantosmia (qualitative dysfunction in the absence of an odour, or 'olfactory hallucinations') and parosmia (distorted perception of an odour stimulus) (Hummel 2016). A recent survey of individuals with COVID-19 indicated that these symptoms occurred in fewer than 10% in the short term (Parma 2020). However, longer-term follow-up may demonstrate further problems at a later stage, and reports of persisting parosmia as a consequence of COVID-19 are increasing (Hopkins 2020b).

The exact mechanism by which the SARS-CoV-2 virus triggers olfactory dysfunction remains unclear (reviewed in Butowt 2020). Many viruses cause conductive olfactory impairment, with inflammation, nasal congestion and rhinorrhoea preventing detection of odours during the acute phase of the infection. These symptoms are not as common in COVID-19 and, when present, do not correlate well with the degree of olfactory dysfunction (Parma 2020). Symptoms may also be caused by direct damage to, or death of, olfactory neurons or cells within the olfactory bulb. However, olfactory neurons lack ACE2 receptors (which facilitate viral entry to cells) and the rapid recovery for most individuals with COVID-19 related smell loss makes this less likely. Infection of supporting cells (sustentacular cells) within the olfactory epithelium has been reported (reviewed in Bilinska 2020). These cells play a critical role in supporting the function of olfactory neurons, and their infection may consequently have an adverse effect on olfactory processing.

For many individuals with COVID-19 related olfactory dysfunction, the condition is temporary, and they recover a normal sense of smell relatively quickly (Chary 2020; Klopfenstein 2020). Complete recovery by two weeks was reported for most people (96.7%) in the study by Lechien 2020. A second case series of individuals with mild coronavirus symptoms found that 89% had complete or partial recovery of olfactory function by four weeks from the onset of the disease (Boscolo-Rizzo 2020). However, for some individuals the problem persists. Some studies report a much higher prevalence of persisting olfactory loss, despite resolution

of other COVID-19 symptoms. Data from the Global Consortium of Chemosensory Research indicates that up to 50.7% of individuals may have persisting olfactory dysfunction at up to 40 days from the onset of COVID-19 (Gerkin 2020). It remains unclear why some individuals experience longer lasting olfactory deficits. This may be due to differing extents of damage (as suggested by Butowt 2020), or different mechanisms for olfactory loss (Hopkins 2020c; Saussez 2020). Differing features of COVID-19 related smell loss may include a potential impact on true gustatory function, as well as a greater severity of olfactory loss itself (Huart 2020); many larger studies are limited by the reliance on self-reporting, so this is more difficult to corroborate.

This review is one of a pair that consider the effects of interventions to prevent or treat persisting olfactory dysfunction following COVID-19. For this review, we considered treatment for individuals who already have persisting olfactory dysfunction at four weeks (or longer) following a diagnosis of COVID-19. For the companion review ('Interventions for the prevention of persisting olfactory dysfunction following COVID-19'; Webster 2022), we considered interventions that may be used in the acute phase (less than four weeks since diagnosis), aiming to prevent individuals from developing persisting olfactory dysfunction.

Description of the intervention

As COVID-19 related persistent olfactory dysfunction is a relatively new condition, there are no established treatments for it. However, a number of interventions have been used for other post-viral causes of anosmia. Corticosteroids are commonly prescribed for olfactory dysfunction - these are typically administered locally as a nasal spray, drops or rinse for conductive causes of olfactory loss - where the nasal cavity is blocked, or partially blocked, by inflammation and oedema. Systemic (oral) corticosteroids may also be used, particularly in cases where no conductive cause is identified.

Olfactory training is also frequently suggested for reduced or absent sense of smell - this involves regular exposure to a number of specific odours. It can be performed in a variety of different ways, using household items or essential oils.

A large number of other interventions have been used for PIOD, and may therefore be of use for post-COVID-19 olfactory dysfunction. A variety of vitamins, minerals and nutritional supplements have been proposed to be of benefit - either taken as an oral supplement or, in some instances, used intranasally (such as intranasal vitamin A drops). Glutamate antagonists and xanthine derivatives are used occasionally in the treatment of post-viral olfactory dysfunction and may therefore be assessed in relation to COVID-19. Trials of acupuncture have also taken place.

Olfactory dysfunction has a considerable impact on quality of life and may be a long-lasting or even permanent condition. Psychological therapies, such as counselling or cognitive behavioural therapy, may therefore help to develop coping mechanisms and improve quality of life, even in the absence of objective improvement in the sense of smell.

Clinical trials are ongoing to assess a variety of interventions for the treatment of COVID-19. These include antivirals, such as remdesivir, and monoclonal antibodies. It is possible that these interventions may also benefit individuals with olfactory dysfunction, if these symptoms are assessed.

For many individuals, smell loss is anticipated to improve with time. There is no intervention that could currently be regarded as standard care for individuals with post-COVID-19 related anosmia. Interventions are therefore likely to be compared to no treatment, or to placebo (dummy) treatment. However, olfactory training is often suggested as an intervention with few, if any, adverse effects, and may be used alongside other treatments, therefore we anticipated that this may be advised to be undertaken concurrently in some studies.

How the intervention might work

Corticosteroids are frequently prescribed to ensure that any intranasal inflammatory component that is exacerbating the PIOD is adequately treated. Whether they have a persisting effect after discontinuation is unclear. Intranasal corticosteroids are used for a number of other conditions, and serious side effects are rare, but they may cause nasal irritation, nosebleeds or other localised complications. Corticosteroids may also be administered systemically - typically as oral tablets, or sometimes parenterally.

Olfactory training aims to stimulate the olfactory neurons with a variety of odours in order to enhance smell detection. It is unclear whether any changes occur within the olfactory epithelium itself, in the olfactory bulb, or involve reorganisation of neural olfactory pathways. Although olfactory training may not restore olfactory function, it may improve the performance of the olfactory system. Two recent reviews suggest that olfactory training may give some benefit to those with olfactory disorders (Pekala 2016; Sorokowska 2017). However, the majority of included studies were prospective cohorts, with only one RCT included.

A number of vitamins and minerals have been suggested to have a beneficial effect on the olfactory epithelium, including vitamins A, B12 and D, and zinc. It is thought that metabolites of vitamin A may play a role in regeneration of tissue in the olfactory epithelium or olfactory bulb, and this has been used intranasally to treat individuals with post-viral olfactory loss (Hummel 2017). Vitamin B12 is known to be important in the maintenance of central and peripheral nervous function, and deficiency of vitamin B12 has been associated with olfactory impairment (Derin 2016). Vitamin D deficiency has also been linked to olfactory impairment (Bigman 2020), and there is ongoing interest in the potential use of vitamin D to prevent or treat other symptoms of COVID-19 infection (Martineau 2020). Zinc deficiency has also been shown to have an association with olfactory dysfunction and zinc was historically used intranasally as a potential treatment for anosmia, although there are concerns over toxicity (Alexander 2006).

Antioxidants, such as alpha lipoic acid and omega 3 fatty acids, have also been suggested as possible interventions to treat anosmia (Hummel 2002). They are thought to have neuroprotective properties that may help restore function within olfactory neurons or the olfactory bulb. Palmitoylethanolamide (PEA) is a fatty acid that is also proposed to have neuroprotective and anti-inflammatory properties. Minocycline has also been trialled in post-viral olfactory loss - due to its neuroprotective properties, rather than its traditional role as an antibiotic (Reden 2011).

The impact of olfactory dysfunction on quality of life is substantial. Adjusting to, and learning to cope with, this life-changing symptom may be helped through psychological therapies, counselling or cognitive behavioural therapy.

It is possible that antiviral agents, some of which have already been shown to impact on the severity of COVID-19, may also affect the olfactory dysfunction. Reducing viral replication (and consequently lowering the viral load in an individual) may result in reduced severity of olfactory loss, or hasten the recovery. Monoclonal antibodies have also been used to treat COVID-19, and could also have an impact on the severity and persistence of olfactory impairment.

There have also been small studies to assess the possible benefit of acupuncture in olfactory loss (Dai 2016; Vent 2010).

Glutamate plays an important role in neurotransmission for olfactory neurons and within the olfactory bulb. Glutamate antagonists, such as caroverine, have been proposed to help protect against neurotoxicity, and consequently improve olfactory function (Quint 2002). Finally, xanthine derivatives such as theophylline and pentoxifylline have been proposed to stimulate olfactory neuron activity, and may therefore have an effect on olfactory function.

It is possible that individuals with a longer duration of anosmia have a different underlying disease process than those with temporary olfactory dysfunction related to COVID-19. Consequently, the efficacy of different interventions may vary between these groups.

Why it is important to do this review

The COVID-19 pandemic has resulted in an enormous number of individuals becoming infected with SARS-CoV-2. Fortunately, many individuals recover completely. However, the long-term consequences of infection are only just becoming apparent. Although the prevalence of persisting olfactory dysfunction may be small, with huge numbers of global infections the actual number of individuals suffering from post-COVID-19 related persistent anosmia is large. We can assume an estimated 60% suffer olfactory dysfunction at the onset of the infection and that at least 10% of these go on to experience PIOD. Of all those infected, 5% to 7% have been found to be functionally anosmic 12 months after exposure (Boscolo-Rizzo 2021; Vaira 2021b). Given the number of infections (> 295 million infections worldwide, as of December 2021), we estimate that nearly 15 million people may have persistent anosmia, while many others will not have fully recovered. The burden of this disorder is also considerable, with significant effects on quality of life, as well as safety implications (due to the inability to detect harmful or dangerous smells). Therefore, identification of potential treatments that may improve the outcome for sufferers is timely and important.

Many interventions carry a risk of adverse effects. If the beneficial effect of treatment is small or negligible, then side effects may be such that individuals do not consider treatments worthwhile. With this review we aimed to comprehensively assess the benefits and harms of interventions to treat post-COVID-19 related olfactory dysfunction, to ensure that patients can make an informed choice regarding the management of their condition.

Given the recent emergence of COVID-19, there is currently a great deal of uncertainty about how best to manage the olfactory dysfunction that occurs as a result of the virus. The sheer number of infected individuals worldwide also means that evidence that supports decision-making for the management of COVID-19 is a priority for decision-makers globally. There is also a strong emphasis on COVID-19 research at present, and we anticipate that there is likely to be new evidence available over the coming months and years. Therefore, this review will be a living systematic review, which will be continually updated to incorporate any important new evidence as it becomes available.

OBJECTIVES

To assess the effects (benefits and harms) of interventions to treat persisting olfactory dysfunction due to COVID-19 infection.

A secondary objective is to keep the evidence up-to-date, using a living systematic review approach.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials (RCTs) and quasi-randomised trials (where trials were designed as RCTs, but the sequence generation for allocation of treatment used methods such as alternative allocation, birth dates, alphabetical order etc.).

We considered that olfactory dysfunction is unlikely to be stable over long periods of time, and individuals may experience considerable fluctuation of symptoms over a given time period. Therefore, cross-over trials are unlikely to be identified in this area. If we do identify any cross-over studies, we will only include data from the first phase of these studies in the review.

We included studies where the main purpose of the trial was to assess the effect of treatment on olfactory function. Many interventions are used in the treatment of COVID-19 (such as corticosteroids, antivirals); these may have beneficial effects on olfactory function, but the primary aim of most trials will be to assess their impact on other features of the disease (such as need for ventilation, mortality etc.). Therefore, we only included studies where olfactory function had been assessed at the trial baseline, and the main aim of the study was to determine the effect of an intervention on olfaction.

We only included studies where patients were followed up for at least one week. The aim of this review is to synthesise evidence for treatments that may have a lasting effect on olfactory function, rather than those that may have a very brief or temporary impact.

We included studies regardless of their publication status or language of publication. We planned to include outcome data reported on a trial registry, even if no published results were available. This was not applicable to any identified study in the current version of this review. If we identify material from a pre-print server then we will initially note this in the 'What's new' section of the review, pending the identification of fully published data. If no published data are identified within four months of the pre-print article being made available then we will incorporate the data in the review.

Types of participants

We included adult participants (aged 18 years or older) with persisting abnormalities of their sense of smell as a consequence of COVID-19. For the purpose of this review, the term 'persisting' refers to olfactory dysfunction being present at four weeks following a diagnosis of COVID-19. We anticipated that some studies will report this as four weeks of olfactory dysfunction, rather than four weeks since a positive test for COVID-19 - either of these measures will be included in the review.

We included individuals with anosmia (absent sense of smell) or hyposmia (reduced sense of smell). We anticipated that some trials may also include a small number of individuals with symptoms of pure parosmia or phantosmia. We included data from these trials, providing the majority of participants (≥ 80%) report anosmia or hyposmia.

We included studies where olfactory dysfunction was identified with either psychophysical (objective) testing, or through self-report of symptoms. We investigated whether this had any impact on the effect estimates using subgroup analysis (see Subgroup analysis and investigation of heterogeneity).

We included studies where COVID-19 had been diagnosed through either objective testing (e.g. viral polymerase chain reaction (PCR) from nasopharyngeal swabs) or through a clinical diagnosis (for example, sudden onset of olfactory dysfunction with other symptoms of COVID-19, or in the context of contact with an infected individual).

For inclusion in this review, all participants in the study must have abnormalities of their sense of smell. We did not include studies where only some participants are eligible (i.e. not all participants had olfactory dysfunction at the start of the trial).

Types of interventions

Interventions

We included any intervention proposed specifically to treat olfactory disturbance. We anticipated that this may include the following interventions:

- Intranasal corticosteroid drops/rinses
- Intranasal corticosteroid sprays
- Systemic corticosteroids
- Olfactory training
- Intranasal vitamin A
- Zinc
- Antioxidants (e.g. omega 3 fatty acids, alpha lipoic acid)
- Counselling
- Antiviral agents (e.g. remdesivir)
- Other antimicrobials (e.g. minocycline)
- Other vitamins and nutritional supplements (to be analysed according to the type of vitamin/supplement, rather than as a pooled comparison)
- Acupuncture
- Monoclonal antibodies
- Glutamate antagonists (e.g. caroverine)
- Xanthine derivatives (e.g. theophylline, pentoxifylline)

If we had identified studies of additional interventions then these would also have been included.

All routes of administration, doses and duration of treatment were included.

We excluded studies that consider surgery, as this is not currently an intervention of interest for post-viral olfactory loss.

We considered olfactory training to be a complex intervention, as the method of delivery varies considerably in different studies. We planned to assess this using subgroup analysis, if we identified any studies of this intervention (see below).

Comparator(s)

The main comparator is:

- placebo or no treatment.

Concurrent treatments

We anticipated that some studies may include olfactory training (or other interventions) as concurrent therapy for both arms. We placed no limits on the type of concurrent treatments used. We planned to pool these studies with those where no concurrent treatment was used and use sensitivity analyses to determine whether the effect estimates are changed because of this.

Types of outcome measures

We analysed the following outcomes in the review, but we did not use them as a basis for including or excluding studies. Where possible, all outcomes were reported at three time points:

- 1 to 3 months (this was the main time point of interest);
- > 3 months to 12 months;
- > 12 months to 3 years.

These time points relate to the time when the treatment was started.

We considered outcomes at less than four weeks following COVID-19 too short to comprehensively assess whether individuals have persisting olfactory problems. However, in the absence of other evidence they may provide some indication about the likely efficacy of treatments to prevent later problems.

As most individuals with temporary problems should have complete resolution of their olfactory symptoms by four weeks (Boscolo-Rizzo 2020), we considered this time frame (> 4 weeks) to be of importance to identify those who truly have persisting problems. However, we recognised that some individuals may experience fluctuations in their symptoms, and develop recurrent olfactory problems at a later stage. We therefore included outcomes that were measured at a later point to identify whether treatment provided sustained recovery.

Primary outcomes

- Recovery of sense of smell:
  - as assessed by the participants;
  - as assessed with psychophysical testing, using Sniffin' Sticks, University of Pennsylvania Smell Identification Test (UPSIT) or another validated test.

- Disease-related quality of life, as assessed by the Olfactory Disorders Questionnaire, or another validated questionnaire (which specifically relates to olfactory dysfunction).
- Serious adverse effects (as defined by the trialists).

It is well recognised that self-rated sense of smell correlates poorly with the results of psychophysical testing of olfactory function. Therefore, we have included both types of outcome measurements separately for the outcome domains that relate to sense of smell. If data had been obtained for both of these measures we would not have combined them, but would have reported them as two separate analyses. However, at present the only included studies include data using psychophysical testing only.

Secondary outcomes

- Change in sense of smell:
  - as assessed by the participants;
  - as assessed by psychophysical testing, using Sniffin' Sticks, UPSIT or another validated test.
- Overall, generic quality of life, as assessed by validated methods (e.g. EQ-5D).
- Presence of parosmia, as reported by the participants.
- Other adverse effects (including nosebleeds/bloody discharge).

We recognise that parosmia is a challenging symptom to define and assess. If we had identified data for this outcome then we would have included any results reported by the study authors, and described the definitions used in the study. However, this outcome was not assessed by the studies included in the review.

Where possible, we planned to compare the threshold for appreciable change in these outcomes to published minimally important differences (MID). These have been reported for psychophysical olfactory testing using Sniffin' Sticks (MID 5.5 points, Gudziol 2006) and the Olfactory Disorders Questionnaire (MID 5.2 points, Mattos 2018).

Search methods for identification of studies

The Cochrane ENT Information Specialist conducted systematic searches for randomised controlled trials and controlled clinical trials. There were no language or publication status restrictions. Some of the search terms were limited by publication year, due to the novel nature of post-COVID-19 olfactory dysfunction. We contacted the original authors for clarification and further data if trial reports were unclear and arranged translations of papers where necessary. The date of the search was 20 October 2021.

Electronic searches

As a living systematic review, the Information Specialist has conducted **monthly** searches of:

- the Cochrane ENT Trials Register (searched via the Cochrane Register of Studies to 20 October 2021);
- the Cochrane Central Register of Controlled Trials (CENTRAL) (searched via the Cochrane Register of Studies to 20 October 2021);
- Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to 20 October 2021);
- Ovid Embase (1974 to 20 October 2021);
- Web of Knowledge, Web of Science (1945 to 20 October 2021);
- ClinicalTrials.gov, www.clinicaltrials.gov (searched via the Cochrane Register of Studies to 20 October 2021);
- World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (searched via the Cochrane Register of Studies to 20 October 2021);
- Cochrane COVID-19 Study Register, https://covid-19.cochrane.org/ (searched via the Cochrane Register to 20 October 2021).

The Information Specialist conducts **quarterly** searches of the following sources, and prior to the publication of any update:

- ClinicalTrials.gov (search via www.clinicaltrials.gov to date);
- World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (search via https://apps.who.int/trialsearch/ to date).

The Information Specialist used appropriate date restrictions and auto-alerts as available and appropriate for each monthly search. Details are available in Appendix 1.

In searches prior to July 2021 we also searched the World Health Organization (WHO) COVID-19 'Global literature on coronavirus disease', https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov to 16 December 2020.

The Information Specialist modelled subject strategies for databases on the search strategy designed for CENTRAL. The strategies were designed to identify all relevant studies for a pair of reviews (O'Byrne 2021; Webster 2022). Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials (as described in the Technical Supplement to Chapter 4 of the *Cochrane Handbook for Systematic Reviews of Interventions* version 6.1) (Lefebvre 2020). In July 2021 the Information Specialist incorporated new MeSH and Emtree terms into the search and in September 2021 corrected typos in the original search. The current search strategies for the major databases are provided in Appendix 2 and the search strategies performed in October 2021 are provided in Appendix 3.

Clinical trials are ongoing to assess a variety of interventions for the treatment of COVID-19. As few studies have currently been published, the search strategy developed is highly sensitive in order to try to capture all interventions as they are introduced. The Information Specialist will review the search methods (the sources and search frequency) and the search terms (index terms and free-text terms) on an annual basis. The search strategy may evolve over time, as a greater body of literature is published and a more focused list of interventions are identified.

Searching other resources

We scanned the reference lists of identified publications for additional trials and contacted trial authors where necessary. In addition, the Information Specialist searched Ovid MEDLINE to retrieve existing systematic reviews relevant to this systematic review, so that we could scan their reference lists for additional trials. The Information Specialist also searched of the Web of Knowledge Science Citation Index for articles referencing the

published review and its companion review (Webster 2022), and the primary references to the included studies of both reviews.

These searches were last conducted on 20 October 2021.

We did not perform a separate search for adverse effects. We considered adverse effects described in included studies only.

We planned to make efforts to identify full-text papers regardless of language of publication and endeavour to seek help with translation; however, we did not encounter this issue. Any papers that we were unable to source in time for the scheduled living review update, or were unable to get translated, would be listed as awaiting assessment. Fortunately, we were able to identify and locate all papers of relevance for this review, and we did not require any translation.

Living systematic review considerations

As a living systematic review, we scanned the reference lists of identified publications for additional trials and contacted trial authors if necessary. In addition, the Information Specialist searched on an **annual** basis Ovid MEDLINE to retrieve existing systematic reviews relevant to this systematic review, so that we could scan their reference lists for additional trials. The Information Specialist conducted **annual** searches of the Web of Knowledge Science Citation Index for articles referencing the published review and its included studies and carried out non-systematic searches of Google Scholar to retrieve grey literature and other sources of potential trials.

For workload and capacity reasons, the monthly searches for this review were temporarily paused following the October 2021 searches and will be restarted later in 2022.

Data collection and analysis

Selection of studies

The Cochrane ENT Information Specialist used the first two components of Cochrane's Screen4Me workflow to help assess the search results. Screen4Me comprises three components:

1. Known assessments – a service that matches records in the search results to records that have already been screened in Cochrane Crowd and been labelled as 'a RCT' or as 'not a RCT'.
2. The machine learning classifier (RCT model) (Wallace 2017), available in the Cochrane Register of Studies (CRS-Web), which assigns a probability of being a true RCT (from 0 to 100) to each citation. For citations that are assigned a probability score below the cut-point at a recall of 99% we will assume these to be non-RCTs. For those that score on or above the cut-point we will either manually dual screen these results or send them to Cochrane Crowd for screening.
3. Cochrane Crowd is Cochrane's citizen science platform where the Crowd help to identify and describe health evidence. For more information about Screen4Me and the evaluations that have been done, please go to the Screen4Me website on the Cochrane Information Specialist's portal and see Marshall 2018, McDonald 2017, Noel-Storr 2018 and Thomas 2017.

We did not use the third component because of the relatively small number of results retrieved by the search.

Two review authors (LOB, KW) independently screened the remaining titles and abstracts retrieved by the search to identify potentially relevant studies. The same authors independently evaluated the full text of each potentially relevant study to determine whether it met the inclusion/exclusion criteria for this review. We resolved any differences by discussion and consensus. We planned to involve a third author where necessary, but this was not required.

Living systematic review considerations

We immediately screened any new citations retrieved by the monthly searches using the approach outlined above.

Data extraction and management

Two review authors (LOB/KW) independently extracted outcome data from each study using a standardised data collection form. Where a study had more than one publication, we retrieved all publications to ensure complete extraction of data. Any discrepancies in the data extracted by the two authors were checked against the original reports, and differences were resolved through discussion and consensus, with recourse to a third author where necessary. If required, we contacted the study authors for clarification.

We collected information on study design and setting, participant characteristics (including disease severity and age), study eligibility criteria, details of the intervention(s) given, the outcomes assessed, the source of study funding and any conflicts of interest stated by the investigators. We also included details of the baseline characteristics of study participants, with particular regard to prognostic features such as age, gender, severity of infection and duration of time since COVID-19 infection.

The primary effect of interest for this review was the effect of treatment assignment (which reflects the outcomes of treatment for people who were assigned to the intervention) rather than a per protocol analysis (the outcomes of treatment only for those who completed the full course of treatment as planned). For the outcomes of interest in this review, we extracted the findings from the studies on an available case basis, i.e. all available data from all participants at each time point, based on the treatment to which they were randomised. This was irrespective of compliance, or whether participants had received the intervention as planned.

In addition to extracting prespecified information about study characteristics and aspects of methodology relevant to risk of bias, we extracted the following summary statistics for each study and outcome:

- For continuous data: the mean values, standard deviation and number of patients for each treatment group at the different time points for outcome measurement. Where endpoint data were not available, we extracted the values for change-from-baseline data instead. If values for the individual treatment groups are not reported, where possible we extracted summary statistics (e.g. mean difference) from the studies.
- For binary data: we extracted information on the number of participants experiencing an event, and the number of participants assessed at that time point. If values for the individual treatment groups were not reported, where possible we extracted summary statistics (e.g. risk ratio) from the studies.

- For ordinal scale data: if we identified data reported on an ordinal scale and if the data appeared to be normally distributed, or if the analysis performed by the investigators indicated that parametric tests were appropriate, then we treated the outcome measure as continuous data. Alternatively, if data were available, we converted these to binary data.
- For time-to-event data: if we identified data reported as time-to-event then, where possible, we extracted data on hazard ratios from individual studies. If these data were not provided then we extracted alternative measures of treatment effect, such as the observed and expected number of events in each group, a P value and the number of events in each arm, or data in a Kaplan Meier curve.

We pre-specified time points of interest for the outcomes in this review. Where studies reported data at multiple time points, we took the longest available follow-up point within each of the specific time frames. For example, if a study reported an outcome at 4 weeks, 8 weeks and 12 weeks of follow-up then we included the 12-week data for the time point 1 to 3 months

Assessment of risk of bias in included studies

Two authors (LOB, KW) undertook assessment of the risk of bias of the included studies independently, with the following taken into consideration, as guided by the *Cochrane Handbook for Systematic Reviews of Interventions* (Handbook 2011):

- sequence generation;
- allocation concealment;
- blinding;
- incomplete outcome data;
- selective outcome reporting; and
- other sources of bias.

We used the Cochrane risk of bias tool in RevMan 5.4 (RevMan 2020), which involved describing each of these domains as reported in the study and then assigning a judgement about the adequacy of each entry: 'low', 'high' or 'unclear' risk of bias. Any discrepancies in judgement between the two authors were resolved through discussion and with recourse to a third author where necessary.

Measures of treatment effect

We summarised the effects of dichotomous outcomes (e.g. recovery of sense of smell) as risk ratios (RR) with 95% confidence intervals (CIs). For the key outcomes that we presented in the summary of findings tables, we also expressed the results as absolute numbers based on the pooled results and compared to the assumed risk. For future iterations of this living review we may also calculate the number needed to treat to benefit (NNTB) using the pooled results. The assumed baseline risk was either (a) the median of the risks of the control groups in the included studies - this being used to represent a 'medium-risk population' or, alternatively, (b) the average risk of the control groups in the included studies - used as the 'study population' (Handbook 2020). As a single study was included for each analysis (no meta-analyses were performed), we used the baseline risk from this study for all calculations. If a large number of studies are available in future (and where appropriate) we may also present additional data based on the assumed baseline risk in (c) a low-risk population and (d) a high-risk population.

For continuous outcomes, we planned to express treatment effects as a mean difference (MD) with standard deviation (SD) or as a standardised mean difference (SMD) where different scales had been used to measure the same outcome. We planned to provide a clinical interpretation of the SMD values using either Cohen's d or by conversion to a recognised scale if possible.

For time-to-event outcomes we planned to summarise the effects as a hazard ratio (HR) with 95% CI. If necessary, and where possible (if sufficient alternative data were provided), we planned to estimate the HR from individual studies according to the methods outlined in Tierney 2007. However, no time-to-event data were identified for the review.

Unit of analysis issues

Cross-over trials and cluster-randomised trials were not anticipated for this review topic and none were identified. Post-COVID-19 related anosmia is unlikely to be a stable condition, and interventions may not have a temporary effect. If cross-over trials were identified then we planned to use only the data from the first phase of the study. If cluster-randomised trials were identified then we would have ensured that analysis methods were used to account for clustering in the data (Handbook 2020).

If we had identified multi-arm trials for inclusion in the review, we would have ensured that multiple intervention groups were analysed in an appropriate way to avoid arbitrary omission of groups or double counting of participants. This may have included combining intervention groups (if appropriate) or splitting the 'shared' group into two or more groups with a smaller sample size. However, no multi-arm trials were identified.

Dealing with missing data

We contacted study authors via email whenever an outcome of interest was not reported, if the methods of the study suggested that the outcome had been measured. We also contacted authors if not all data required for meta-analysis had been reported. If standard deviation data were not available from the publication or the authors, we would have approximated these using the standard estimation methods from P values, standard errors or 95% CIs if these were reported, as detailed in the *Cochrane Handbook for Systematic Reviews of Interventions* (Handbook 2020).

Apart from imputations for missing standard deviations, we planned to conduct no other imputations. We extracted and analysed all data using the available case analysis method.

Assessment of heterogeneity

We planned to assess clinical heterogeneity (which may be present even in the absence of statistical heterogeneity) by examining the included studies for potential differences between them in the types of participants recruited, interventions or controls used and the outcomes measured. However, this was not possible due to the inclusion of a single study for each comparison.

We planned to assess statistical heterogeneity by visually inspecting the forest plots and by considering the Chi^2 test (with a significance level set at P value < 0.10) and the I^2 statistic, which calculates the percentage of variability that is due to heterogeneity rather than chance (Handbook 2020). Again, this was not necessary due to the inclusion of a single study for each comparison.

Assessment of reporting biases

We assessed reporting bias as within-study outcome reporting bias and between-study publication bias.

Outcome reporting bias (within-study reporting bias)

We assessed within-study reporting bias by comparing the outcomes reported in the published report against the study protocol or trial registry, whenever this could be obtained. If the protocol or trial registry entry was not available, we compared the outcomes reported to those listed in the methods section. If results were mentioned but not reported adequately in a way that allows analysis (e.g. the report only mentions whether the results were statistically significant or not), bias in a meta-analysis is likely to occur. In this situation, we sought further information from the study authors. If no further information was found, we noted this as being a 'high' risk of bias when the risk of bias tool is used. If there was insufficient information to judge the risk of bias we noted this as an 'unclear' risk of bias (Handbook 2011).

Publication bias (between-study reporting bias)

We would have assessed funnel plots if sufficient studies (more than 10) were available for an outcome. If we had observed asymmetry of the funnel plot, we would have conducted more formal investigation using the methods proposed by Egger 1997. We also reported on whether there were any studies identified through trial registries and other sources (Searching other resources) with unpublished reports.

Data synthesis

Where possible and appropriate (if participants, interventions, comparisons and outcomes were sufficiently similar in the studies identified) we planned to conduct a quantitative synthesis of results. We planned to conduct all meta-analyses using a fixed-effect method in RevMan 5.4. However, at present a single study for each comparison is included in this review, precluding meta-analysis.

We planned to include all studies in the meta-analyses, regardless of their risk of bias. However, we intended to incorporate a summary assessment of risk of bias in the measure of certainty of the evidence for each outcome, using the GRADE system.

For dichotomous data, we analysed treatment differences as a risk ratio (RR) calculated using the fixed-effect Mantel-Haenszel methods.

For continuous outcomes, we planned to use the inverse variance, fixed-effect method of meta-analysis. If all data were from the same scale, we planned to pool mean follow-up values with change-from-baseline data and report this as a mean difference. If there was a need to report standardised mean differences then we would not have pooled endpoint and change-from-baseline data.

For time-to-event data we planned to use a generic inverse variance, fixed-effect method of meta-analysis.

Sense of smell may be tested using a variety of methods, which consider different aspects of the sense of smell. These are:

- identification - the ability to identify and name a specific odour;
- threshold - the concentration of an odour that can be detected;
- discrimination - the ability to discriminate between odours.

We included methods that considered any or all of the above aspects of sense of smell. If meta-analysis is appropriate in future iterations of this review, we will only pool results that look at the same individual aspect (or aspects) of sense of smell.

If meta-analysis was not possible (for example, due to incompletely reported outcomes/effect estimates or different effect measures that cannot be combined) then we considered presenting alternative synthesis methods. This included summarising the effect estimates from individual studies, combining P values or vote counting based on the direction of effect, depending on the data available.

Living systematic review considerations

Whenever new evidence relevant to the review is identified in our monthly searches, we will extract the data, assess risk of bias and incorporate it into the synthesis every four months, as appropriate. Formal sequential meta-analysis approaches will not be used for updated meta-analyses.

Subgroup analysis and investigation of heterogeneity

A number of factors are likely to impact on the outcomes included in this review. At present, we have insufficient studies and data to conduct any subgroup analysis. For future versions of this review (if appropriate data are reported), we plan to consider the following subgroups, regardless of whether statistical heterogeneity is identified:

- Age of participants in the study (under 60 years versus those aged 60 or over):
  - age is well recognised to impact on olfactory function, with sense of smell worsening with time. The ability to detect smells may therefore differ considerably between younger and older adults.
- Gender of participants in the study (female versus male):
  - gender has an influence on olfactory function and may also impact recovery rates.
- Method used to determine olfactory dysfunction at study baseline (self-reported versus psychophysical testing):
  - rates of olfactory dysfunction vary depending on whether self-report or psychophysical testing is used to identify olfactory loss. Effect estimates in these two groups may therefore differ.

If studies did not report data for particular subgroups of participants we planned to synthesise data at the level of the individual study, where appropriate. We would have identified studies as belonging to a particular subgroup if more than 2/3 participants (66%) belonged to that category.

If studies presented data for subgroups of individuals within the study we would have used this for subgroup analysis, where applicable, regardless of whether studies had stratified their randomisation according to those subgroups.

We anticipated that the varying methods used for olfactory training may be a source of heterogeneity in effects. If we identified heterogeneity in the comparison of olfactory training then we would have explored this considering the following factors:

- classical versus modified olfactory training (using the same scents throughout compared to changing the scents);
- the duration of the intervention.

Due to the inclusion of only two studies in the review, we have not conducted any subgroup analysis.

Sensitivity analysis

We planned to carry out sensitivity analyses to determine whether the findings were robust to the decisions made in the course of identifying, screening and analysing the studies. We would have conducted sensitivity analysis for the following factors, whenever possible:

- impact of model chosen: to investigate whether the use of a random-effects model impacts on the effect estimates;
- inclusion of studies with concurrent treatments: to exclude these studies from the pooled estimates of effect for any intervention;
- method of COVID-19 diagnosis: to exclude studies where only a clinical method of COVID-19 diagnosis was used (rather than laboratory confirmed).

As only two studies were included in the review, and both assess different comparisons, sensitivity analyses were not appropriate at this point.

Summary of findings and assessment of the certainty of the evidence

Two independent authors (LOB/KW) used the GRADE approach to rate the overall certainty of evidence using GRADEpro GDT (https://gradepro.org/). The certainty of evidence reflects the extent to which we are confident that an estimate of effect is correct and we applied this in the interpretation of results. There are four possible ratings: high, moderate, low and very low. A rating of high certainty of evidence implies that we are confident in our estimate of effect and that further research is very unlikely to change our confidence in the estimate of effect. A rating of very low certainty implies that any estimate of effect obtained is very uncertain.

The GRADE approach rates evidence from RCTs that do not have serious limitations as high certainty. However, several factors can lead to the downgrading of the evidence to moderate, low or very low. The degree of downgrading is determined by the seriousness of these factors:

- study limitations (risk of bias);
- inconsistency;
- indirectness of evidence;
- imprecision; and
- publication bias.

We planned to include a summary of findings table, constructed according to the recommendations described in Chapter 14 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Handbook 2020), for the following comparison(s):

- intranasal corticosteroid drops/rinses versus no treatment/placebo;
- intranasal corticosteroid sprays versus no treatment/placebo;
- olfactory training versus no treatment/placebo;
- intranasal vitamin A versus no treatment/placebo.

However, at present there are only two comparisons in this review: systemic corticosteroids plus intranasal corticosteroid/mucolytic/decongestant solution compared to no intervention, and palmitoylethanolamide and luteolin compared to no intervention. We therefore present a summary of findings table for each of these comparisons.

We included the following outcomes in the summary of findings tables:

- recovery of sense of smell (as reported by the participants);
- disease-related quality of life, as assessed by the Olfactory Disorders Questionnaire (or another validated questionnaire);
- serious adverse effects;
- change in sense of smell (as identified by psychophysical testing);
- overall, generic quality of life, as assessed by validated methods (e.g. EQ-5D);
- presence of parosmia;
- other adverse effects (including nosebleeds/bloody discharge).

Methods for future updates

Living systematic review considerations

We will review the scope and methods of this review approximately yearly (or more frequently if appropriate) in the light of potential changes in the topic area, or the evidence being included in the review (for example, additional comparisons, interventions or outcomes, or new review methods available).

Conditions under which the review will no longer be maintained as a living systematic review

The review will no longer be maintained as a living systematic review once there is high-certainty evidence obtained for the primary effectiveness outcomes of the review; once new studies are not expected to be conducted regularly for the interventions included in this review; or once the review topic is no longer a priority for health care decision-making.

RESULTS

Description of studies

Results of the search

The searches (December 2020, and monthly searches from July 2021 to October 2021) retrieved a total of 3572 records. This reduced to 2463 after the removal of duplicates. The Cochrane ENT Information Specialist sent all 2463 records to the Screen4Me workflow. The Screen4Me workflow identified 109 records as having previously been assessed: 75 had been rejected as not RCTs and 34 had been assessed as possible RCTs. The RCT classifier rejected an additional 893 records as not RCTs (with 99% sensitivity). We did not send any records to the Cochrane Crowd for assessment. Following this process, the Screen4Me workflow had rejected 968 records and identified 1495 possible RCTs for title and abstract screening.

	Possible RCTs	Rejected
Known assessments	34	75
RCT classifier	1461	893
Total	1495	968

We identified 743 additional duplicates. We screened the titles and abstracts of the remaining 752 records. We discarded 672 records and assessed 80 full-text records. We discarded six additional records at the full-text screening stage.

We excluded 43 records (linked to 39 studies) with reasons recorded in the review (see Excluded studies). We identified one additional record to a published paper linked to an excluded study identified by the search. The paper was published after the search was run.

We included two studies (two records) where results were available (D'Ascanio 2021; Vaira 2021a).

One study (two records) is awaiting assessment (Mohamad 2021). It is unclear from this article whether participants had symptoms for less than four weeks at baseline. We have attempted to contact the authors to clarify this, but are awaiting a response.

We identified 25 ongoing studies (27 records). See Characteristics of ongoing studies for further details. Some studies will assess more than one intervention. The interventions that will be assessed include:

- corticosteroid nasal irrigation or sprays (COVIDORL (NCT04361474); IRCT20200522047542N1; NCT04964414; TCTR20210714006; UMIN000043537);
- systemic corticosteroids (NCT04528329; NCT04530409; NL9635);
- antihistamines (UMIN000043537);
- vitamin A (IRCT20210205050247N; NCT04900415);
- retinoic acid + vitamin D (NCT05002530);
- omega-3 fatty acids (NCT04495816);
- palmitoylethanolamide and luteolin (NCT04853836);
- ivermectin (NCT04951362);
- theophylline (SCENT2 (NCT04789499));
- olfactory training (IRCT20210202050231N1; IRCT20210205050247N; NCT04764981; NCT04900415; NCT05037110; Odorat-Covid (NCT04598763); VOLT (NCT04710394));
- physical activity (NCT05037110);
- acupuncture (IRCT20210311050671N1; NCT04952389; NCT04959747);
- whole body cryotherapy (IRCT20210708051817N1);
- transauricular vagus nerve stimulation (NCT04638673).

It should be noted that some of the studies assess more than one intervention, and that - for some studies - it is unclear whether participants will have at least four weeks of olfactory loss at baseline. Some of these studies may therefore not be eligible for inclusion in the review once the published data are available.

A flow chart of study retrieval and selection is provided in Figure 1.

Figure 1.



Figure 1. (Continued)



Included studies

Two studies were included in the review (D'Ascanio 2021; Vaira 2021a).

Study design

Both of the included studies were randomised controlled trials. Both were open-label studies, with no placebo (Vaira 2021a), although they reported that outcome assessors were blinded to the group allocation. The studies were both small, with one including 12 participants (D'Ascanio 2021), and the other including 18 participants (Vaira 2021a).

Participants

Participants in Vaira 2021a had all had COVID-19 related olfactory disturbance for at least 30 days. This was assessed using the Connecticut Chemosensory Clinical Research Center test, and all participants were required to have a score of ≤ 40 on entry to the study (scores range from 0 to 100, a score of ≤ 40 defines as severe hyposmia or anosmia). Participants in D'Ascanio 2021 had a history of COVID-19 and self-reported anosmia/hyposmia that had lasted for at least 90 days following clearance of the virus (indicated by a negative COVID-19 nasopharyngeal swab). Olfactory disturbance was self-reported at entry to the study, but all participants also had a confirmed score of ≤ 30.75 using Sniffin' Sticks: mean scores in the intervention group were 21.1 (SD 5.5) and in the control group were 28.8 (SD 1.2). Normosmia on Sniffin' Sticks is reported to be a score of ≥ 31.

Both studies were conducted in adults and excluded participants with previous symptoms of olfactory dysfunction, or with underlying medical conditions that may affect olfaction.

Interventions and comparisons

Comparison 1: Systemic corticosteroids plus intranasal corticosteroid/mucolytic/decongestant versus no intervention

One study assessed this comparison (Vaira 2021a). Participants in the intervention arm received prednisone (starting with 1 mg/kg and tapering the dose over the next 15 days). In addition they received nasal irrigation with betamethasone, ambroxol and rinazine for 15 days. No further details were provided. Participants in the control group received no intervention.

Comparison 2: palmitoylethanolamide and luteolin versus no intervention

One study compared the use of palmitoylethanolamide and luteolin to no intervention (D'Ascanio 2021). Participants in the intervention group were given a daily tablet containing 700 mg palmitoylethanolamide and 70 mg luteolin for 30 days.

Outcomes

Recovery of sense of smell

Assessed by the participants

Neither of the included studies assessed this outcome.

Assessed using psychophysical testing

One study assessed and reported this outcome (Vaira 2021a). The CCCRC was used to assess olfactory function. This includes a butanol threshold assessment and odour identification test, but no assessment of odour discrimination. The scores are converted into CCCRC composite scores, with a range from 0 to 100, where higher scores represent better olfactory function. Normosmia was defined as a score of 90 to 100. The study reports the number of participants with normosmia at baseline, 20 and 40 days of follow-up.

D'Ascanio 2021 used Sniffin' Sticks to assess olfactory function, but did not report on the number of participants with normosmia at follow-up. However, the authors of the study were able to provide us with these data for this review.

Disease-related quality of life

Neither of the included studies assessed this outcome.

Serious adverse events

Vaira 2021a provides some information on adverse effects during the study, but it is not clear if these were systematically or opportunistically collected during the study. D'Ascanio 2021 did not report on the occurrence of serious adverse events.

Change in sense of smell

Assessed by the participants

Neither of the included studies assessed this outcome.

Assessed using psychophysical testing

Both studies assessed and reported this outcome, but used different methods of measurement. Vaira 2021a used the CCCRC to assess olfactory function, as described above. D'Ascanio 2021 used Sniffin' Sticks to assess olfactory function. This includes assessment of the detection threshold for odours, odour discrimination and identification. Scores range from 1 to 48, with higher scores representing better olfactory function.

Overall, generic quality of life

Neither of the included studies assessed this outcome.

Prevalence of parosmia

Neither of the included studies assessed this outcome.

Other adverse events

As above, Vaira 2021a refers to adverse events in the results of the study, but it is not clear whether these were systematically assessed. D'Ascanio 2021 does not report on adverse events.

Excluded studies

We excluded 39 studies. We present the main reasons for the exclusion of the studies below, although some studies had multiple reasons for exclusion:

Twenty studies assessed the wrong population:

- Ten studies included all individuals with COVID-19 and not just those with olfactory dysfunction (ACTION (NCT04332107); COPPS (NCT04662060); COVIDAtoZ (NCT04342728); CTRI/2020/08/027477; NCT04414124; NCT04458519; NCT04474483; NCT04513184; NCT04622891; NCT04662086).
- Seven studies included those with olfactory dysfunction but for less than four weeks (Abdelalim 2021; Abdelmaksoud 2021; Kasiri 2021; Rashid 2021; NCT04797936; UMIN000045185; Yildiz 2021).
- Two studies included any post-viral olfactory dysfunction, not specifically COVID-19 (Klug 2021; NCT04406584).
- One study included participants with nasal obstruction and rhinorrhoea, but not specifically olfactory dysfunction (NCT04916639).

Seventeen studies were incorrectly designed to meet our inclusion criteria:

- Twelve studies were not randomised controlled trials (Bulbuloglu 2021; IRCT20180205038619N2; IRCT20200629047953N1; Islek 2021; Le Bon 2021; NCT04382547; NCT04427332; NCT04806880; NCT04830943; Saussez 2021; Singh 2021; Varricchio 2021).
- Two studies were narrative review articles without any primary data (Begam 2020; Vroegop 2020).
- Three studies were letters to the editor without any primary data (Patel 2021; Pinna 2020; Vaira 2021c).

Finally, two studies were withdrawn prior to participant enrolment and therefore may have been relevant but could not be included in this review (Co-STAR (NCT04422275); NCT04374474).

One study is listed as awaiting assessment (Mohamad 2021). This published paper describes the use of intranasal insulin for olfactory disturbance following COVID-19. The time since COVID-19 infection is reported, but the article does not state whether this is measured in days or weeks, therefore we are not certain whether this study is appropriate for inclusion in this review, or for inclusion in the companion review that considers prevention of persistent olfactory dysfunction (Webster 2022). We have attempted to contact the authors to confirm this, but have received no response.

Risk of bias in included studies

We considered both included studies to carry a high risk of performance bias due to a lack of blinding of participants. We also considered D'Ascanio 2021 to have a high risk of bias from baseline imbalance in the participants. Other risks of bias were either low or unclear (see Figure 2).

Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.



Allocation

Both studies ensured adequate randomisation using computer-generated random sequences. However, concealment of allocation sequence was not described in the text. Correspondence from authors of both studies confirmed that computerised randomisation lists were compiled, but it remains unclear whether it would have been possible to determine the group allocation for new participants.

Blinding

Neither study involved blinding of participants and the control groups did not receive any treatment; we felt this represented a high risk of performance bias. However, both studies reported that outcome assessors for psychophysical tests were blinded to the treatment allocation of participants, therefore we judged there to be at low risk of detection bias.

Incomplete outcome data

As all participants in both studies completed follow-up with no incomplete data reported, we concluded that there was a low risk of attrition bias.

Selective reporting

Neither of the included studies published a protocol, or registered with a trial registry. Therefore we considered that there was an unclear risk of selective reporting, as we were unable to determine whether outcomes were reported according to a pre-specified plan.

Other potential sources of bias

We did not detect any additional potential sources of bias for Vaira 2021a. We noted considerable baseline imbalance between the intervention and control group in D'Ascanio 2021. Participants in the control group had a shorter duration of olfactory disturbance and less severe olfactory disturbance than those in the intervention group. These differences may be compatible with chance, given the small sample size in this study (12 participants). However, the difference in baseline characteristics may cause a bias in the results of the study.

Effects of interventions

See: **Summary of findings 1** Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant compared to no intervention for persistent post-COVID-19 olfactory dysfunction; **Summary of findings 2** Palmitoylethanolamide and luteolin compared to no intervention for the treatment of persistent post-COVID-19 olfactory dysfunction

Comparison 1: Systemic corticosteroids plus intranasal corticosteroid/mucolytic/decongestant versus no intervention

One study (18 participants, Vaira 2021a) investigated systemic corticosteroids with intranasal corticosteroid/mucolytic/decongestant therapy in comparison to no treatment (see Summary of findings 1).

Recovery of sense of smell

At one to three months

Vaira 2021a used psychophysical testing with the CCCRC score (0 to 100) to measure olfactory function at baseline, 20 and 40 days. Normosmia was defined as a CCCRC score of ≥ 90. At 40 days, five participants had normal olfactory function in the intervention group (5 out of 9) compared to no participants with normal olfactory function in the control group (0 out of 9). However, the evidence is very uncertain for the effect of the intervention on the presence of normal olfactory function at one to three months given the small sample size and the very wide confidence intervals around the effect (risk ratio (RR) 11, 95% confidence interval (CI) 0.70 to 173.66; 1 study; 18 participants; very low-certainty evidence; Analysis 1.1).

No data were reported for later time points of interest in this review, and no data on self-rated olfactory function were reported.

Disease-related quality of life

This was not assessed or reported.

Serious adverse effects

At one to three months

Vaira 2021a reported that no patient had an adverse event, however it is unclear how this outcome was assessed (1 study; 18 participants; very low-certainty evidence).

No data were reported for later time points of interest in this review.

Change in sense of smell

At one to three months

Vaira 2021a reported a median change in smell using the CCCRC score at 40 days. As the data were reported using medians no effect estimate could be calculated. This study reported an improvement in sense of smell in the intervention group from baseline (median improvement in CCCRC score 60, interquartile range (IQR) 40) compared to the control group (median improvement in CCCRC score 30, IQR 25) (P = 0.024; 1 study; 18 participants; very low-certainty evidence). The evidence is very uncertain regarding the efficacy of systemic corticosteroids and nasal spray and change in olfactory function at one to three months.

No data were reported for later time points of interest in this review, and no data on self-rated olfactory function were reported.

Generic quality of life

This was not assessed or reported.

Prevalence of parosmia

This was not assessed or reported.

Other adverse effects

At one to three months

Vaira 2021a reported that no participant had an adverse event, however it is unclear how this outcome was assessed (1 study; 18 participants; very low-certainty evidence).

No data were reported for later time points of interest in this review.

Comparison 2: Palmitoylethanolamide and luteolin versus no intervention

One study (12 participants) investigated palmitoylethanolamide and luteolin in comparison to no treatment (D'Ascanio 2021).

Recovery of sense of smell

This outcome was not reported in the article, but the authors were able to provide these data for inclusion in this review. Sense of smell was assessed using Sniffin' Sticks and the number of participants who had 'recovered' their sense of smell was defined as those who had a score of ≥ 31 on Sniffin' Sticks. The evidence was very uncertain regarding the effect of palmitoylethanolamide/luteolin on recovery of sense of smell. One participant (out of seven) in the intervention group recovered, compared to three participants (out of five) in the control group, with a RR of recovery of 0.24 (95% CI 0.03 to 1.67; 1 study; 12 participants; very low-certainty evidence; Analysis 2.1). We noted that there was considerable imbalance in baseline characteristics between the two arms of the study, with the control group having higher scores when assessed with Sniffin' Sticks at baseline, which may have impacted the results.

Disease-related quality of life

This was not assessed or reported.

Serious adverse effects

At one to three months

This was not assessed or reported in the article. Communication from the authors confirmed that no adverse events were noted during the study, but it is unclear whether these were systematically assessed (RR not estimable; 1 study; 12 participants; very low-certainty evidence).

Change in sense of smell

At one to three months

D'Ascanio 2021 reported on the sense of smell using Sniffin' Sticks. The authors provided data on the change in score for each group, and the standard deviation of the change to enable this analysis.

The mean change in sense of smell was 2.2 points higher in those who received palmitoylethanolamide/luteolin as compared to those who received no intervention (95% CI 4.4 points lower to 8.8 points higher; 1 study; 12 participants; very low-certainty evidence; Analysis 2.2). However, it should be noted that there was considerable baseline imbalance in this study, with worse Sniffin' Sticks scores in the palmitoylethanolamide/luteolin group, therefore regression to the mean would tend to favour the intervention group at follow-up.

Generic quality of life

This was not assessed or reported.

Prevalence of parosmia

This was not assessed or reported.

Other adverse effects

D'Ascanio 2021 did not report on the occurrence of adverse events. Communication from the authors confirmed that no adverse events were noted during the study, but it is unclear whether these were systematically assessed.

DISCUSSION

Summary of main results

This review includes two randomised controlled trials; one evaluated the effect of systemic corticosteroids and nasal irrigation (intranasal corticosteroid/mucolytic/decongestant) used for 15 days compared to no treatment, and one compared palmitoylethanolamide/luteolin to no treatment for 30 days. All patients had persistent hyposmia or anosmia for at least 30 days following COVID-19 infection, as confirmed by psychophysical testing.

The small size of the studies means that there is considerable uncertainty over the results and the benefits and harms of these two interventions are unclear.

Overall completeness and applicability of evidence

This review is inherently limited by only having two included studies. Furthermore, these studies only recruited a total of 30 participants, and this small sample size leads to great uncertainty in the results. A particular issue with small studies is the difficulty in obtaining prognostic balance across the randomised groups, which can lead to challenges in interpreting the data. Although participants may have been randomly allocated to each group, there may still be considerable differences in the two groups at baseline, which can contribute to the effect size seen at follow-up.

A number of our pre-specified outcomes of interest were not assessed by either of these studies, including disease-related quality of life, generic quality of life and the presence of parosmia, therefore we cannot draw any conclusions regarding the effect of the interventions on these outcomes. Finally, the studies followed up participants for a maximum of 40 days, therefore the long-term effects of these intervention remain unknown.

The sense of smell is also important to help distinguish flavour – whilst the true tastes of sweet, sour, salty, bitter and umami can be sensed with the tongue, awareness of different flavours requires a functioning olfactory system. Consequently, changes in olfactory function are typically accompanied by altered flavour perception. Assessment of taste using self-reporting is challenging (due to the need to distinguish between true taste and retronasal olfaction) and there is a lack of widespread use of psychophysical testing methods, which are needed to determine the accurate picture of olfactory and gustatory performance. Therefore we have focused predominantly on the sense of smell for this review, but we acknowledge that an impaired sense of taste may be a real or perceived issue for many individuals who are recovering from COVID-19.

Quality of the evidence

We judged the certainty of the evidence to be very low for all outcomes assessed. This was largely a consequence of the fact that each comparison included evidence from a single study with a small sample size, leading to a lack of precision in the effect estimates. In addition, concerns around high risk of performance bias existed in relation to the lack of blinding of participants. For one of the included studies we noted considerable imbalance in participant characteristics at baseline, which may have impacted on the results of the study (D'Ascanio 2021).

Potential biases in the review process

This review is one of a pair that address the prevention and treatment of olfactory dysfunction related to COVID-19. As olfactory dysfunction has been found to carry a high rate of resolution within the first month after COVID-19 infection we felt this was a clinically important distinction to make in evaluating prospective interventions for prevention and treatment. Therefore, we excluded studies from this review if participants had less than four weeks of olfactory disturbance at baseline - these studies are included in the companion review on the prevention of olfactory dysfunction (Webster 2022).

Agreements and disagreements with other studies or reviews

To the best of our knowledge this is the first and only review of its kind evaluating the treatment of persistent anosmia post-COVID-19 infection therefore it is impossible to draw any comparisons to other studies or reviews.

AUTHORS' CONCLUSIONS

Implications for practice

Currently there are only data available from two studies. At present, the evidence is very uncertain regarding the potential benefits and harms of either palmitoylethanolamide and luteolin or systemic steroids (coupled with intranasal corticosteroids, a mucolytic and a decongestant) on the treatment of persisting olfactory dysfunction following COVID-19. Therefore, we are unable to draw any definite conclusions on the efficacy and risks of treatments involved in treating anosmia in this setting. As this is a living systematic review the data will be updated regularly, as new evidence becomes available.

Implications for research

The treatment of persistent anosmia as a sequela of COVID-19 infection is a rapidly evolving field, therefore this review will be maintained as a living systematic review. We are aware of a large number of ongoing trials in the area and will incorporate emerging evidence into this review as data become available.

The natural history of olfactory dysfunction related to COVID-19 remains to be seen. High rates of spontaneous resolution have been reported but further research is required into the area to specifically determine which groups will benefit from therapy and what the associated risks may be. The distinction between prevention and treatment is an important one to make when designing clinical trials to investigate this complex group of patients.

As with the treatment of post-viral olfactory dysfunction, the method of evaluation of olfactory dysfunction is of particular importance with a combination of psychophysical testing and self-rated evaluation giving greater opportunities to assess the meaningful impact of treatment interventions.

ACKNOWLEDGEMENTS

This review forms part of NIHR132103 - *The prevention and treatment of persisting olfactory dysfunction following COVID-19 infection; a suite of Cochrane living systematic reviews*. This study is one of a number of COVID-19 studies that have been funded by the National Institute for Health Research (NIHR) as part of its Recovery and Learning call, totalling £5.5m in funding, to help better manage current and future waves of the COVID-19 pandemic and investigate its long-term impacts on the health and care system beyond the acute phase.

This project was also supported by the National Institute for Health Research, via Cochrane Infrastructure, Cochrane Programme Grant or Cochrane Incentive funding to Cochrane ENT. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

Lisa O' Byrne, Evidence Synthesis Ireland Fellow, was part-supported by the Health Research Board (Ireland) and the HSC Public Health Agency (Grant number CBES-2018-001) through Evidence Synthesis Ireland/Cochrane Ireland.

The authors would like to extend their sincere thanks to the board members of AbScent and Fifth Sense for their insights and significant contributions to the development of the protocol for this review. We would also like to thank the many individuals affected by smell loss who took the time to complete our surveys, which were invaluable when prioritising outcomes for this review.

The authors would like to acknowledge Lee Yee Chong for her work on generic methods content, some of which has been adapted for use in this review (with permission).

The authors are grateful to Joanne Abbott, Information Specialist with Cochrane Pain, Palliative and Supportive Care, for providing peer review comments on the draft search methods, and Iris Gordon, Information Specialist with Cochrane Eyes & Vision, for providing peer review comments on the update search methods introduced in July 2021.

Lastly, we would like to thank Professor Peter Tugwell, Senior Editor Cochrane MOSS Network, for acting as sign-off editor for the initial version of this review and Professor Richard Harvey, Cochrane ENT Editor, for acting as sign-off editor for the August 2022 update.

Editorial and peer reviewer contributions

Cochrane ENT supported the authors in the development of this review.

The following people conducted the editorial process for this article:

- Sign-off Editor (final editorial decision): Professor Peter Tugwell, Senior Editor Cochrane MOSS Network (initial version) and Professor Richard Harvey, Cochrane ENT Editor (2022 update).
- Managing Editor (selected peer reviewers, collated peer reviewer comments, provided editorial guidance to authors, edited the article): Jenny Bellorini, Cochrane ENT
- Copy Editor (copy editing and production): Jenny Bellorini, Cochrane ENT
- Peer reviewers (provided comments and recommended an editorial decision): Richard Rosenfeld and Richard Harvey, Cochrane ENT Editors (clinical/content review); Emma Jackson, Cochrane Airways (consumer review); Iris Gordon, Information Specialist, Cochrane Eyes & Vision (search review). One additional peer reviewer provided clinical peer review, but chose not to be publicly acknowledged.

REFERENCES

References to studies included in this review

D'Ascanio 2021 *{published data only}*

D'Ascanio L, Vitelli F, Cingolani C, Maranzano M, Brenner MJ, Di Stadio A. Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with palmitoylethanolamide and luteolin": preliminary results. *European Review for Medical and Pharmacological Sciences* 2021;**25**(11):4156-62. [CENTRAL: CN-02288715] [EMBASE: 2013167573] [PMID: 34156697]

NCT04853836. Olfactory disfunction and Co-ultraPEALut [Olfactory disfunction after COVID-19: conventional therapy versus intervention treatment with Co-ultraPEALut]. https://clinicaltrials.gov/show/NCT04853836 (first received 21 April 2021). [CENTRAL: CN-02269702]

Vaira 2021a *{published data only}*

Vaira LA, Hopkins C, Petrocelli M, Lechien JR, Cutrupi S, Salzano G, et al. Efficacy of corticosteroid therapy in the treatment of long-lasting olfactory disorders in COVID-19 patients. *Rhinology* 2021;**59**(1):21-5. [CENTRAL: CN-02210463] [EMBASE: 633663621] [PMID: 33290446]

References to studies excluded from this review

Abdelalim 2021 *{published data only}*

* Abdelalim AA, Mohamady AA, Elsayed RA, Elawady MA, Ghallab AF. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: a randomized controlled trial. *American Journal of Otolaryngology* 2021;**42**(2):102884. [PMID: 33429174]

NCT04484493. Corticosteroid nasal spray in COVID-19 anosmia [Role of corticosteroid nasal spray in recovery of smell sensation in COVID-19 patients]. https://clinicaltrials.gov/show/NCT04484493 (first received 23 July 2020). [CENTRAL: CN-02145535]

Abdelmaksoud 2021 *{published data only}*

Abdelmaksoud AA, Ghweil AA, Hassan MH, Rashad A, Khodeary A, Aref ZF, et al. Olfactory disturbances as presenting manifestation among Egyptian patients with COVID-19: possible role of zinc. *Biological Trace Element Research* 2021;**199**(11):4101-8. [CENTRAL: CN-02254314] [EMBASE: 2010124825] [PMID: 33409924]

ACTION (NCT04332107) *{published data only}*

NCT04332107. Azithromycin for COVID-19 treatment in outpatients nationwide [Azithromycin for prevention of disease progression in patients with mild or moderate COVID-19]. https://clinicaltrials.gov/show/NCT04332107 (first received 2 April 2020).

Begam 2020 *{published data only}*

Begam N, Bashar MA. Olfactory and taste disorders in patients with SARS-CoV-2 infection. *International Archives of Otorhinolaryngology* 2020;**24**(3):e391-2. [PMID: 32754254]

Bulbuloglu 2021 *{published data only}*

Bulbuloglu S, Altun Y. The effect of sniffing Turkish coffee on olfactory disorders in COVID-19 patients: an experimental clinical study. *Ideggyogyaszati Szemle* 2021;**74**(3-4):117-23. [PMID: 33938667]

COPPS (NCT04662060) *{published data only}*

NCT04662060. COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol [COVID-19 outpatient pragmatic platform study (COPPS): a pragmatic multi-arm, adaptive, phase 2, blinded, randomized placebo-controlled platform trial to assess the efficacy of different investigational therapeutics in reducing time to disease resolution or viral load cessation, as compared to standard supportive care in outpatients with COVID-19]. https://clinicaltrials.gov/show/NCT04662060 (first received 10 December 2020).

Co-STAR (NCT04422275) *{published data only}*

NCT04422275. Coronavirus smell therapy for anosmia recovery. https://clinicaltrials.gov/show/NCT04422275 (first received 9 June 2020). [CENTRAL: CN-02118715]

COVIDAtoZ (NCT04342728) *{published data only}*

NCT04342728. Coronavirus 2019 (COVID-19) - using ascorbic acid and zinc supplementation [Coronavirus disease 2019 - using ascorbic acid and zinc supplementation (COVIDAtoZ) research study a randomized, open label single center study]. https://clinicaltrials.gov/show/NCT04342728 (first received 13 April 2020).

CTRI/2020/08/027477 *{published data only}*

CTRI/2020/08/027477. Evaluation of safety and efficacy of T-AYU-HM premium and onion steam vaporization/nebulization in Covid-19 patients. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/08/027477 (first received 2020).

IRCT20180205038619N2 *{published data only}*

IRCT20180205038619N2. Evaluation of the effectiveness of TDCS (transcranial direct current stimulation) in the treatment of prolonged decreased of sense of smell in patients with Covid-19. http://en.irct.ir/trial/53545 (first received 30 August 2021).

IRCT20200629047953N1 *{published data only}*

IRCT20200629047953N1. Effect of olfactory training on anosmia of COVID-19 [Assessment of the effect of olfactory training on anosmia following COVID-19 infection]. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200629047953N1 (first received 17 March 2021). [CENTRAL: CN-02282666]

Islek 2021 *{published data only}*

Islek A, Balcı MK. Evaluation of effects of chronic nasal steroid use on rhinological symptoms of COVID-19 with SNOT-22 questionnaire. *Pharmacological Reports: PR* 2021;**73**(3):781-5. [PMID: 33625686]

Kasiri 2021 *{published data only}***IRCT20190804044429N6**

IRCT20190804044429N6. Nasal spray of mometasone 0.05% effects on olfactory improvement in COVID-19 [Efficacy and

safety of nasal spray of mometasone 0.05%on olfactory improvement in patients with COVID-19: a randomized, double blind clinical trial]. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190804044429N6 (first received 20 February 2021). [CENTRAL: CN-02240855]

Kasiri H, Rouhani N, Salehifar E, Ghazaeian M, Fallah S. Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: a randomized, double blind clinical trial. *International Immunopharmacology* 2021;**98**:107871. [CENTRAL: CN-02283597] [EMBASE: 2013103141] [PMID: 34147912]

Klug 2021 *{published data only}*

Klug T, Rosen D, Chaskes M, Souza GD, Pribitkin E. Treatment of refractory anosmia with topical platelet rich plasma. *Otolaryngology - Head and Neck Surgery* 2021;**165**(Suppl 1):344-5.

Le Bon 2021 *{published data only}*

Le Bon SD, Konopnicki D, Pisarski N, Prunier L, Lechien JR, Horoi M. Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell. *European Archives of Oto-rhino-laryngology* 2021;**278**(8):3113-7. [PMID: 33423106]

NCT04374474 *{published data only}*

NCT04374474. Anosmia rehabilitation in patients post coronavirus disease (COVID 19) [Olfactory retraining therapy and budesonide nasal rinse for anosmia treatment in patients post-COVID 19. A randomized controlled trial]. https://clinicaltrials.gov/show/NCT04374474 (first received 5 May 2020). [CENTRAL: CN-02093904]

NCT04382547 *{published data only}*

NCT04382547. Treatment of Covid-19 associated pneumonia with allogenic pooled olfactory mucosa-derived mesenchymal stem cells. https://clinicaltrials.gov/show/NCT04382547 (first received 11 May 2020).

NCT04406584 *{published data only}*

NCT04406584. Intranasal injection of PRP versus saline for treatment of olfactory dysfunction [Intranasal injection of platelet-rich plasma versus saline for treatment of olfactory dysfunction]. https://clinicaltrials.gov/show/NCT04406584 (first received 28 May 2020). [CENTRAL: CN-02124993]

NCT04414124 *{published data only}*

NCT04414124. A clinical study to assess the natural history of COVID-19 and effects of KB109 and supportive self-care in outpatients with mild-to-moderate COVID-19 [A randomized, open label, prospective, parallel group study to assess the natural history of COVID-19 and effects of KB109 in addition to supportive self care (SSC) compared to SSC alone on measures of health in non-hospitalized patients with mild-moderate COVID-19]. https://clinicaltrials.gov/show/NCT04414124 (first received 4 June 2020).

NCT04427332 *{published data only}*

NCT04427332. Smell and taste disorders in COVID-19 patients [Smell and taste disorders in COVID-19 patients: prospective observational study]. https://clinicaltrials.gov/ct2/show/NCT04427332 (first received 11 June 2020).

NCT04458519 *{published data only}*

NCT04458519. Efficacy of intranasal probiotic treatment to reduce severity of symptoms in COVID19 infection [Randomised single blinded clinical study of efficacy of intranasal probiotic treatment to reduce severity of symptoms in COVID19 infection]. https://clinicaltrials.gov/show/NCT04458519 (first received 7 July 2020).

NCT04474483 *{published data only}*

NCT04474483. Safety and efficacy of melatonin in outpatients infected with COVID-19 [A pilot placebo-controlled randomized double-blind trial of melatonin in outpatients with COVID-19 infection]. https://clinicaltrials.gov/show/NCT04474483 (first received 16 July 2020).

NCT04513184 *{published data only}*

NCT04513184. Randomized clinical trial of intranasal dexamethasone as an adjuvant in patients with COVID-19. https://clinicaltrials.gov/show/NCT04513184 (first received 14 August 2020). [CENTRAL: CN-02146132]

NCT04622891 *{published data only}*

NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 infection [Efficacy of clarithromycin in comparison to azithromycin in treatment of mild COVID-19 infection, randomized controlled trial]. https://clinicaltrials.gov/show/NCT04622891 (first received 10 November 2020). [CENTRAL: CN-02184257]

NCT04662086 *{published data only}*

NCT04662086. COVID-19 Outpatient Pragmatic Platform Study (COPPS) - master protocol [COVID-19 outpatient pragmatic platform study (COPPS): a pragmatic multi-arm, adaptive, phase 2, blinded, randomized placebo-controlled platform trial to assess the efficacy of different investigational therapeutics in reducing time to disease resolution or viral load cessation, as compared to standard supportive care in outpatients with COVID-19]. https://clinicaltrials.gov/show/NCT04662086 (first received 10 December 2020).

NCT04797936 *{published data only}*

NCT04797936. BNO 1030 extract (Imupret) in the treatment of mild forms of COVID-19 [A randomized, open-label, multicentre, comparative study of therapeutic efficacy, safety, and tolerability of BNO 1030 extract, in the treatment of mild forms of COVID-19]. https://clinicaltrials.gov/show/NCT04797936 (first received 15 March 2021). [CENTRAL: CN-02249917]

NCT04806880 *{published data only}*

NCT04806880. Study evaluating the olfactory recovery of anosmia post COVID-19 by olfactory rehabilitation assisted by web-application. https://clinicaltrials.gov/show/NCT04806880 (first received 19 March 2021).

NCT04830943 *{published data only}*

NCT04830943. Cerebrolycin for treatment of COVID-related anosmia and ageusia [The effectiveness of cerebrolycin for treatment of post-COVID olfactory and gustatory dysfunctions:

a pilot study]. https://clinicaltrials.gov/show/NCT04830943 (first received 5 April 2021).

NCT04916639 *{published data only}*

NCT04916639. Seawater nasal wash to relieve COVID-19 nasal symptoms and reduce SARS-CoV-2 viral load. https://clinicaltrials.gov/show/NCT04916639 (first received 7 June 2021).

Patel 2021 *{published data only}*

Levy JM. Regarding use of topical steroids in patients with COVID-19-associated olfactory loss - Reply. *JAMA Otolaryngology - Head & Neck Surgery* 2021;**147**(1):110-1.

* Patel ZM. Regarding use of topical steroids in patients with COVID-19-associated olfactory loss. *JAMA Otolaryngology - Head & Neck Surgery* 2021;**147**(1):110.

Pinna 2020 *{published data only}*

Pinna FR, Brandao Neto D, Fornazieri MA, Voegels RL. Olfaction and COVID: the little we know and what else we need to know. *International Archives of Otorhinolaryngology* 2020;**24**(3):e386-7. [PMID: 32754252]

Rashid 2021 *{published data only}*

NCT04569825. Effect of nasal steroid in the treatment of anosmia due to COVID-19 disease. https://clinicaltrials.gov/show/NCT04569825 (first received 30 September 2020). [CENTRAL: CN-02181592]

Rashid RA, Zgair A, Al-Ani RM. Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: a randomised double-blind placebo-controlled study. *American Journal of Otolaryngology* 2021;**42**(5):103033. [CENTRAL: CN-02268100] [EMBASE: 2011632217] [PMID: 33839489]

Saussez 2021 *{published data only}*

Saussez S, Vaira LA, Chiesa-Estomba CM, Bon SL, Horoi M, Deiana G, et al. Short-term efficacy and safety of oral and nasal corticosteroids in COVID-19 patients with olfactory dysfunction: a European multicenter study. *Pathogens* 2021;**10**(6):698. [CENTRAL: CN-02284588] [EMBASE: 2007537787] [PMID: 34199734]

Singh 2021 *{published data only}*

Singh CV, Jain S, Parveen S. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients. *American Journal of Otolaryngology* 2021;**42**(3):102892. [PMID: 33493729]

UMIN000045185 *{published data only}*

UMIN000045185. "Additional value" of nasal therapy in standard therapy for COVID-19 patients with olfactory disorders: a preliminary randomized controlled clinical trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000045185 (first received 18 August 2021).

Vaira 2021c *{published data only}*

Vaira LA, Lechien JR, Dore S, Boccaletti R, Saussez S, De Riu G. Specific therapy of olfactory disorders in COVID-19 patients is essential for the prevention of long-term dysfunction. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2021;**2021**:1-2. [DOI: https://doi.org/10.1007/s12070-021-02818-z]

Varricchio 2021 *{published data only}*

Varricchio A, La Mantia I, Brunese FP, Ciprandi G. Smell recovery in patients with COVID-19: an experience with nebulized nasal treatment. *Journal of Biological Regulators and Homeostatic Agents* 2021;**35**(2):683-6. [PMID: 33728831]

Vroegop 2020 *{published data only}*

Vroegop AV, Eeckels AS, Van Rompaey V, Vanden Abeele D, Schiappoli M, Alobid I, et al. COVID-19 and olfactory dysfunction - an ENT perspective to the current COVID-19 pandemic. *B-ENT* 2020;**16**(1):81-5.

Yildiz 2021 *{published data only}*

Yildiz E, Koca Yildiz S, Kuzu S, Gunebakan C, Bucak A, Kahveci OK. Comparison of the healing effect of nasal saline irrigation with triamcinolone acetonide versus nasal saline irrigation alone in COVID-19 related olfactory dysfunction: a randomized controlled study. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2021;**2021**:1-6. [PMID: 34277384]

References to studies awaiting assessment

Mohamad 2021 *{published data only}*

Mohamad SA, Badawi AM, Mansour HF. Insulin fast-dissolving film for intranasal delivery via olfactory region, a promising approach for the treatment of anosmia in COVID-19 patients: design, in-vitro characterization and clinical evaluation. *International Journal of Pharmaceutics* 2021;**601**:120600. [PMID: 33862126]

NCT04657809. Clinical assessment of insulin fast dissolving film in treatment of post infection anosmia [Insulin fast dissolving film for intranasal delivery via olfactory region, a promising approach for the treatment of anosmia in COVID 19 patients: design, in-vitro characterization and clinical evaluation]. https://clinicaltrials.gov/show/NCT04657809 (first received 8 December 2020).

References to ongoing studies

COVIDORL (NCT04361474) *{published data only}*

Daval M, Corre A, Palpacuer C, Housset J, Poillon G, Eliezer M, et al. Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: a structured summary of a study protocol for a randomised controlled trial. *Trials* 2020;**21**(1):666. [CENTRAL: CN-02177639] [EMBASE: 632388256] [PMID: 32690074]

NCT04361474. Trial evaluating the efficacy of local budesonide therapy in the management of hyposmia in COVID-19 patients without signs of severity [A randomized controlled trial evaluating the efficacy of local budesonide therapy in the management of hyposmia in COVID-19 patients without signs of severity]. https://clinicaltrials.gov/show/NCT04361474 (first received 24 April 2020). [CENTRAL: CN-02180471]

IRCT20200522047542N1 *{published data only}*

IRCT20200522047542N1. Effect of Corton on olfactory dysfunction in COVID-19 patients [Effect of inhaled corticosteroids in the treatment of anosmia in patients with COVID-19]. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200522047542N1 (first received 2020). [CENTRAL: CN-02187839]

IRCT20210202050231N1 *{published data only}*

* IRCT20210202050231N1. Comparison of the effect of vanilla essential oil with eucalyptus essential oil on the return of olfactory sense in COVID-19 patients. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20210202050231N1 (first received 8 July 2021).

IRCT20210205050247N *{published data only}*

IRCT20210205050247N. The effect of olfactory training and vitamin A in the olfactory loss of patients with covid-19. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20210205050247N1 (first received 2021).

IRCT20210311050671N1 *{published data only}*

IRCT20210311050671N1. Evaluation of the effect of laser acupuncture on improving the sense of smell in patients with COVID-19 [Effect of auricular acupuncture with the laser in post-viral anosmia during the COVID-19 pandemic]. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20210311050671N1 (first received 13 April 2021). [CENTRAL: CN-02281866]

IRCT20210708051817N1 *{published data only}*

IRCT20210708051817N1. Whole body cryotherapy (WBC) for treating anosmia / hyposmia. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20210708051817N1 (first received 14 July 2021).

NCT04495816 *{published data only}*

Lerner D, Garvey K, Arrighi-Allisan A, Filimonov A, Filip P, Liu K, et al. Letter to the editor: Study summary - randomized control trial of omega-3 fatty acid supplementation for the treatment of COVID-19 related olfactory dysfunction. *Trials* 2020;**21**(1):942. [CENTRAL: CN-02200204] [EMBASE: 2007355105] [PMID: 33225989]

NCT04495816. COVID-19 anosmia study. https://clinicaltrials.gov/show/NCT04495816 (first received 3 August 2020). [CENTRAL: CN-02145765]

NCT04528329 *{published data only}*

NCT04528329. Anosmia and / or ageusia and early corticosteroid use [Time to recover of anosmia and / or ageusia and early corticosteroid use]. https://clinicaltrials.gov/ct2/show/NCT04528329 (first received 27 August 2020).

NCT04530409 *{published data only}*

NCT04530409. Timing of corticosteroids in COVID-19. https://clinicaltrials.gov/show/NCT04530409 (first received 28 August 2020).

NCT04638673 *{published data only}*

NCT04638673. NeuroCovid rehab and recovery related to COVID-19 diagnosis [Testing a wearable telemedicine-controllable taVNS device for neuroCovid recovery and rehab]. https://clinicaltrials.gov/show/NCT04638673 (first received 20 November 2020).

NCT04764981 *{published data only}*

NCT04764981. Olfactory training for olfactory dysfunction after coronavirus disease - 19 (COVID-19) [Clinical outcomes of olfactory training for treatment of olfactory dysfunction after COVID-19]. https://clinicaltrials.gov/show/NCT04764981 (first received 21 February 2021). [CENTRAL: CN-02249160]

NCT04853836 *{published data only}*

NCT04853836. Olfactory Disfunction and Co-ultraPEALut. https://clinicaltrials.gov/ct2/show/NCT04853836 (first received 21 April 2021).

NCT04900415 *{published data only}*

NCT04900415. Olfactory and neurosensory rehabilitation in COVID-19-related olfactory dysfunction [Olfactory and neurosensory rehabilitation in coronavirus 2019 (COVID-19)-related olfactory dysfunction (OD)]. Https://clinicaltrials.gov/show/NCT04900415 (first received 25 May 2021). [CENTRAL: CN-02277857]

NCT04951362 *{published data only}*

NCT04951362. Role of ivermectin nanosuspension as nasal spray in treatment of persistant post covid19 anosmia [Studying the expected effect of ivermectin nanosuspension as nasal spray upon post covid19 persistant anosmia]. https://clinicaltrials.gov/show/NCT04951362 (first received 6 July 2021). [CENTRAL: CN-02290152]

NCT04952389 *{published data only}*

NCT04952389. Acupuncture therapy for COVID-related olfactory loss. https://clinicaltrials.gov/show/NCT04952389 (first received 7 July 2021). [CENTRAL: CN-02290173]

NCT04959747 *{published data only}*

NCT04959747. Acupuncture for olfactory dysfunction in infected COVID-19 patients [Acupuncture for olfactory dysfunction in infected COVID-19 patients: a randomized, sham-controlled clinical trial]. https://clinicaltrials.gov/show/NCT04959747 (first received 13 July 2021). [CENTRAL: CN-02279670]

NCT04964414 *{published data only}*

NCT04964414. Treatment of pediatric patients that lost sense of smell due to COVID-19 [Prospective randomized study of the treatment of pediatric patients that lost sense of smell due to COVID-19]. https://clinicaltrials.gov/show/NCT04964414 (first received 16 July 2021). [CENTRAL: CN-02283179]

NCT05002530 *{published data only}*

NCT05002530. Investigating the potential role of aerosolized all-trans retinoic acid for treating COVID-19 anosmia and regaining sense of smell. https://clinicaltrials.gov/show/NCT05002530 (first received 12 August 2021).

NCT05037110 *{published data only}*

NCT05037110. Physical activity and smell trainings to help individuals with coronavirus disease (COVID-19) recover from persistent smell and taste impairments - a pilot study. https://clinicaltrials.gov/show/NCT05037110 (first received 8 September 2021).

NL9635 *{published data only}*

NL9635. Corticosteroids for COVID-19 induced loss of smell [Corticosteroids for COVID-19 induced loss of smell (COCOS trial)]. https://trialregister.nl/trial/9635 (first received 28 July 2021).

Odorat-Covid (NCT04598763) *{published data only}*

NCT04598763. Evaluation of two methods of olfactory rehabilitation in post-viral loss of smell: classic and intensive. https://clinicaltrials.gov/show/NCT04598763 (first received 22 October 2020).

SCENT2 (NCT04789499) *{published data only}*

NCT04789499. Smell in Covid-19 and efficacy of nasal theophylline. https://clinicaltrials.gov/show/NCT04789499 (first received 9 March 2021). [CENTRAL: CN-02249745]

TCTR20210714006 *{published data only}*

TCTR20210714006. Corticosteroid nasal irrigation as early treatment of olfactory dysfunction in COVID-19: a prospective randomized controlled trial. http://www.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20210714006.

UMIN000043537 *{published data only}*

UMIN000043537. Post COVID-19 anosmia [Post COVID-19 anosmia treatments - anosmia treatments]. http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000043537 (first received 5 March 2021). [CENTRAL: CN-02256500]

VOLT (NCT04710394) *{published data only}*

NCT04710394. Visual-olfactory training in participants with COVID-19 resultant loss of smell [Efficacy of bimodal visual-olfactory training in participants with COVID-19 resultant hyposmia or anosmia using participant-preferred scents]. https://clinicaltrials.gov/show/NCT04710394 (first received 14 January 2021). [CENTRAL: CN-02234021]

Additional references

Alexander 2006

Alexander TH, Davidson TM. Intranasal zinc and anosmia: the zinc-induced anosmia syndrome. *Laryngoscope* 2006;**116**(2):217-20. [DOI: 10.1097/01.mlg.0000191549.17796.13] [PMID: 16467707]

Bigman 2020

Bigman G. Age-related smell and taste impairments and vitamin D associations in the U.S. Adults National Health and Nutrition Examination Survey. *Nutrients* 2020;**12**(4):984. [DOI: 10.3390/nu12040984] [PMID: 32252288]

Bilinska 2020

Bilinska K, Butowt R. Anosmia in COVID-19: a bumpy road to establishing a cellular mechanism. *ACS Chemical Neuroscience* 2020;**11**(15):2152-5.

Boscolo-Rizzo 2020

Boscolo-Rizzo P, Borsetto D, Fabbris C, Spinato G, Frezza D, Menegaldo A, et al. Evolution of altered sense of smell or taste in patients with mildly symptomatic COVID-19. *JAMA Otolaryngology--Head & Neck Surgery* 2020;**146**(8):729-32. [PMID: 32614442]

Boscolo-Rizzo 2021

Boscolo-Rizzo P, Hummel T, Hopkins C, Dibattista M, Menini A, Spinato G, et al. High prevalence of long-term olfactory, gustatory, and chemesthesis dysfunction in post-COVID-19 patients: a matched case-control study with one-year follow-up using a comprehensive psychophysical evaluation. *Rhinology* 2021;**59**(6):517-27. [DOI: 10.4193/Rhin21.249]

Butowt 2020

Butowt R, von Bartheld CS. Anosmia in COVID-19: underlying mechanisms and assessment of an olfactory route to brain infection. Neuroscientist 2020 Sep 11 [Epub ahead of print]. [DOI: 10.1177/1073858420956905] [PMID: 32914699]

Cain 1988

Cain WS, Gent JF, Goodspeed RB, Leonard G. Evaluation of olfactory dysfunction in the Connecticut Chemosensory Clinical Research Center. *Laryngoscope* 1988;**98**(1):83-8. [PMID: 3336267]

Chary 2020

Chary E, Carsuzaa F, Trijolet J-P, Capitaine A-L, Roncato-Saberan M, Fouet K, et al. Prevalence and recovery from olfactory and gustatory dysfunctions in COVID-19 infection: a prospective multicenter study. *American Journal of Rhinology & Allergy* 2020;**34**(5):686-93. [DOI: 10.1177/1945892420930954]

Croy 2014

Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life--an updated review. *Chemical Senses* 2014;**39**(3):185-94. [DOI: 10.1093/chemse/bjt072]

Dai 2016

Dai Q, Pang Z, Yu H. Recovery of olfactory function in postviral olfactory dysfunction patients after acupuncture treatment. *Evidence-based Complementary and Alternative Medicine: eCAM* 2016;**2016**:4986034. [PMID: 27034689]

Damm 2004

Damm M, Temmel A, Welge-Lüssen A, Eckel HE, Kreft MP, Klussmann JP, et al. Olfactory dysfunctions. Epidemiology and therapy in Germany, Austria and Switzerland [Riechstörungen. Epidemiologie und Therapie in Deutschland, Osterreich und der Schweiz]. *HNO* 2004;**52**(2):112-20. [PMID: 14968312]

Derin 2016

Derin S, Koseoglu S, Sahin C, Sahan M. Effect of vitamin B12 deficiency on olfactory function. *International Forum of Allergy & Rhinology* 2016;**6**(10):1051-5. [PMID: 27119316]

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**(7109):629.

Erskine 2020

Erskine SE, Philpott CM. An unmet need: patients with smell and taste disorders. *Clinical Otolaryngology* 2020;**45**(2):197-203.

Fuccillo 2020

Fuccillo E, Saibene AM, Canevini MP, Felisati G. Olfactory disorders in coronavirus disease 2019 patients: a systematic literature review. Journal of Laryngology & Otology 2020 Sep 15 [Epub ahead of print]. [DOI: 10.1017/S0022215120002005]

Gerkin 2020

Gerkin RC, Ohla K, Veldhuizen MG, Joseph PV, Kelly CE, Bakkeet AJ, et al. The best COVID-19 predictor is recent smell loss: a cross-sectional study. https://www.medrxiv.org/content/10.1101/2020.07.22.20157263v2 2020. [DOI: 10.1101/2020.07.22.20157263]

Gudziol 2006

Gudziol V, Lötsch J, Hähner A, Zahnert T, Hummel T. Clinical significance of results from olfactory testing. *Laryngoscope* 2006;**116**(10):1858-63. [PMID: 17003712]

Handbook 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Handbook 2020

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Available from www.training.cochrane.org/handbook: Cochrane, 2020.

Hopkins 2020a

Hopkins C, Kumar N. Loss of sense of smell as a marker of COVID-19 infection. https://www.sforl.org/wp-content/uploads/2020/03/Loss-of-sense-of-smell-as-marker-of-COVID-21-Mar-2020.pdf.

Hopkins 2020b

Hopkins C, Burges Watson DL, Kelly C, Deary V, Smith BC. Managing long COVID: don't overlook olfactory dysfunction. *BMJ* 2020;**370**:m3736.

Hopkins 2020c

Hopkins C, Lechien JR, Saussez S. More that ACE2? NRP1 may play a central role in the underlying pathophysiological mechanism of olfactory dysfunction in COVID-19 and its association with enhanced survival. Medical Hypotheses 2020 Nov 20 [Epub ahead of print]. [DOI: 10.1016/j.mehy.2020.110406]

Huart 2020

Huart C, Philpott C, Konstantinidis I, Altundag A, Whitcroft KL, Trecca EMC, et al. Comparison of COVID-19 and common cold chemosensory dysfunction. *Rhinology* 2020;**58**(6):623-5. [DOI: 10.4193/Rhin20.251] [PMID: 32812014]

Hummel 2002

Hummel T, Heilmann S, Hüttenbriuk KB. Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract. *Laryngoscope* 2002;**112**(11):2076-80. [PMID: 12439184]

Hummel 2016

Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM, et al. Position paper on olfactory dysfunction. *Rhinology* 2016;**56**(1):1-30. [PMID: 28623665]

Hummel 2017

Hummel T, Whitcroft KL, Rueter G, Haehner A. Intranasal vitamin A is beneficial in post-infectious olfactory loss. *European Archives of Oto-rhino-laryngology* 2017;**274**(7):2819-25. [PMID: 28434127]

Klopfenstein 2020

Klopfenstein T, Kadiane-Oussou NJ, Toko L, Royer PY, Lepiller Q, Gendrin V, et al. Features of anosmia in COVID-19. *Medecine et Maladies Infectieuses* 2020;**50**(5):436-9. [DOI: 10.1016/j.medmal.2020.04.006]

Landis 2003

Landis BN, Hummel T, Hugentobler M, Giger R, Lacroix JS. Ratings of overall olfactory function. *Chemical Senses* 2003;**28**(8):691-4. [DOI: 10.1093/chemse/bjg061] [PMID: 14627537]

Lechien 2020

Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *European Archives of Oto-rhino-laryngology* 2020;**277**(8):2251-61. [DOI: 10.1007/s00405-020-05965-1]

Lefebvre 2020

Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-I, et al. Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al, editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020.

Lötsch 2019

Lötsch J, Hummel T. Clinical usefulness of self-rated olfactory performance-a data science-based assessment of 6000 patients. *Chemical Senses* 2019;**44**:357-64. [DOI: 10.1093/chemse/bjz029] [PMID: 31077277]

Mao 2020

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus

disease 2019 in Wuhan, China. *JAMA Neurology* 2020;**77**(6):683-90.

Marshall 2018

Marshall J, Noel-Storr AH, Kuiper J, Thomas J, Wallace BC. Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide. *Research Synthesis Methods* 2018;**9**(4):602-14.

Martineau 2020

Martineau AR, Forouhi NG. Vitamin D for COVID-19: a case to answer? *Lancet. Diabetes & Endocrinology* 2020;**8**(9):735-6. [PMID: 32758429]

Mattos 2018

Mattos JL, Schlosser RJ, Mace JC, Smith TL, Soler ZM. Establishing the minimal clinically important difference for the Questionnaire of Olfactory Disorders. *International Forum of Allergy & Rhinology* 2018;**8**(9):1041-6. [PMID: 29719139]

McDonald 2017

McDonald S, Noel-Storr AH, Thomas J. Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews. In: Global Evidence Summit; 2017 Sep 13-17; Cape Town, South Africa. 2017.

Meng 2020

Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia: a review based on up-to-date knowledge. *American Journal of Otolaryngology* 2020;**41**(5):102581.

Menni 2020

Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nature Medicine* 2020;**26**(7):1037-40. [DOI: 10.1038/s41591-020-0916-2]

Noel-Storr 2018

Noel-Storr AH. The Project Transform Team. Cochrane Crowd: new ways of working together to produce health evidence. In: Evidence Live; 2018 Jun 18-20; Oxford, UK. 2018.

Parma 2020

Parma V, Ohla K, Veldhuizen MG, Niv MY, Kelly CE, Bakke AJ, et al. More than smell - COVID-19 is associated with severe impairment of smell, taste and chemesthesis. *Chemical Senses* 2020;**45**(7):609-22. [DOI: 10.1093/chemse/bjaa041]

Pekala 2016

Pekala K, Chandra RK, Turner JH. Efficacy of olfactory training in patients with olfactory loss: a systematic review and meta-analysis. *International Forum of Allergy & Rhinology* 2016;**6**(3):299-307.

Philpott 2014

Philpott CM, Boak D. The impact of olfactory disorders in the United Kingdom. *Chemical Senses* 2014;**39**(8):711-8.

Quint 2002

Quint C, Temmel AF, Hummel T, Ehrenberger K. The quinoxaline derivative caroverine in the treatment of sensorineural smell disorders: a proof-of-concept study. *Acta Oto-Laryngologica* 2002;**122**(8):877-81. [PMID: 12542209]

Reden 2011

Reden J, Herting B, Lill K, Kern R, Hummel T. Treatment of postinfectious olfactory disorders with minocycline: a double-blind, placebo-controlled study. *Laryngoscope* 2011;**121**(3):679-82. [PMID: 21287560]

RevMan 2020 [Computer program]

The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.

Rocke 2020

Rocke J, Hopkins C, Philpott C, Kumar N. Is loss of sense of smell a diagnostic marker in COVID-19: a systematic review and meta-analysis. *Clinical Otolaryngology* 2020;**45**(6):914-22.

Saussez 2020

Saussez S, Lechien JR, Hopkins C. Anosmia: an evolution of our understanding of its importance in COVID-19 and what questions remain to be answered. European Archives of Oto-rhino-laryngology 2020 Sep 9 [Epub ahead of print]. [DOI: 10.1007/s00405-020-06285-0] [PMID: 32909060]

Seiden 2001

Seiden AM, Duncan HJ. The diagnosis of a conductive olfactory loss. *Laryngoscope* 2001;**111**(1):9-14.

Sorokowska 2017

Sorokowska A, Drechsler E, Karwowski M, Hummel T. Effects of olfactory training: a meta-analysis. *Rhinology* 2017;**55**(1):17-26. [DOI: 10.4193/Rhin16.195] [PMID: 28040824]

Spinato 2020

Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. *JAMA* 2020;**323**(20):2089-90.

Thomas 2017

Thomas J, Noel-Storr AH, Marshall I, Wallace B, McDonald S, Mavergames C, et al, Living Systematic Review Network. Living systematic reviews 2: combining human and machine effort. *Journal of Clinical Epidemiology* 2017;**91**:31-7.

Tierney 2007

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007;**8**:16.

Vaira 2021b

Vaira LA, Salzano G, Le Bon SD, Maglio A, Petrocelli M, Steffens Y, et al. Prevalence of persistent olfactory disorders in patients with COVID-19: a psychophysical case-control study with 1-year follow-up. Otolaryngology - Head and Neck Surgery 2021 Nov 23 [Epub ahead of print]. [DOI: 10.1177/01945998211061511]

Vent 2010

Vent J, Wang DW, Damm M. Effects of traditional Chinese acupuncture in post-viral olfactory dysfunction. *Otolaryngology - Head and Neck Surgery* 2010;**142**(4):505-9. [PMID: 20304268]

von Bartheld 2020

von Bartheld CS, Hagen MM, Butowt R. Prevalence of chemosensory dysfunction in COVID-19 patients: a systematic review and meta-analysis reveals significant ethnic differences. *ACS Chemical Neuroscience* 2020;**11**(19):2944-61. [DOI: 10.1021/acschemneuro.0c00460]

Wallace 2017

Wallace BC, Noel-Storr AH, Marshall IJ, Cohen AM, Smalheiser NR, et al. Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowdsourcing approach. *Journal of the American Medical Informatics Association* 2017;**24**(6):1165-8.

Webster 2022

Webster KE, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction. *Cochrane Database of Systematic Reviews* 2022, Issue 8. Art. No: CD013877. [DOI: 10.1002/14651858.CD013877.pub3]

Welge-Luessen 2005

Welge-Luessen A, Hummel T, Stojan T, Wolfensberger M. What is the correlation between ratings and measures of olfactory function in patients with olfactory loss? *American Journal of Rhinology* 2005;**19**(6):567-71. [DOI: 10.1177/194589240501900606]

References to other published versions of this review

O'Byrne 2021

O'Byrne L, Webster KE, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction. *Cochrane Database of Systematic Reviews* 2021, Issue 7. Art. No: CD013876. [DOI: 10.1002/14651858.CD013876.pub2]

Webster 2021

Webster KE, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction. *Cochrane Database of Systematic Reviews* 2021, Issue 2. Art. No: CD013876. [DOI: 10.1002/14651858.CD013876]

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies *[ordered by study ID]*

D'Ascanio 2021

Study characteristics	
Methods	Two-arm, non-blinded, single-centre, parallel-group RCT with 30 days duration of treatment and follow-up

Participants	**Location:** single centre, Italy
	
	Setting of recruitment and treatment: outpatients, study based at Santa Croce Hospital
	
	Sample size: 12
	
	• **Number randomised:** 7 to intervention, 5 to comparison
	• **Number completed:** 7 in intervention, 5 in comparison
	
	Participants:
	
	Outpatients with a history of COVID-19 and anosmia/hyposmia for at least 90 days after negative COVID-19 swab
	
	Baseline characteristics:
	
	• **Age:** reported for whole sample as 42.2 (SD 14.1) years
	• **Gender:** intervention group: 2 (28.6%) male and 5 (71.4%) female; control group: 2 (40%) male and 3 (60%) female
	• **Olfactory function at baseline**
	  ◦ Measured using Sniffin' Sticks scores
	  ◦ Intervention group: mean 21.1 (SD 5.5); control group: mean 28.8 (SD 1.2)
	
	Inclusion criteria for the study:

D'Ascanio 2021 *(Continued)*

- Outpatients
- Aged 18 to 90 years
- Confirmed history of COVID-19 (positive nasopharyngeal swab for SARS-CoV-2)
- Anosmia/hyposmia persisting ≥ 90 days after negative COVID-19 nasopharyngeal swab

Exclusion criteria for the study:

- Previous history of olfactory-gustatory disorders
- Impaired cognitive function
- History of neurodegenerative disease
- Medical therapy with possible effects on olfactory function
- Presence of rhinological disorders (sinusitis, rhinosinusitis, sinonasal polyposis, atrophic rhinitis, allergy)
- History of chemo-radiotherapy of the head and neck region
- History of stroke or neurotrauma
- Severe nasal blockage from stenosis or deformity
- Severe psychiatric illness (e.g. schizophrenia, bipolar disorder, olfactory hallucination)
- Previous sinonasal or nasopharyngeal tumours

Interventions	**Intervention group:** daily treatment with palmitoylethanolamide (PEA) 700 mg and luteolin 70 mg **Comparator group:** no intervention **Use of additional interventions:** both groups also received olfactory rehabilitation through Sniffin' Sticks, administered twice every day (10 minute session) for 30 days
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Not reported. Sniffin' Sticks were used to assess the sense of smell, but data regarding recovery (i.e. the number of participants who were normosmic at the end of the trial) were not reported Disease-related quality of life • Not assessed or reported Serious adverse effects • Not assessed or reported **Secondary outcomes:** Change in sense of smell • Change of sense of smell assessed using psychophysical testing (Sniffin' Sticks). The Sniffin' Sticks battery was administered using pen-like devices filled with odorants. Three score subtests were conducted to measure olfactory function: 1) detection threshold ("T", the lowest concentration at which an odour can be perceived), 2) odour discrimination ("D", ability to distinguish between odours) and 3) odour identification ("I" ability to assign names to odours). Possible scores ranged from 1 to 16 for the detection threshold subtest and 0 to 16 for both the discrimination and identification subtests. Adding these the subtests yielded a "Sniffin' score". Anosmia was defined as a score of < 17, hyposmia by a score of 17 to 30.75, and normosmia by a score of ≥ 31 Overall, generic quality of life • Not assessed Prevalence of parosmia

D'Ascanio 2021 *(Continued)*

- Not assessed

Other adverse effects (including nosebleeds/bloody discharge)

- Not assessed

Other outcomes reported by the study:

- Evaluated correlation between months since COVID-19 resolution (based on negative test) and Sniffin' score

Funding sources	No information provided
Declarations of interest	Authors state no conflicts of interest or disclosures
Notes	—

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "After patient counseling and consent, the physician used a computer-generated for simple randomization of patients." The text directly states that after patient counselling and consent, the physician used a computer-generated list for simple randomisation of patients.
Allocation concealment (selection bias)	Unclear risk	No information provided regarding concealment of allocation, and whether random allocation was generated at the time of recruitment or in advance.
Blinding of participants and personnel (performance bias) All outcomes	High risk	The study is described as a single-blinded randomised clinical trial. Open trial, no blinding of participants.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	When performing psychophysical testing "clinicians conducting the scoring were blinded to the treatment group of patients". Outcome assessors were blinded to group allocation.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts reported. Data were available for all participants.
Selective reporting (reporting bias)	Unclear risk	No protocol/trial registry entry is available to assess selective outcome reporting.
Other bias	High risk	Baseline imbalance noted between intervention arms: control arm had 4.6 (SD 3.6) months of smell disturbance, compared to 9.7 (SD 2.5) months for the treatment group. There was also a significant difference in baseline Sniffin' Sticks score between the 2 groups, with worse scores in the treatment arm. This may have occurred by chance, due to the small study size. However, the difference is likely to affect the results of the study.

Vaira 2021a

Study characteristics

Vaira 2021a *(Continued)*

Methods	Multicentre randomised controlled trial with 40 days of follow-up

Participants	**Location:** multicentre, Italy
	
	Setting of recruitment and treatment: University Hospital of Sassari and the Bellaria-Maggiore Hospital in Bologna (Italy)
	
	Sample size: 18
	
	• **Number randomised:** 9 to intervention, 9 to comparison
	• **Number completed:** 9 to intervention, 9 to comparison
	
	Participants:
	
	Participants with COVID-19 related anosmia for more than 30 days defined as a Connecticut Chemosensory Clinical Research Center (CCCRC) test score ≤ 40
	
	Baseline characteristics:
	
	• **Age:** intervention group: median 44.5 years (IQR 36 to 50.5); control group: median 42 years (IQR 34 to 48)
	• **Gender:** intervention group: 4 (44.44%) male and 5 (55.56%) female; control group: 3 (33.33%) male and 6 (66.67%) female
	• **Olfactory function at baseline**
	  ○ Measured using CCCRC scores
	  ■ Normal (score 90 to 100)
	  ■ Mild hyposmia (70 to 80)
	  ■ Moderate (50 to 60)
	  ■ Severe (20 to 40)
	  ■ Anosmia (0 to 10)
	• Intervention group: median 10 (IQR 15); control group: median 20 (IQR 30)
	
	Inclusion criteria for the study:
	
	• > 18 years of age
	• SARS-CoV-2 infection confirmed
	• Recovery from SARS-CoV-2 infection confirmed by at least 2 negative swabs
	• CCCRC test score ≤ 40 (i.e. anosmia or severe hyposmia) at 30 days after clinical onset
	
	Exclusion criteria for the study:
	
	• Previous olfactory dysfunction
	• Trauma
	• Nasal surgery
	• Radiation therapy in the oral or nasal cavities
	• Self-reported allergic rhinitis or rhinosinusitis
	• Psychiatric or neurological disease
	• Contraindication to corticosteroid

Interventions	**Intervention group:** systemic cortisone therapy with prednisone starting with 1 mg/kg and tapering the dose for 15 days accompanied by nasal irrigation with betamethasone, ambroxol and rinazine for 15 days **Comparator group:** the control group did not receive any therapy **Use of additional interventions:** none noted
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:**

Vaira 2021a *(Continued)*

Recovery of sense of smell

- Using psychophysical testing (CCCRC)
- The CCCRC includes a butanol threshold assessment and odour identification test; these scores are converted into CCCRC composite scores, which allows classification of patients
- Normosmia (recovery) defined as a CCCRC score of 90 to 100
- Assessed at baseline, 20 and 40 days

Disease-related quality of life

- Not assessed

Serious adverse effects

- None noted

Secondary outcomes:

Change in sense of smell

- Using psychophysical testing (CCCRC)
- The CCCRC includes a butanol threshold assessment and odour identification test; these scores are converted into CCCRC composite scores, which allows classification of patients
- Assessed at baseline, 20 and 40 days

Overall, generic quality of life

- Not assessed

Prevalence of parosmia

- Not assessed

Other adverse effects (including nosebleeds/bloody discharge)

- None noted

Other outcomes reported by the study:

- None reported

Funding sources	None reported
Declarations of interest	No conflicts of interest declared
Notes	—

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "The patients included in the study were randomly divided into two groups using a computer generated random number table" Comment: author contacted and confirmed randomisation
Allocation concealment (selection bias)	Unclear risk	No information provided Comment: author contacted; remains unclear
Blinding of participants and personnel (performance bias)	High risk	Quote: "Study was not blinded to participants. No placebo was used for the comparator group."

Vaira 2021a *(Continued)*

All outcomes		Comment: the control group did not undergo any placebo treatment
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Both the researcher who performed the pre- and post-treatment psychophysical assessment of smell and the statistician who analyzed the data were blinded to the patient allocation group" Comment: appropriate blinding performed
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: all 18 patients enrolled were followed up and outcomes reported
Selective reporting (reporting bias)	Unclear risk	Comment: no trial protocol or registration could be identified to assess this
Other bias	Low risk	Comment: no additional sources of bias detected

CCCRC: Connecticut Chemosensory Clinical Research Center
IQR: interquartile range
RCT: randomised controlled trial
SD: standard deviation

Characteristics of excluded studies *[ordered by study ID]*

Study	Reason for exclusion
Abdelalim 2021	Wrong population: all participants in the study had symptoms of olfactory disturbance for less than 4 weeks. This study is relevant for the companion review, which considers prevention of olfactory dysfunction (Webster 2022).
Abdelmaksoud 2021	Wrong population: all participants in the study had symptoms of olfactory disturbance for less than 4 weeks. This study is relevant for the companion review, which considers prevention of olfactory dysfunction (Webster 2022).
ACTION (NCT04332107)	Wrong population: study does not specifically include participants with olfactory dysfunction
Begam 2020	Narrative review article, no primary data
Bulbuloglu 2021	Wrong study design: not a randomised controlled trial
COPPS (NCT04662060)	Wrong population: study does not specifically include participants with olfactory dysfunction
Co-STAR (NCT04422275)	Study withdrawn
COVIDAtoZ (NCT04342728)	Wrong population: study does not specifically include participants with olfactory dysfunction
CTRI/2020/08/027477	Wrong population: study does not specifically include participants with olfactory dysfunction
IRCT20180205038619N2	Wrong study design: not a randomised controlled trial
IRCT20200629047953N1	Wrong study design: not a randomised controlled trial
Islek 2021	Wrong study design: not a randomised controlled trial

Study	Reason for exclusion
Kasiri 2021	Wrong population: all participants in the study had symptoms of olfactory disturbance for less than 4 weeks. This study is relevant for the companion review, which considers prevention of olfactory dysfunction (Webster 2022).
Klug 2021	The authors have confirmed that not all participants in this trial had COVID-19 related olfactory dysfunction
Le Bon 2021	Wrong study design: not a randomised controlled trial
NCT04374474	Although this study fits the inclusion criteria for the review, it was withdrawn prior to any participant enrolment
NCT04382547	Wrong study design: not a randomised controlled trial
NCT04406584	Wrong population: includes participants with any post-viral olfactory disturbance (not specifically COVID-19)
NCT04414124	Wrong population: study does not specifically include participants with olfactory dysfunction
NCT04427332	Wrong study design: observational study, not a randomised controlled trial
NCT04458519	Wrong population: study does not specifically include participants with olfactory dysfunction
NCT04474483	Wrong population: study does not specifically include participants with olfactory dysfunction
NCT04513184	Wrong population and wrong comparator: study does not specifically include participants with olfactory dysfunction; intervention is compared to intravenous dexamethasone
NCT04622891	Wrong population: study does not specifically include participants with olfactory dysfunction
NCT04662086	Wrong population: study does not specifically include participants with olfactory dysfunction
NCT04797936	Wrong population: participants are in the active phase of COVID-19 (less than 4 weeks since diagnosis). This ongoing trial may be relevant for the companion review, which considers prevention of olfactory dysfunction (Webster 2022).
NCT04806880	Wrong study design: not a randomised controlled trial
NCT04830943	Wrong study design: not a randomised controlled trial
NCT04916639	Wrong patient population: participants in this trial had nasal obstruction and rhinorrhoea, but not necessarily olfactory disturbance
Patel 2021	Letter to the editor: no primary data
Pinna 2020	Letter to the editor: no primary data
Rashid 2021	Wrong population: all participants in the study had symptoms of olfactory disturbance for less than 4 weeks. This study is relevant for the companion review, which considers prevention of olfactory dysfunction (Webster 2022).
Saussez 2021	Wrong study design: not a randomised controlled trial
Singh 2021	Wrong study design: not a randomised controlled trial

Study	Reason for exclusion
UMIN000045185	Wrong population: the authors have confirmed that all participants in the study had symptoms of olfactory disturbance for less than 4 weeks. This study is listed as an ongoing study in the companion review, which considers prevention of olfactory dysfunction (Webster 2022).
Vaira 2021c	Wrong study design: this is a letter to the Editor, and does not report any primary data
Varricchio 2021	Wrong study design: not a randomised controlled trial
Vroegop 2020	Narrative review article: no primary data
Yildiz 2021	Wrong population: all participants in the study had symptoms of olfactory disturbance for less than 4 weeks. This study is relevant for the companion review, which considers prevention of olfactory dysfunction (Webster 2022).

Characteristics of studies awaiting classification *[ordered by study ID]*

Mohamad 2021

Methods	Parallel-group randomised controlled trial
Participants	Adult participants with loss of sense of smell after COVID-19 infection **Inclusion criteria** • Aged 18 to 70 years • Anosmia after COVID-19 infection (no further details provided) **Exclusion criteria** • Nasal polyps • Fracture of the nose < 6 months before enrolment to the trial • Nasal surgery < 6 months before enrolment to the trial **Planned sample size:** estimated enrolment 40 participants
Interventions	**Intervention:** insulin fast-dissolving film containing 100 IU of insulin applied intranasally 3 times a week for 4 weeks **Comparator:** formulated bio-adhesive fast-dissolving film containing no drugs applied intranasally 3 times a week for 4 weeks
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Presence of normal olfactory function • Not reported Serious adverse effects • Not reported Change in sense of smell • Improvement in sense of smell as measured with the butanol threshold test. This test establishes smell threshold through identification of an odour (butyl alcohol) versus water. The detection

Mohamad 2021 *(Continued)*

	threshold is recorded as the concentration at which the patient correctly identifies the butanol on 5 consecutive trials. The scoring relates the patient's threshold to a normal subject population. • Measured at 4 weeks **Secondary outcomes:** Prevalence of parosmia • Not reported Change in sense of taste • Not reported Disease-related quality of life • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • No additional outcomes are reported
Notes	Trial registered in Egypt It is unclear from the description of this trial whether participants had symptoms of olfactory disturbance for at least 4 weeks from the onset of COVID-19. The duration of anosmia is reported in the publication, with a range of 2 to 10, but it is not clear whether this is days or weeks. We have attempted to contact the authors for clarification, but are awaiting a response.

Characteristics of ongoing studies *[ordered by study ID]*

COVIDORL (NCT04361474)

Study name	Trial evaluating the efficacy of local budesonide therapy in the management of hyposmia in COVID-19 patients without signs of severity (COVIDORL)
Methods	Parallel-group randomised controlled trial
Participants	Individuals with persistent hyposmia at 30 days following the onset of SARS-CoV-2 infection **Inclusion criteria for the study:** • Patients over 18 years of age • Patient with a suspected SARS-CoV-2 infection (whether or not confirmed by PCR), or contact close to a PCR-confirmed case, typical chest CT scan (unsystematised frosted glass areas predominantly sub-pleural, and at a later stage of alveolar condensation with no excavations neither nodules nor masses) or positive serology • Isolated acute hyposmia persisting at 30 days after SARS-CoV-2 symptom onset • Absence of PCR-confirmed SARS-CoV-2 carriage at the time of inclusion **Exclusion criteria for the study:** • Hypersensitivity to budesonide or any excipients of the medicine • Haemostasis disorder, or epistaxis • Oral/nasal/ophthalmic herpes virus infection • Long-term corticosteroid infection

COVIDORL (NCT04361474) *(Continued)*

- Treatment with CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone or HIV proteases)
- Respiratory signs or other symptoms of SARS-CoV-2 persisting at day 30 from the onset of infection
- Hyposmia persisting for more than 90 days after onset of symptoms
- Other causes of hyposmia revealed on interrogation or MRI

Planned sample size: estimated enrolment 120 participants

Interventions

Intervention: nasal irrigation with budesonide and physiological saline (budesonide 1 mg/2 mL diluted in 250 mL of physiological saline: 3 syringes of 20 mL in each nasal cavity, morning and evening, for 30 days

Comparator: nasal irrigation with physiological saline only: 3 syringes of 20 mL in each nasal cavity, morning and evening, for 30 days

Additional intervention to be used in both groups: olfactory training twice a day

Outcomes

Outcomes of interest in the review

Primary outcomes:

Recovery of sense of smell

- Self-reported by the participants, as a response to the question "Have you fully recovered the olfactory capacities that you had before the onset of the symptoms of COVID-19?"

Disease-related quality of life

- Not reported

Serious adverse effects

- Protocol states "evaluate the tolerance of budesonide" with a description of serious adverse events

Secondary outcomes:

Change in sense of smell

- Percentage of patients who show an improvement in sense of smell of more than 2 points on the ODORATEST score. From the protocol: ODORATEST overall score, and detection and identification subscores at 30 days.
- Measured after 30 days of treatment

Overall, generic quality of life

- Not reported

Prevalence of parosmia

- Not reported

Other adverse effects (including nosebleeds/bloody discharge)

- Protocol states "evaluate the tolerance of budesonide" with a description of serious adverse events

Other outcomes reported by the study:

- Olfactory and gustatory capacities of the patients using a self-assessment questionnaire
- Presence of inflammatory filling of the olfactory cleft on MRI or the presence of neurological damage to the olfactory bulb

COVIDORL (NCT04361474) *(Continued)*

Starting date	18 May 2020
Contact information	Mary Daval Email: mdaval@for.paris
Notes	Estimated study completion date: 25 May 2021 Trial registered in France A further extension study is planned for those who have not fully recovered by day 30, including additional budesonide for 30 days for those in the intervention arm, and starting budesonide for those in the placebo arm

IRCT20200522047542N1

Study name	Effect of inhaled corticosteroids in the treatment of anosmia in patients with COVID-19
Methods	Parallel-group randomised controlled trial
Participants	Individuals with COVID-19, confirmed by RT-PCR testing or COVID-19 IgG/IgM Rapid Test Cassette who had persistent (more than 30 days) olfactory dysfunction **Inclusion criteria:** • Aged 18 to 65 years • Patients with COVID-19 who have been referred or admitted to Qaem, Imam Reza or Shariati Hospital diagnosed with a protocol defined by the World Health Organization • Confirmed COVID-19 cases by positive RT-PCR or the COVID-19 IgG/IgM Rapid Test Cassette • Have not experienced any signs of reduced sense of smell and taste for at least 2 weeks before the onset of the first manifestation of COVID-19 • Diagnosed with hyposmia or anosmia (persisting for more than 30 days) **Exclusion criteria:** • People with certain underlying conditions, such as: Parkinson's, Alzheimer's, severe nutritional disorders, acute rhinitis, acute catarrhal sinusitis, SICA syndrome (especially after radiation), nasal mucosal congestion, for example after rhinoplasty, olfactory nerve damage in trauma, etc. • People who experienced other viral and bacterial infections simultaneously with COVID-19 • History of asthma and allergies • Refusal to participate in follow-up, provide data or withdrew consent **Planned sample size:** estimated enrolment 70 participants
Interventions	**Intervention:** • Intranasal corticosteroid spray (0.05% mometasone), 1 puff twice daily in each nostril for 4 weeks **Comparator:** • Intranasal sodium chloride spray (0.65%, Decosalin), 1 puff twice daily in each nostril for 4 weeks
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Not reported

IRCT20200522047542N1 *(Continued)*

	Disease-related quality of life • Not reported Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell • Assessed with a 10-point VAS (0 = worst, 10 = best) • Measured at day 7, 14 and 30 after treatment Overall, generic quality of life • Not reported Prevalence of parosmia • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • None reported
Starting date	18 July 2020
Contact information	Dr Masoomeh Hosseinpoor Email: drmh2018@gmail.com
Notes	Trial registered in Iran Estimated recruitment end date: 18 September 2020

IRCT20210202050231N1

Study name	Comparison of the effect of vanilla essential oil with eucalyptus essential oil on the return of olfactory sense in COVID-19 patients
Methods	Parallel-group, randomised, controlled, double-blind trial
Participants	Individuals with a positive PCR test and olfactory impairment **Inclusion criteria:** • Informed consent • Positive PCR test • No loss of sense of smell/taste in the 2 weeks preceding COVID-19 infection • Non-smoker • Living in the city • 18 years and over **Exclusion criteria:**

IRCT20210202050231N1 *(Continued)*

	• People with certain underlying conditions (such as asthma and history of allergies, Parkinson's, Alzheimer's, severe eating disorders, acute rhinitis, acute sinusitis, nasal congestion, previous rhinoplasty, traumatic nerve damage, having other viral/bacterial infections at the same time as COVID-19) • People who deal with 'thick' odours in their job, such as working with paint or acid **Planned sample size:** 84 participants
Interventions	**Intervention:** • Olfactory stimulation for 1 week with either vanilla or eucalyptus scents, using 2.5 mL of 100% pure essential oil to be inhaled every day, 6 times per day after washing the nose with 0.9% saline **Comparator:** • Placebo (no further details given)
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • UPSIT will be used to assess olfaction. Unclear whether this will be reported as 'recovery' or only as change in score. Disease-related quality of life • Not reported Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell • Assessed with UPSIT, at 1 and 2 weeks follow-up Overall, generic quality of life • Not reported Prevalence of parosmia • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • None reported
Starting date	30 April 2021
Contact information	Mohamad Ali Yadegary E-mail: ma.yadegary@gmail.com
Notes	Trial registered in Iran Estimated recruitment end date: 21 August 2021

IRCT20210202050231N1 *(Continued)*

	It is unclear if participants will have had symptoms for ≥ 4 weeks at baseline, therefore this trial may not be suitable for inclusion in this review. Further details will be obtained when the trial is published.

IRCT20210205050247N

Study name	A comparative study of the effect of olfactory training and vitamin A in the olfactory loss of patients with COVID-19
Methods	Single-centre, 3-arm, double-blind, parallel-group RCT with 12 weeks duration of treatment and follow-up
Participants	Adults with COVID-19 and olfactory disturbance for more than 2 weeks **Inclusion criteria:** • Aged between 20 and 65 years • Olfactory disturbance for more than 2 weeks • No underlying disease, including hypertension, hypo/hyperthyroidism, seizures, diabetes, asthma, Bell's palsy (No details given on COVID-19 status, but general inclusion criteria indicate that COVID-19 positive patients will be included) **Exclusion criteria:** • Patient not willing to participate • Prolonged exposure to some chemical agents (detergents) • History of head trauma • History of sinus surgery or septorhinoplasty, rhinoplasty, turbinectomy and radiation therapy • Neurodegenerative disease (e.g. Alzheimer's, Parkinson's, MS, epilepsy, seizures) • Neuropsychiatric conditions (e.g. autism, Asperger's) • Repeated use of the following drugs: metronidazole, benzocaine, clofibrate, amphotericin B, ampicillin, allopurinol, captopril, baclofen, codeine, carbamazepine and amphetamines **Estimated sample size:** 90 participants
Interventions	**Intervention group A:** Olfactory rehabilitation for 12 weeks, using a kit that includes eucalyptus, lemon, rose and dianthus scents. Participants are asked to inhale each scent twice a day for 10 seconds each time. **Intervention group B:** Olfactory rehabilitation (as above) plus vitamin A tablets (10,000 units per day) for 12 weeks **Control group:** The third group of patients will not receive any treatment intervention and these patients will be followed up for 12 weeks
Outcomes	**Outcomes of interest in the review** **Primary outcomes:** Recovery of sense of smell • Clinical recovery. Reported at 12 weeks using the Clinical Global Impression Severity (CGI-S) scale. Unclear whether this will be reported as a dichotomous outcome. Disease-related quality of life

IRCT20210205050247N *(Continued)*

- Olfactory Dysfunction Outcomes Rating (ODOR) at 12 weeks using pre and post test questionnaires. Unclear whether this questionnaire assesses disease-related quality of life.

Serious adverse effects

- Not reported

Secondary outcomes:

Change in sense of smell

- Primary outcome reported as smell identification, using the 4 scents in the olfactory rehabilitation kit
- Secondary outcomes include Olfactory Dysfunction Outcomes Rating (ODOR) questionnaire
- Unclear which of these assesses change in sense of smell

Overall, generic quality of life

- Not reported

Prevalence of parosmia

- Not reported

Other adverse effects (including nosebleeds/bloody discharge)

- Not reported

Other outcomes reported by the study:

- No additional outcomes

Starting date	18 February 2021
Contact information	Abolfazi Taheri Email: abolfzl.taheri@gmail.com
Notes	Study registered in Iran Anticipated study completion date 21 June 2021 It is unclear if participants will have had symptoms for ≥ 4 weeks at baseline, therefore this study may not be suitable for inclusion in this review. Further details will be obtained when the study is published.

IRCT20210311050671N1

Study name	Effect of auricular acupuncture with the laser in post-viral anosmia during the COVID-19 pandemic
Methods	Two-arm, single-blinded, single-centre, parallel-group RCT with 12 weeks duration of treatment and follow-up
Participants	Participants with COVID-19 and olfactory dysfunction for at least 1 month **Inclusion criteria:** • Definite diagnosis of COVID-19 • Olfactory disorder (anosmia) • No improvement within 1 month

IRCT20210311050671N1 *(Continued)*

	Exclusion criteria: • History of surgery or head trauma • Chronic and severe inflammatory diseases • Degenerative diseases • Nasal allergies • Abnormal anatomy of the nose **Estimated sample size:** 90 participants
Interventions	**Intervention group:** Acupuncture will be performed in 2 sessions with an interval of 1 week. Each session will last for 20 minutes. **Control group:** "Laser-off acupuncture" will be used as a placebo **Use of additional interventions in both group;** Both groups will received betamethasone drops (no further information is provided)
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Described as "the percentage of people with a reduced sense of smell", according to psychophysical testing using the 24-item Iranian olfactory test (no further details provided) Disease-related quality of life • Not assessed Serious adverse effects • Not assessed **Secondary outcomes:** Change in sense of smell • Not assessed Overall, generic quality of life • Not assessed Prevalence of parosmia • Not assessed Other adverse effects (including nosebleeds/bloody discharge) • Not assessed **Other outcomes reported by the study:** • None reported
Starting date	4 April 2021
Contact information	Alireza Mohebbi

IRCT20210311050671N1 *(Continued)*

	Email: mohebbi.ar@iums.ac.ir
Notes	Registered in Iran Estimated study completion date 6 July 2021 It is unclear if participants will have had symptoms for ≥ 4 weeks at baseline, therefore this study may not be suitable for inclusion in this review. Further details will be obtained when the study is published.

IRCT20210708051817N1

Study name	Whole body cryotherapy (WBC) for treating anosmia / hyposmia
Methods	Parallel-group randomised controlled trial
Participants	Individuals who had recovered from COVID-19 with residual anosmia or severe hyposmia **Inclusion criteria:** • Recovered COVID-19 patients (asymptomatic for at least 3 weeks) • Anosmia or severe hyposmia (more than 50% reduction of olfactory acuity - method of assessment not described) • Aged 18 to 79 years **Exclusion criteria:** • Medical contraindications to whole body cryotherapy **Planned sample size:** target sample size 42 participants, actual sample size reached 45 participants
Interventions	**Intervention:** Whole body cryotherapy administered in a cryotherapy chamber at a temperature of -90°C for 3 minutes per day for either 2 days (low-dose group) or 5 days (high-dose group) **Comparator:** No intervention
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Not reported Disease-related quality of life • Not reported Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell

IRCT20210708051817N1 *(Continued)*

- Assessed with a 100-point VAS (0 = complete loss of sense of smell, 100 = full recovery)
- Measured the day following the intervention

Overall, generic quality of life

- Not reported

Prevalence of parosmia

- Not reported

Other adverse effects (including nosebleeds/bloody discharge)

- Not reported

Other outcomes reported by the study:

- None reported

Starting date	1 February 2021
Contact information	Fabien Legrand Email: fabien.legrand@univ-reims.fr
Notes	Trial registered in France Trial completion date 1 May 2021

NCT04495816

Study name	Randomised control trial of omega-3 fatty acid supplementation for the treatment of COVID-19 related olfactory dysfunction
Methods	Parallel-group randomised controlled trial
Participants	Adults with self-reported new onset olfactory dysfunction and COVID-19 infection **Inclusion criteria:** • Adults (18 years of age or older) with self-reported new onset olfactory dysfunction • Positive COVID-19 diagnosis **Exclusion criteria:** • Patients who are less than 18 years of age • Patients without a positive COVID-19 PCR result, obtained through nasopharyngeal swab • Patients with COVID-19 diagnosis, but without self-reported anosmia • Patients with severe COVID-19 disease, as defined by the Mount Sinai Health System (requiring high flow nasal cannula, nonrebreather, CPAP/BiPAP, mechanical ventilation, pressor medication or evidence of end-organ damage) • Pre-existing self-reported olfactory dysfunction • History of chronic nasal/sinus infections (rhinosinusitis) or history of endoscopic sinus surgery • Use of nasal steroid sprays or irrigations for any reason • Prisoners of the state • Presence of psychiatric or developmental conditions that may impair the ability to provide informed consent

NCT04495816 *(Continued)*

	• Allergy to fish or omega-3 supplements, or do not eat fish/fish-containing substances for any reason **Planned sample size:** estimated enrolment 126 participants (from clinical trial register). Additional publication states estimated sample size of 176 (88 per group).
Interventions	**Intervention:** omega-3 fatty acid, 1000 mg (administered as 2 soft gels, containing 683 mg eicosapentaenoic acid and 252 mg docosahexaenoic acid) twice daily for 6 weeks **Comparator:** placebo (administered as 2 placebo soft gels) twice daily for 6 weeks
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Not reported Disease-related quality of life • Assessed with the mQOD-NS. This is a 17-item instrument: each item is graded 0 to 3, with a total score range of 0 to 51. Higher scores indicate better olfactory-specific quality of life. • Measured at 1 week, 2 weeks, 4 weeks and 6 weeks after initiation of treatment Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell • Assessed with the BSIT (psychophysical testing). This is a 12-item instrument, with a total score range of 0 to 12. Higher scores indicate better olfactory performance. • Measured at 6 weeks after initiation of treatment Overall, generic quality of life • Not reported Prevalence of parosmia • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • SNOT-22. This is a 22-item instrument, with a total range of 0 to 110. Higher scores indicate more severe quality of life impact. It was designed to address the burden of symptoms of chronic rhinosinusitis, rather than anosmia or hyposmia. It will be measured at 1, 2, 4 and 6 weeks after initiation of treatment.
Starting date	15 July 2020
Contact information	Alfred-Marc Iloreta Email: alfred-marc.iloreta@mountsinai.org
Notes	Estimated study completion date: June 2021

NCT04495816 *(Continued)*

	It is unclear from the description of this trial whether participants will have symptoms of olfactory disturbance for longer than 4 weeks from the onset of COVID-19. Correspondence with the study team has confirmed that they will recruit a mixed population, comprising individuals with fewer than and longer than 4 weeks of symptoms.

NCT04528329

Study name	Anosmia and/or ageusia and early corticosteroid use
Methods	Randomised controlled trial
Participants	Adult participants with mild to moderate severity COVID-19 **Inclusion** • Diagnosis of COVID-19 • ≥ 18 years of age • Mild to moderate severity **Exclusion** • Diabetes • Contraindication to dexamethasone • Mental disability **Planned sample size:** 300 participants
Interventions	**Intervention:** "Early dexamethasone use as early as confirmation of inflammation" **Comparator:** "Late dexamethasone use as soon as deterioration"
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Time to recovery from anosmia (no further details provided) Disease-related quality of life • Not reported Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell • Not reported Overall, generic quality of life • Not reported Prevalence of parosmia • Not reported

NCT04528329 *(Continued)*

	Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • None reported
Starting date	30 August 2020
Contact information	Emad R Issak Email: dr.emad.r.h.issak@gmail.com
Notes	Estimated study completion date: 15 December 2020 Trial registered in Egypt **Uncertainty over future inclusion in the review:** It is not clear from the description provided whether participants will all have olfactory dysfunction at baseline and, if so, whether they will have ≥ 4 weeks of olfactory dysfunction. We are awaiting confirmation from the study authors.

NCT04530409

Study name	Timing of corticosteroids in COVID-19
Methods	Randomised controlled trial
Participants	Adult participants with mild or moderate COVID-19 **Included** • Any case with COVID-19 more than or equal to 18 years • Mild and moderate severity **Excluded** • Any contraindication to steroids • Mental disability **Planned sample size:** 450 patients
Interventions	**Intervention:** "Early dexamethasone use as early as confirmation of inflammation" **Comparator:** "Late dexamethasone use as soon as deterioration"
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Time to recovery from anosmia (no further details provided) Disease-related quality of life • Not reported Serious adverse effects

NCT04530409 *(Continued)*

- Not reported

Secondary outcomes:

Change in sense of smell

- Not reported

Overall, generic quality of life

- Not reported

Prevalence of parosmia

- Not reported

Other adverse effects (including nosebleeds/bloody discharge)

- Not reported

Other outcomes reported by the study:

Primary outcomes:

- Percentage of cases that will need hospitalisation
- Percentage of cases that deteriorate to acute respiratory distress syndrome

Secondary outcomes:

- Percentage of cases with increased d-dimer
- Time to recovery of diarrhoea
- Percentage reduction in CRP
- Percentage reduction in LDH
- Percentage reduction in ALT
- Percentage reduction in ferritin
- Time to recovery of lymphopenia
- Time to recovery of cough
- Time to recovery of fever
- Time to recovery of myalgia
- Time to recovery of dyspnoea

Starting date	26 August 2020
Contact information	Emad R Issak Email: dr.emad.r.h.issak@gmail.com
Notes	Estimated study completion date: 1 December 2020 Trial registered in Egypt **Uncertainty over future inclusion in the review:** It is not clear from the description provided whether participants will all have olfactory dysfunction at baseline and, if so, whether they will have ≥ 4 weeks of olfactory dysfunction.

NCT04638673

Study name	NeuroCovid rehab and recovery related to COVID-19 diagnosis

NCT04638673 *(Continued)*

Methods	To evaluate a transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of the neurological symptoms of COVID-19 termed NEUROCOVID
Participants	Patients with COVID-19 suffering from the neurological symptoms associated with infection **Inclusion criteria:** • COVID-positive • At home • Afebrile • Anxiety • Depression • Vertigo • Anosmia • Headaches • Irritability • Cognitive processing **Exclusion criteria:** • Damage to left ear anatomy • Unstable haemodynamic effects • Ischaemic or haemorrhagic stroke after developing COVID • Unable to give consent, follow instructions • Unable to read or write or speak English • No access to home WiFi **Planned sample size:** estimated enrolment 30 participants
Interventions	**Intervention group** Active-Active Stimulation Group • Participants will receive active taVNS stimulation for weeks 1 to 4 of the stimulation portion of this study using Soterix taVNS model 0125-LTE **Comparator Group** Sham-Active Stimulation Group • Participants will receive sham taVNS stimulation for weeks 1 and 2 and active stimulation for weeks 3 and 4 of the stimulation portion of this study

Outcomes	**Outcomes of interest in the review:**
	
	Primary outcomes:
	
	Recovery of sense of smell
	
	• Not reported
	
	Disease-related quality of life
	
	• The primary outcome was change in score of Patient Health Questionnaire-9 from baseline to week 4 (end of treatment)
	• The PPHQ-9 is a 9-question instrument given to patients in a primary care setting to screen for the presence and severity of depression. Scores range from 0 to 27. Higher scores mean worse symptoms. For the purpose of this study:
	  ○ remission: minimal to absence of symptoms; PHQ-9 score < 5;
	  ○ response: 50% or greater decrease in PHQ-9 baseline severity; residual symptoms remain;

NCT04638673 *(Continued)*

- partial response: 26% to 49% decrease in PHQ-9 baseline severity;
- non-response: less than 25% decrease in PHQ-9 baseline severity.

Serious adverse effects

- Not reported

Secondary outcomes:

Change in sense of smell

- Not reported

Overall, generic quality of life

- Not reported

Prevalence of parosmia

- Not reported

Other adverse effects (including nosebleeds/bloody discharge)

- Not reported

Other outcomes reported by the study:

- None reported

Starting date	19 November 2020
Contact information	Sarah Huffman Email: huffmans@musc.edu Morgan Dancy Email: maddoxm@musc.edu
Notes	Estimated study completion date: June 2021 Trial registered in USA **Uncertainty over future inclusion in the review:** It is not clear from the description provided whether participants will all have olfactory dysfunction at baseline and, if so, whether they will have had ≥ 4 weeks of olfactory dysfunction. We are awaiting confirmation from the study authors.

NCT04764981

Study name	Olfactory training for olfactory dysfunction after coronavirus disease - 19 (COVID-19)
Methods	Two-arm, unblinded, single-centre, parallel-group RCT with 3 months duration of treatment and follow-up NB trial registry states double-blinded, but no intervention used in comparator group, therefore must be unblinded to participants
Participants	Individuals with persistent olfactory dysfunction following COVID-19. Duration of dysfunction unclear. **Inclusion criteria:**

NCT04764981 *(Continued)*

- Confirmed diagnosis of COVID-19 by real-time polymerase chain reaction for SARS-CoV-2 or serological tests for SARS-CoV-2 antigens
- Olfactory dysfunction confirmed by Connecticut Chemosensory Clinical Research Test (CCCRC-T)

Exclusion criteria:

- Smokers
- Individuals with diagnosed rhinitis
- Individuals with diagnosed neurological diseases
- Individuals undergoing brain surgery
- Previous history of hyposmia and/or anosmia
- Pregnancy
- Allergy to any of the substances present in the olfactory test kit
- Individuals who are undergoing another treatment for olfactory dysfunction

Estimated sample size: 300 participants (additional 50 healthy controls will be recruited for a separate study arm)

Interventions	**Intervention group:** Olfactory training: 4 odours (rose, eucalyptus, lemon and cloves), twice-daily training for 30 seconds per odour for a total of 3 months **Control group:** No intervention
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • CCCRT olfactory test will be used to assess olfactory function, and classify individuals as having normosmia Disease-related quality of life • Not reported Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell • CCCRT olfactory test will be used to assess olfactory function. An olfactory function score (0 = worst score, 7 = best score) will also be assessed. It is unclear whether these will be reported as dichotomous or continuous outcomes. Overall, generic quality of life • Not reported Prevalence of parosmia • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported

NCT04764981 *(Continued)*

	Other outcomes reported by the study: • MRI of the olfactory bulb.
Starting date	May 2021
Contact information	Alna Carolina Mendes Parahnos; no contact details provided
Notes	Registered in Brazil Estimated study completion date 1 May 2024 It is unclear if participants will have had symptoms for ≥ 4 weeks at baseline, therefore this study may not be suitable for inclusion in this review. Further details will be obtained when the study is published.

NCT04853836

Study name	Olfactory disfunction and Co-ultraPEALut
Methods	Parallel-group randomised controlled trial
Participants	Individuals with persistent hyposmia at ≥ 90 days following the onset of SARS-CoV-2 infection **Inclusion criteria for the study:** • Patients aged 18 to 90 years old • Confirmed history of COVID-19 (positive nasopharyngeal swab for SARS-CoV-2) • Subjective olfactory dysfunction persisting for ≥ 90 days after follow-up negative COVID-19 swab **Exclusion criteria for the study:** • Previous history of olfactory/gustatory disorders • Impaired cognitive function • History of neurodegenerative disease • Medical therapy with possible effects on olfactory function • Presence of rhinological disorders (sinusitis, rhinosinusitis, sinonasal polyposis, atrophic rhinitis, allergy) • History of chemo-radiotherapy of head and neck region • History of stroke or neurotrauma • Severe nasal blockage from stenosis or deformity • Severe psychiatric illness • Nasopharyngeal tumours **Planned sample size:** 200 participants
Interventions	**Intervention:** 700 mg palmitoylethanolamide and 70 mg luteolin daily. Duration of treatment is not reported, but follow-up will be up to 90 days. **Comparator:** no intervention **Additional intervention to be used in both groups:** olfactory training twice a day for 10 minutes, using Sniffin' Sticks
Outcomes	**Outcomes of interest in the review** **Primary outcomes:**

NCT04853836 *(Continued)*

Recovery of sense of smell

- States that Sniffin' Sticks will be used, but reports that this will be assessed as a continuous outcome. Unclear if dichotomous data on the number of participants who recover will be reported. Normosmia was defined with a score of ≥ 31.

Disease-related quality of life

- Not reported

Serious adverse effects

- Not reported

Secondary outcomes:

Change in sense of smell

- Assessed using Sniffin' Sticks score at 30, 60 and 90 days, using change from baseline measures

Overall, generic quality of life

- Not reported

Prevalence of parosmia

- States that parosmia after treatment will be assessed at 60 and 90 days. No details on measurement method, and description states "prevalence of anosmia among the groups", therefore unclear if anosmia or parosmia will be assessed.

Other adverse effects (including nosebleeds/bloody discharge)

- Not reported

Other outcomes reported by the study:

- None reported

Starting date	15 November 2020
Contact information	No contact details provided
Notes	Estimated study completion date: 1 October 2021 Trial registered in Italy

NCT04900415

Study name	Olfactory and neurosensory rehabilitation in COVID-19-related olfactory dysfunction
Methods	3-arm, open-label, parallel-group RCT with 4 weeks of treatment and follow-up
Participants	Adult participants with persisting olfactory dysfunction following confirmed COVID-19 **Inclusion criteria:** • Aged ≥ 18 years • Previous diagnosis of COVID-19 with laboratory confirmation • Subjective complaint of persisting olfactory disturbance • Confirmed olfactory dysfunction using butanol threshold test or smell identification test • Written, informed consent

NCT04900415 *(Continued)*

- Available to complete the study and comply with study procedures

Exclusion criteria:

- Inability to comprehend and follow study procedures
- Allergy or severe reaction to the study drug or smell training
- Pregnant or breastfeeding women
- Other causes of olfactory dysfunction (e.g. nasal polyps, anatomical malformations)
- Received an experimental agent within 1 month, or expect to receive one during the study period
- Any condition that may interfere with successful completion of the study

Estimated sample size: planned enrollment 25 participants

Interventions	**Intervention group A** Vitamin A 7500 µg plus smell training 3 times per day for 4 weeks **Intervention group B** Smell training 3 times per day for 4 weeks **Comparator:** No intervention
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Olfactory assessment using the butanol threshold test and the smell identification test at 4 weeks. Unclear whether these will be reported as dichotomous or continuous outcomes. Disease-related quality of life • Not reported Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell • Olfactory assessment using the butanol threshold test and the smell identification test at 4 weeks. Unclear whether these will be reported as dichotomous or continuous outcomes. Overall, generic quality of life • Not reported Prevalence of parosmia • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • Subjective olfactory assessment using SNOT-22 • Neuroradiological changes assessed using MRI

NCT04900415 *(Continued)*

Starting date	22 July 2020
Contact information	Ivan Fan Ngai Hung Email: ivanhung@hku.hk
Notes	Registered in Hong Kong Estimated study completion 30 June 2021 It is unclear if participants will have had symptoms for ≥ 4 weeks at baseline, therefore this study may not be suitable for inclusion in this review. Further details will be obtained when the study is published.

NCT04951362

Study name	Role of ivermectin nanosuspension as nasal spray in treatment of persistant post covid19 anosmia
Methods	Two-arm, open-label, parallel-group RCT with 14 days duration of treatment and follow-up
Participants	Adults with anosmia following COVID-19 **Inclusion criteria:** • Post COVID-19 anosmia • Negative swab for COVID-19 **Exclusion criteria:** • Other types of anosmia • No local or central other causes of anosmia • Active COVID-19 (positive swab test) **Estimated sample size:** 117 participants
Interventions	**Intervention group:** Ivermectin (and corticosteroid?) nanosuspension nasal spray. Unclear whether corticosteroid is co-administered with the ivermectin spray. **Comparator group:** Saline nasal spray
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Regaining of sense of smell; method of assessment not reported; time frame: 14 days Disease-related quality of life • Not reported Serious adverse effects • Not reported **Secondary outcomes:**

NCT04951362 *(Continued)*

	Change in sense of smell • Not reported Overall, generic quality of life • Not reported Prevalence of parosmia • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • None reported
Starting date	20 April 2021
Contact information	Zaky Aref Email: doctor.aref@hotmail.com
Notes	Trial registered in Egypt Estimated study completion 12 September 2021 It is unclear if participants will have had symptoms for ≥ 4 weeks at baseline, therefore this study may not be suitable for inclusion in this review. Further details will be obtained when the study is published.

NCT04952389

Study name	Acupuncture therapy for COVID-related olfactory loss
Methods	Two-arm, open-label, parallel-group RCT with 5 weeks duration of treatment and a further 7 weeks of follow-up
Participants	Adult participants with post-viral olfactory dysfunction for over 4 weeks and a history of COVID-19 **Inclusion criteria:** • Aged 18 years or older • Post-viral olfactory dysfunction for > 4 weeks • History of positive COVID-19 PCR **Exclusion criteria:** • Active sinus infection • New diagnosis of untreated chronic rhinosinusitis • Prior diagnosis of dementia or Parkinson's disease • Prior head trauma or neurosurgical procedure resulting in olfactory loss • Patients who do not speak or read English • Patients unable to understand and sign the study consent **Planned sample size:** 100 participants
Interventions	**Intervention group:**

NCT04952389 *(Continued)*

	Participants will undergo 10 sessions of acupuncture therapy with a licensed acupuncturist; 2 treatments per week for 5 weeks **Comparator:** No intervention **Use of additional interventions in both groups:** Both groups will receive twice daily rinses with budesonide plus olfactory training with 4 essential oils (rose, lemon clove and eucalyptus) twice a day for 20 seconds each, following the steroid rinse
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Change in patient-reported subjective olfactory loss, measured by a 10-point visual analogue scale with 0 = no sense of smell and 10 = normal sense of smell • Change in UPSIT scores • Both outcomes measured at approximately 12 weeks. Unclear whether these will be reported as dichotomous or continuous outcomes. Disease-related quality of life • Not reported Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell • Change in patient-reported subjective olfactory loss, measured by a 10-point visual analogue scale with 0 = no sense of smell and 10 = normal sense of smell • Change in UPSIT scores • Both outcomes measured at approximately 12 weeks. Unclear whether these will be reported as dichotomous or continuous outcomes. Overall, generic quality of life • Not reported Prevalence of parosmia • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • Change in SNOT-22 score, measured at 12 weeks
Starting date	October 2021
Contact information	Janalee Stokken, no contact details provided
Notes	Registered in USA

NCT04952389 *(Continued)*

	Estimated completion date August 2023

NCT04959747

Study name	Acupuncture for olfactory dysfunction in infected COVID-19 patients
Methods	Two-arm, single-blinded (to the participant), cross-over RCT with 4 weeks duration of treatment, followed by 2 weeks of follow-up, then cross-over to the opposite group
Participants	Adult participants, with moderate to severe olfactory dysfunction following COVID-19 **Inclusion criteria:** • Previously diagnosed with COVID-19 • Post-COVID-19 olfactory dysfunction with moderate to severe symptoms (based on UPSIT score of ≤ 29.5 for males and ≤ 30.5 for females) • Have not undergone treatment for olfactory dysfunction, no history of trauma, injury or surgery to the head or nose, nor any bleeding from the nose • Aged 18 to 80 years and able to read and write Chinese **Exclusion criteria:** • Olfactory or gustatory dysfunction before the pandemic • Chronic rhinosinusitis or nasal polyposis • Previous nasal surgery • Pregnant or breastfeeding women • Cancers, neurological disorders (e.g. Alzheimer's or Parkinson's) or other serious medical conditions • Unstable medical conditions • In receipt of acupuncture treatment within 1 month • Alcoholism or drug abuse in the past year • Needle phobic • History of severe adverse reaction to acupuncture **Estimated sample size:** 20 participants
Interventions	**Intervention group:** Body acupuncture will involve 8 acupoints as Yingxiang (LI20), Shangxing (GV23), BiTong, Yintang, Hegu. A disposable acupuncture needle (0.25 mm in diameter and 25 mm to 30 mm in length) will be inserted at a depth of 10 mm to 25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straight into face/body acupuncture points (Yingxiang, BiTong, Hegu). Electro-acupuncture will be applied to the face points at fast and dispersed waves through an electric needle stimulator for 30 minutes. Participants will undergo a total of 8 sessions, 30 minutes per session, delivered twice per week over a 4-week period. **Comparator group:** Sham control. Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2"/0.30 x 30 mm) will be applied to serve as sham control at the same acupuncture points.
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • UPSIT score (range 0 to 40) will be used; unclear if this will be reported as a dichotomous or continuous outcome; time frame: 14 weeks

NCT04959747 *(Continued)*

- Assessment of Subjective Olfactory function Tool (ASOF) will be used to assess olfactory capability and quality of life. This includes a 0 to 10 VAS score of subjective olfactory capability (0 = unable to smell, 10 = best possible sense of smell). It also includes a 5-item assessment of ability to detect odours (5 different odour scenarios, each rated 1 to 5, higher scores = better, summed score is a simple average). Unclear if this will be reported as a continuous or dichotomous outcome.

Disease-related quality of life

- Assessment of Subjective Olfactory function Tool (ASOF) will be used to assess olfactory capability and quality of life. This includes a 6-item assessment of impairment due to problems with olfaction (6 different situations, each rated 1 to 5, higher scores = better, summed score is a simple average).
- The short version of the QOD-NS will also be used; 7 items, each scored 0 to 3, total score range 0 to 21, higher scores = better.

Serious adverse effects

- Not reported

Secondary outcomes:

Change in sense of smell

- UPSIT score (range 0 to 40) will be used; unclear if this will be reported as a dichotomous or continuous outcome; time frame: 14 weeks
- Assessment of Subjective Olfactory Function tool (ASOF) will be used to assess olfactory capability and quality of life. This includes a 0 to 10 VAS score of subjective olfactory capability (0 = unable to smell, 10 = best possible sense of smell). It also includes a 5-item assessment of ability to detect odours (5 different odour scenarios, each rated 1 to 5, higher scores = better, summed score is a simple average). Unclear if this will be reported as a continuous or dichotomous outcome.

Overall, generic quality of life

- Not reported

Prevalence of parosmia

- Not reported

Other adverse effects (including nosebleeds/bloody discharge)

- Not reported

Other outcomes reported by the study:

- None reported

Starting date	1 August 2021
Contact information	Linda Zhong Email: ldzhong0305@gmail.com
Notes	Trial registered in Hong Kong Estimated study completion date 30 September 2022 It is unclear if participants will have had symptoms for ≥ 4 weeks at baseline, therefore this study may not be suitable for inclusion in this review. Further details will be obtained when the study is published.

NCT04964414

Study name	Treatment of pediatric patients that lost sense of smell due to COVID-19
Methods	Two-arm, open-label, parallel-group RCT with 8 weeks duration of treatment and follow-up
Participants	Children and young adults with olfactory dysfunction thought to have occurred due to COVID-19 **Inclusion criteria:** • Aged 6 to 21 years • Anosmia or dysosmia thought to have occurred due to COVID-19 • Able to complete the UPSIT, self-report their loss of sense of smell and carry out the assigned daily therapy **Exclusion criteria:** • Duration of anosmia or dysosmia < 60 days • Previous smell retraining • Prior interventions for loss of smell (excluding those on Flonase and azelastine) • Contraindications for nasal budesonide treatment, as determined by the treating physician • Active cigarette smoker or use of vapes • Previous head trauma • Congenital anosmia • History of brain tumour • Neurocognitive disorders • Multiple sclerosis • Seizure disorder • Cystic fibrosis • Primary ciliary dyskinesia • History of nasal polyps • Inability to self-report **Estimated sample size:** 60 participants
Interventions	**Intervention group:** Nasal irrigation with 0.5 mg/2 mL budesonide once daily **Comparator group:** No intervention **Use of additional interventions in both groups:** Both groups will carry out olfactory training using household scented items. Each week, participants will choose 4 scents. They will smell each item for 15 seconds very close to the nose, once per day.
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Change in self-rated loss of sense of smell on a scale of 0 to 10, 0 = no loss, 10 = total loss. Reported at 8 to 12 weeks. Unclear if this will be reported as a dichotomous outcome. • Unclear whether UPSIT score will also be reported as a dichotomous outcome. Disease-related quality of life • Not reported

NCT04964414 *(Continued)*

	Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell • Change in UPSIT score from baseline to first follow up, and to 6 months and 12 months. Change in self-rated loss of sense of smell on a scale of 0 to 10, 0 = no loss, 10 = total loss. Reported at 8 to 12 weeks. Overall, generic quality of life • Not reported Prevalence of parosmia • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • Change in loss of taste from baseline to first follow-up • Change in SNOT-22 score at 8 to 12 weeks, 6 months and 12 months • Change in anxiety question score from baseline to first follow-up
Starting date	September 2021
Contact information	Jennifer L McCoy Email: nelsonjl2@upmc.edu Amber D Shaffer Email: shafferad@upmc.edu
Notes	Trial registered in the USA Estimated completion date December 2024 It is unclear if participants will have had symptoms for ≥ 4 weeks at baseline, therefore this study may not be suitable for inclusion in this review. Further details will be obtained when the study is published.

NCT05002530

Study name	Investigating the potential role of aerosolized all-trans retinoic acid for treating COVID-19 anosmia and regaining sense of smell
Methods	Parallel-group, open-label randomised controlled trial
Participants	People with a confirmed case of COVID-19 (positive PCR) who have now recovered from COVID-19 **Inclusion criteria:** • Adults 18 years or older • Confirmed case (positive PCR) • Recovered/discharged (2 negative PCR)

NCT05002530 *(Continued)*

- Suffered from sudden recent anosmia or hyposmia

Exclusion criteria:

- Patients < 18 years of age
- Patients who are unable to provide informed consent
- Anosmia improved before COVID-19 recovery
- Pregnancy
- Patients who will not complete the follow-up period
- Patients with severe COVID-19 disease as defined by the Mouth Sinai Health System Treatment Guidelines for SARS-COV-2 (requiring high flow nasal cannula, nonrebreather, CPAP/BiPAP, or mechanical ventilation OR patients requiring pressor medication OR patients with evidence of end organ damage)
- Patients with pre-existing self-reported olfactory dysfunction
- Patients with a history of chronic nasal/sinus infections (rhinosinusitis) or history of endoscopic sinus surgery
- Hypercholesterolaemia
- Hypertriglyceridaemia
- Patients using nasal steroid sprays or irrigations for any reason
- Patients who are prisoners of the state
- Patients who have psychiatric or developmental disorder conditions that may impair ability to provide informed consent
- Permanent blindness in one eye
- History of iritis, endophthalmitis, scleral inflammation or retinitis 15 to 90 days of retinal detachment or eye surgery
- The competent physician considered it inappropriate to participate in the study

Planned sample size: 10,000 participants*

*as this sample size is considerably larger than all other studies in this review, and the recruitment period is extremely short (2 months), we have attempted to contact the authors and confirm if this is correct.

Interventions

Intervention:

Aerosolised 13 cis retinoic acid or all trans retinoic acid plus vitamin D (2 intervention groups). Retinoic acid therapy will be delivered as an inhalation in 2 divided doses, increasing from 0.2 mg/kg/day to 4 mg/kg/day for 3 weeks. Vitamin D will be administered as an intramuscular injection of 600,000 units for 2 doses given at week 0 and week 4.

Comparator:

Standard therapy

Outcomes

Outcomes of interest in the review:

Primary outcomes:

Recovery of sense of smell

- A VAS score will be used to assess olfaction, rated from 0 (total loss of smell) to 10 (completely normal smell sensation). It is unclear whether this will be reported as recovery, i.e. the number of participants who have a score of 10 at follow-up.

Disease-related quality of life

- The Modified Brief Questionnaire of Olfactory Dysfunction - negative statements will be used at 1, 2, 4 and 6 weeks of follow-up

Serious adverse effects

NCT05002530 *(Continued)*

	• Assessed at 3 weeks of follow-up **Secondary outcomes:** Change in sense of smell • A VAS score will be used to assess olfaction, rated from 0 (total loss of smell) to 10 (completely normal smell sensation) Overall, generic quality of life • Not reported Prevalence of parosmia • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • SNOT-22 at 1, 2, 4 and 6 weeks • Angiotensin converting enzyme expression in lungs and olfactory region • STRA6 expression in lungs and olfactory region • Retinoic acid blood levels • IL-6 blood levels
Starting date	November 2021
Contact information	Mahmoud R Mahmoud Email: mahmoudramadan2051@yahoo.com Tamer Haydara Email: tamerhaydara@yahoo.com
Notes	Estimated trial end date December 2021 Registration from Egypt, but multi-centre trial based in Saudi Arabia, China, USA and Egypt. Note the very large sample size and short duration of the trial (2 months) - we have contacted the trial authors for clarification on this. Also, we note that the outcomes report the use of softgels (some outcomes are described as being "1 week after softgel initiation". This is not described as part of the intervention. It is unclear if participants will have had symptoms for ≥ 4 weeks at baseline, therefore this study may not be suitable for inclusion in this review. Further details will be obtained when the study is published.

NCT05037110

Study name	Physical activity and smell trainings to help individuals with coronavirus disease (COVID-19) recover from persistent smell and taste impairments - a pilot study
Methods	Parallel-group, open-label, randomised controlled trial

NCT05037110 *(Continued)*

Participants	People with persistent problems with their sense of smell and/or taste for at least 3 months following recovery from COVID-19 **Inclusion criteria:** • Aged ≥ 18 years • COVID-19 diagnosed by laboratory tests • Recovered from COVID-19 • Persistent problems with sense of smell and/or taste for at least 3 months • Access to a computer and internet connection, and a smart phone • Living in Canada **Exclusion criteria:** • Do 150 minutes or more of physical activity that makes you out of breath every week • Have limitations related to a training aiming to improve the sense of smell • Have physical limitations that may limit physical activity • Be part of another study that may influence the current study **Planned sample size:** 75 participants
Interventions	**Intervention A:** Physical activity: 150 minutes of moderate physical activity per week for 12 weeks, plus fortnightly meetings with a kinesiologist **Intervention B:** Smell training: 4 odours to be used (eucalyptol, phenyl ethanol, citronella and eugenol) for 5 minutes every morning and evening for 12 weeks **Comparator:** No intervention
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Not reported Disease-related quality of life • Not reported Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell • Assessed with UPSIT; change from baseline recorded at week 14 and change from week 14 to week 26 Overall, generic quality of life • Change from baseline in quality of life using the 26-item World Health Organization Quality of Life-Bref, measured at week 14 and the change from week 14 to 26

NCT05037110 *(Continued)*

	Prevalence of parosmia • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • Change from baseline in gustatory score on the Waterless Empirical Taste Test • Change from baseline in food preference on the Leeds Food Preference Questionnaire at week 14, and change from week 14 to 26 • Change from baseline in brain responses following smell stimulations and taste stimulations at week 14, and change from week 14 to 26 • Change from baseline in food intake on the 4-hour dietary recall at week 14, and change from week 14 to 26 • Change from baseline in physical activity level on the International Physical Activity Questionnaire at week 14, and from week 14 to 26
Starting date	25 October 2021
Contact information	Marie-Eve Mathieu Email: me.mathieu@umontreal.ca
Notes	Trial registered in Canada Estimated completion date June 2023

NL9635

Study name	Corticosteroids for COVID-19 induced loss of smell
Methods	Parallel-group, double-blind, single-centre randomised controlled trial

Participants	People with recent COVID-19 infection and persisting loss of smell for at least 1 month
	Inclusion criteria:
	• Recent COVID-19 infection (< 3 months), confirmed with a positive test
	• Persistent loss of smell after 1 month, objectified by TDI < 30.5 on Sniffin' Stick test
	• Age 18 years or older, capable of giving informed consent
	Exclusion criteria:
	• Pre-existing olfactory disorders
	• Chronic rhinitis or rhinosinusitis (with or without nasal polyps)
	• Pregnancy
	• Corticosteroids (nasal, oral or intravenously) in last month
	• Contra-indications to steroid use
	  ◦ Insulin dependent diabetes mellitus
	  ◦ Peptic ulcer
	Planned sample size: 116 participants

Interventions	**Intervention:**

NL9635 *(Continued)*

	• 40 mg prednisolone once daily for 10 days **Comparator:** • Matching placebo treatment
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Registry reports that "objective olfactory function by means of Sniffin' Sticks" will be used. Unclear if this will be reported as recovery or change in sense of smell. Disease-related quality of life • Participants will fill in questionnaires related to quality of life. No further details provided. Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell • Registry reports that "objective olfactory function by means of Sniffin' Sticks" will be used. Unclear if this will be reported as recovery or change in sense of smell. Overall, generic quality of life • Participants will fill in questionnaires related to quality of life. No further details provided. Prevalence of parosmia • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • Objective gustatory function by means of Taste Strips • Questionnaires related to smell and taste ability, trigeminal sensations and nasal symptoms
Starting date	1 October 2021
Contact information	Digna Kamalski Email: d.m.a.kamalski@umcutrecht.nl
Notes	Trial registered in the Netherlands Estimated completion: 1 April 2023

Odorat-Covid (NCT04598763)

Study name	Evaluation of two methods of olfactory rehabilitation in post-viral loss of smell: classic and intensive (Odorat-Covid)

Odorat-Covid (NCT04598763) *(Continued)*

Methods	Parallel-group randomised controlled trial
Participants	Individuals presenting to the otolaryngology clinic with > 5 weeks (and less than 12 months) of acute olfactory dysfunction linked to a viral infection (including SARS-CoV-2) **Inclusion criteria:** • 18 years and older • Sudden loss of smell for > 5 weeks, linked to a viral infection (including SARS-CoV-2) of the upper respiratory tract • Willing to undertake olfactory rehabilitation • Confirmed hyposmia/anosmia, as assessed by the Sniffin' Sticks kit • Affiliated to/beneficiary of a social security scheme • Informed consent **Exclusion criteria:** • Persons referred to in Articles L. 1121-5 to L. 1121-8 and L1122-2 of the Public Health Code: pregnant woman, parturient or nursing mother, persons deprived of liberty by a judicial or administrative decision, persons undergoing psychiatric treatment under Articles L.3212-1 and L.3213-1 of the Public Health Code Minor (non-emancipated), adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice), adult person unable to express consent and who is not the subject of a legal protection measure • Qualitative smell disorder (cacosmia, hyperosmia, phantosmia, parosmia) • Neurological, post-traumatic, neurodegenerative, congenital odour disorders • Post-infectious loss of smell > 12 months **Planned sample size:** 80 participants
Interventions	**Intervention:** The "intensive" group receiving olfactory rehabilitation using 8 scents (rose, eucalyptus, lemon, cloves, strawberries, cut grass, lavender, spruce) Regardless of the randomisation group, the patient will smell each odour for 10 seconds with a 10-second interval between odours. The patient will carry out olfactory rehabilitation at home twice a day (morning and evening) for 32 weeks (i.e. 448 sessions). Each training will be recorded by the patient in their olfactory rehabilitation agenda. **Comparator:** The "classic" group receives classic olfactory rehabilitation using 4 scents most used in the literature (rose, eucalyptus, lemon, clove) Regardless of the randomisation group, the patient will smell each odour for 10 seconds with a 10-second interval between odours. The patient will carry out olfactory rehabilitation at home twice a day (morning and evening) for 32 weeks (i.e. 448 sessions). Each training will be recorded by the patient in their olfactory rehabilitation agenda.
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Self-assessment by participants using a VAS of smell with score 0 (no smell) to 10 (normal smell) • Psychophysical testing using Sniffin' Sticks score to classify patients with normosmia, hyposmia and functional anosmia • Both assessed at 8 months Disease-related quality of life

Odorat-Covid (NCT04598763) *(Continued)*

- Self-assessment using the Dynachron-olfaction questionnaire (assesses 6 domains related to chronic nasal dysfunction, including quality of life aspects)

Serious adverse effects

- Not reported

Secondary outcomes:

Change in sense of smell

- Improvement in smell based on the comparison of the results of the olfactory assessment before/after rehabilitation assessed with: psychophysical testing (Sniffin' Sticks) Threshold Test Score and Actual Identification Test Score. TI score: sum of the individual scores of the threshold and identification measures (TI score varying from 0 to 32). It is used to classify patients in terms of normosmia, hyposmia and functional anosmia based on normative values of "Sniffin' Sticks" (according to the age and sex of each subject) with the threshold at the 10th percentile. Self-assessment by patients using a digital scale of smell, from 0 (no smell) to 10 (normal smell).

Overall, generic quality of life

- Not reported

Prevalence of parosmia

- Not reported

Other adverse effects (including nosebleeds/bloody discharge)

- Not reported

Other outcomes reported by the study:

- No additional outcomes reported

Starting date	1 July 2020
Contact information	Julie Lecomte Email: ju.lecomte@chru-nancy.fr Duc Trung Nguyen Email: dt.nguyen@chru-nancy.fr
Notes	Trial registered in France Estimated study completion: 1 January 2021

SCENT2 (NCT04789499)

Study name	Smell in Covid-19 and efficacy of nasal theophylline
Methods	Two-arm, double-blinded, parallel-group RCT with 6 weeks duration of treatment and follow-up
Participants	Participants with olfactory dysfunction for at least 3 months following COVID-19 infection **Inclusion criteria:** • 18 to 70 years of age • Olfactory dysfunction that has persisted for > 3 months following suspected COVID-19 infection • Residing within the states of Missouri or Illinois • Can read, write and understand English

SCENT2 (NCT04789499) *(Continued)*

	Exclusion criteria: • History of olfactory dysfunction prior to COVID-19 infection • Use of concomitant therapies specifically for the treatment of olfactory dysfunction • History of olfactory dysfunction longer than 12 months • Known existence of nasal polyps, prior sinonasal or anterior skull-based surgery • Dependence on theophylline for co-morbid conditions such as asthma and COPD • History of an allergic reaction to theophylline or other methylxanthines • History of neurodegenerative disease (i.e. Alzheimer's dementia, Parkinson's disease, Lewy body dementia, frontotemporal dementia) • Pregnant or breastfeeding mothers • Current use of medications with significant interactions with theophylline, which include cimetidine, ciprofloxacin, disulfiram, enoxacin, fluvoxamine, interferon-alpha, lithium, mexiletine, phenytoin, propafenone, propranolol, tacrine, thiabendazole, ticlopidine and troleandomycin • Pre-existing arrhythmias or seizures **Planned sample size:** 50 participants
Interventions	**Intervention group:** 400 mg theophylline capsule diluted in 240 mL isotonic saline and used as a nasal irrigation fluid, twice daily **Control group:** 500 mg lactose capsule diluted in 240 mL isotonic saline and used as a nasal irrigation fluid, twice daily
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • UPSIT carried out at baseline and 6 weeks. Unclear whether the results will be reported as a dichotomous outcome (normosmia ≥ 34 for males and ≥ 35 for females) • CGI Severity scale will be assessed, range 1 to 7, 1 = normal, 7 = complete loss of smell • Both reported at 6 weeks Disease-related quality of life • Questionnaire for Olfactory Dysfunction (QOD) reported at 6 weeks • Olfactory Dysfunction Outcomes Rating (ODOR) at 6 weeks Serious adverse effects • Not assessed **Secondary outcomes:** Change in sense of smell • UPSIT carried out at baseline and 6 weeks. Unclear whether the results will be reported as a continuous outcome (MID reported as ≥ 4 points). • Clinical Global Impression Scale: self-reported change in symptoms, according to the CGI-improvement scale. Range 1 to 7, 1 = very much improved, 2 much improved and 3 minimally improved deemed as responders to treatment; (7 = very much worsened); both reported at 6 weeks Overall, generic quality of life • 36-item Short Form Health Survey. Assessed at baseline; not stated whether this will be used in follow-up. Prevalence of parosmia • Not assessed

SCENT2 (NCT04789499) *(Continued)*

	Other adverse effects (including nosebleeds/bloody discharge) • Not assessed **Other outcomes reported by the study:** • None reported
Starting date	15 March 2021
Contact information	Jay F Piccirillo, no contact details provided
Notes	Registered in USA Estimated study completion date December 2021

TCTR20210714006

Study name	Corticosteroid nasal irrigation as early treatment of olfactory dysfunction in COVID-19: a prospective randomized controlled trial
Methods	Parallel-group, open-label, randomised controlled trial
Participants	Patients with new onset of smell dysfunction following a positive COVID-19 test **Inclusion criteria:** • Confirmed COVID-19 test positive with new onset of smell dysfunction • Capable of performing nasal irrigation • Aged ≥ 18 years **Exclusion criteria:** • History of smell loss before COVID-19 era • Previous history of rhinological diseases such as chronic rhinosinusitis, nasal tumour, anatomical abnormalities of the nose • Pregnancy • The patients who refuse to enrol in the study **Planned sample size:** estimated 200 participants
Interventions	**Intervention A:** • Nasal steroid. 1 mg budesonide and 4.5 g sodium chloride powder will be mixed with 500 mL boiled water. Nasal irrigation will be performed with 125 mL in each nostril, 2 times per day for 2 weeks. **Intervention B:** • Nasal saline. 4.5 g sodium chloride powder will be mixed with 500 mL boiled water. Nasal irrigation will be performed with 125 mL in each nostril, 2 times per day for 2 weeks. **Comparator:** • No intervention
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:**

TCTR20210714006 *(Continued)*

	Recovery of sense of smell • Assessed with a 10-point VAS (0 = completely normal smell sensation, 10 = total loss of smell) • Measured at 1, 2, 3, 4 and 6 weeks after treatment • Unclear if this will be reported as 'recovery' (i.e. the number of participants who score 0) Disease-related quality of life • Not reported Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell • Assessed with a 10-point self-rated VAS (0 = completely normal smell sensation, 10 = total loss of smell) • Measured at 1, 2, 3, 4 and 6 weeks after treatment • Smell perception of specific odours also assessed using a 10-point VAS, using fish sauce, organce, coffee and jasmine • Time to correct identification of 4 well-recognised odours Overall, generic quality of life • Not reported Prevalence of parosmia • Not reported Other adverse effects (including nosebleeds/bloody discharge) • Pharyngeal and nasal burning/dryness will be evaluated **Other outcomes reported by the study:** • Nasal symptoms, using VAS
Starting date	Not reported
Contact information	Jidapa Tragoonrungsea Email: janjy.t@gmail.com
Notes	Registered in Thailand Estimated completion date 12 January 2022 It is unclear if participants will have had symptoms for ≥ 4 weeks at baseline, therefore this study may not be suitable for inclusion in this review. Further details will be obtained when the study is published.

UMIN000043537

Study name	Post COVID-19 anosmia
Methods	4-arm, double-blinded, parallel-group RCT; duration of treatment and follow-up unclear

UMIN000043537 *(Continued)*

Participants	Adults with olfactory dysfunction following COVID-19 **Inclusion criteria:** • Aged 40 to 65 years • Post-COVID-19 smell dysfunction (no further details) **Exclusion criteria:** • Current use of nasal or systemic steroids • Previous chronic rhinological pathology • Anosmia that had improved before recovery from COVID-19 • Pregnant women • Those who did not complete follow-up **Estimated sample size:** 200 participants
Interventions	**Intervention A** Combination of local corticosteroid and antihistamine nasal spray **Intervention B** Local corticosteroid nasal spray **Intervention C** Antihistamine nasal spray **Comparator:** Normal saline nasal spray 0.2% No further details provided on any of the interventions or comparator
Outcomes	**Outcomes of interest in the review:** **Primary outcomes:** Recovery of sense of smell • Butanol threshold test and discrimination test. Unclear if this will be reported as a dichotomous or continuous outcome. Disease-related quality of life • Not reported Serious adverse effects • Not reported **Secondary outcomes:** Change in sense of smell • Butanol threshold test and discrimination test. Unclear if this will be reported as a dichotomous or continuous outcome. Overall, generic quality of life • Not reported Prevalence of parosmia

UMIN000043537 *(Continued)*

	• Not reported Other adverse effects (including nosebleeds/bloody discharge) • Not reported **Other outcomes reported by the study:** • None reported
Starting date	1 January 2021
Contact information	Asmaa Salah Mohamed Email: asmaa.elsadorry@yahoo.com
Notes	Registered in Egypt Trial end date not reported It is unclear if participants will have had symptoms for ≥ 4 weeks at baseline, therefore this study may not be suitable for inclusion in this review. Further details will be obtained when the study is published.

VOLT (NCT04710394)

Study name	Visual-OLfactory Training in participants with COVID-19 resultant loss of smell (VOLT)
Methods	Two-by-two factorial, single-centre, double-blind, parallel-group RCT with 12 weeks duration of treatment and follow-up
Participants	Participants with olfactory dysfunction for ≥ 3 months, which was initially diagnosed within 2 weeks of COVID-19 infection **Inclusion criteria:** • Olfactory dysfunction for ≥ 3 months, initially diagnosed within 2 weeks of a COVID-19 infection **Exclusion criteria:** • Olfactory dysfunction due to head trauma • Chronic rhinosinusitis • Congenital olfactory dysfunction • Nasal polyps • Neurodegenerative disorders (e.g. Alzheimer or Parkinson disease) • Pre-assessment UPSIT score ≥ 34 for males and ≥ 35 for females • Pregnant • Inability to read, write and understand English • Residence outside the USA • Previously conducting smell training **Planned sample size:** 240 participants
Interventions	**Intervention group:** Bimodal visual olfactory training (focusing on a picture of the scent) with conventional odours (rose, lemon, eucalyptus and clove) or patient preferred odours (choice of 4 scents out of possible 24)

VOLT (NCT04710394) *(Continued)*

Control group:

Unimodal olfactory training with conventional odours or patient preferred odours

Additional interventions common to both groups:

Olfactory training will occur in both groups, but the intervention group will additionally have visual stimulation
This is a 4-arm (2 x 2 factorial) trial, investigating the use of visual stimulation and patient preferred odours

Outcomes

Outcomes of interest in the review:

Primary outcomes:

Recovery of sense of smell

- UPSIT test measured at baseline and 12 weeks. Normosmia is defined as ≥ 34 for males and ≥ 35 for females. A change of 4 points or more indicates a meaningful result. Unclear whether this will be reported as a dichotomous outcome.
- Clinical Global Impression Severity and Improvement scales (CGI-S and CGI-I). Self-rated scale for severity (1 = normal sense of smell, 4 = moderate smell loss and 7 = complete smell loss) and improvement (1 = very much improved, 4 = no change, 7 = very much worse) in sense of smell. Assessed at baseline and 12 weeks. Unclear whether this will be reported as a dichotomous outcome.

Disease-related quality of life

- Olfactory Dysfunction Outcomes Rating (ODOR). A 28-item health-related quality of life instrument specific for olfactory dysfunction (not apparently published yet).

Serious adverse effects

- Not reported

Secondary outcomes:

Change in sense of smell

- UPSIT test measured at baseline and 12 weeks. Normosmia is defined as ≥ 34 for males and ≥ 35 for females. A change of 4 points or more indicates a meaningful result. Unclear whether this will be reported as a continuous or dichotomous outcome.
- Clinical Global impression Severity and Improvement scales (CGI-S and CGI-I). Self-rated scale for severity (1 = normal sense of smell, 4 = moderate smell loss and 7 = complete smell loss) and improvement (1 = very much improved, 4 = no change, 7 = very much worse) in sense of smell. Assessed at baseline and 12 weeks. Unclear whether this will be reported as a dichotomous or continuous outcome.

Overall, generic quality of life

- Not assessed

Prevalence of parosmia

- Not assessed

Other adverse effects (including nosebleeds/bloody discharge)

- Not assessed

Other outcomes reported by the study:

- Not assessed

VOLT (NCT04710394) *(Continued)*

Starting date	11 January 2021
Contact information	Jay F Piccirillo, no contact details provided
Notes	Registered in USA Estimated study completion date 11 March 2021

ALT: alanine transaminase
BiPAP: bilevel positive airway pressure
BSIT: Brief Smell Identification Test
COPD: chronic obstructive pulmonary disease
CPAP: continuous positive airway pressure
CRP: c-reactive protein
CT: computerised tomography
LDH: lactate dehydrogenase
MRI: magnetic resonance imaging
mQOD-NS: Modified Brief Questionnaire of Olfactory Dysfunction
PCR: polymerase chain reaction
RCT: randomised controlled trial
RT-PCR: real time polymerase chain reaction
SNOT-22: Sinonasal Outcomes Test
TDI: threshold (T), discrimination (D) and identification (I) composite score
UPSIT: University of Pennsylvania Smell Identification Test
VAS: visual analogue scale

DATA AND ANALYSES

Comparison 1. Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant versus no intervention

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Recovery of sense of smell (as assessed with psychophysical testing)	1	18	Risk Ratio (M-H, Fixed, 95% CI)	11.00 [0.70, 173.66]
1.1.1 1 to 3 months	1	18	Risk Ratio (M-H, Fixed, 95% CI)	11.00 [0.70, 173.66]

Analysis 1.1. Comparison 1: Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant versus no intervention, Outcome 1: Recovery of sense of smell (as assessed with psychophysical testing)



Footnotes

(1) Assessed using CCCRC at 40 days. Range 0-100, score 90-100 = normosmia.

Comparison 2. Palmitoylethanolamide and luteolin versus no intervention

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Recovery of sense of smell (as assessed with psychophysical testing)	1	12	Risk Ratio (M-H, Fixed, 95% CI)	0.24 [0.03, 1.67]
2.2 Change in sense of smell (as assessed with psychophysical testing)	1	12	Mean Difference (IV, Fixed, 95% CI)	2.20 [-4.40, 8.80]
2.2.1 At 1 to 3 months	1	12	Mean Difference (IV, Fixed, 95% CI)	2.20 [-4.40, 8.80]

Analysis 2.1. Comparison 2: Palmitoylethanolamide and luteolin versus no intervention, Outcome 1: Recovery of sense of smell (as assessed with psychophysical testing)



Footnotes

(1) 'Recovery' considered to be a score of ≥31 with Sniffin' Sticks.

Analysis 2.2. Comparison 2: Palmitoylethanolamide and luteolin versus no intervention, Outcome 2: Change in sense of smell (as assessed with psychophysical testing)

Study or Subgroup	PEA and luteolin Mean	SD	Total	No intervention Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
2.2.1 At 1 to 3 months								
D'Ascanio 2021 (1)	4.5	4.5	7	2.3	6.5	5	100.0%	2.20 [-4.40 , 8.80]
Subtotal (95% CI)			**7**			**5**	**100.0%**	**2.20 [-4.40 , 8.80]**
Heterogeneity: Not applicable								
Test for overall effect: Z = 0.65 (P = 0.51)								
Total (95% CI)			**7**			**5**	**100.0%**	**2.20 [-4.40 , 8.80]**
Heterogeneity: Not applicable								
Test for overall effect: Z = 0.65 (P = 0.51)								
Test for subgroup differences: Not applicable								



Footnotes

(1) Change-score data, assessed from baseline to day 30. Assessed using Sniffin' Sticks, range 1-48, higher scores = better olfactory function.

APPENDICES

Appendix 1. Update search - date limits

	CENTRAL	ENT Register	COVID-19 Register	MEDLINE	Embase	WOS	Trial registries via CRS	ClinicalTrials.gov	ICTRP
July 2021	16/11/2020_TO_22/07/2021:CRSNT CENTRAL AND CENTRAL:TARGET	22/07/2021:CRSNT	#1 Anosmia_202012_COVID Register FID_109833:FOLDER AND COVID19:INREGISTER	31 limit 30 to ed=20201116-20210722 32 limit 30 to dt=20201116-20210722 33 31 or 32	limit 63 to dd=20201116-20210722	Monthly alerts: 30/12/2020 28/01/2021 24/02/2021 25/03/2021 21/04/2021 20/05/2021 17/06/2021 15/07/2021	16/11/2020_TO_22/07/2021:CRSNT CENTRAL AND CENTRAL:TARGET	n/a	n/a
August 2021	22/06/2021_TO_17/08/2021:CRSNT CENTRAL AND CENTRAL:TARGET	17/08/2021:CRSNT	#1 Anosmia_202107_COVID Register FID_133410:FOLDER OR "Anosmia_202012_COVID Register FID_109833":FOLDER	31 limit 30 to ed=20210622-20210817 32 limit 30 to dt=20210622-20210817 33 33 31 or 32	limit 63 to dd=20210622-20210817	Monthly alert: 11/08/2021	22/06/2021_TO_17/08/2021:CRSNT CENTRAL AND CENTRAL:TARGET	n/a	n/a
September 2021	All years	All years	All years	All years	All years	All years	All years	n/a	n/a

Appendix 2. Search strategies - July 2021 onwards

The strategies were designed to identify all relevant studies for a pair of reviews (O'Byrne 2021; Webster 2022).

CENTRAL (CRS)	Cochrane ENT Register (CRS)	COVID-19 Register (CRS)	MEDLINE (Ovid)
1 MESH DESCRIPTOR COVID-19 EXPLODE ALL AND CENTRAL:TARGET 2 MESH DESCRIPTOR SARS-CoV-2 EXPLODE ALL AND CENTRAL:TARGET 3 (("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "novel corona virus" or "SARS CoV-2" or SARS-CoV2 or SARSCoV2 or "2019-novel CoV" or ncov19 or ncov-19 or nCov 2019 or COVID-19 or SARSCoV-2 or SARS-CoV-2)):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET 4 ((Wuhan and (coronavirus or "corona virus"))):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET 5 (((coronavirus or "corona virus" or COVID) adj3 "2019")):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET 6 ((wuhan adj2 (disease or virus))):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET 7 ((coronavirus or "corona virus" or COVID)):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET 8 MESH DESCRIPTOR Coronavirus AND CENTRAL:TARGET 9 #7 or #8 AND CENTRAL:TARGET 10 (2020 or 2021 or 2022):YR AND CENTRAL:TARGET 11 #9 AND #10 AND CENTRAL:TARGET 12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #11 AND CENTRAL:TARGET 13 MESH DESCRIPTOR Olfaction Disorders EXPLODE ALL AND CENTRAL:TARGET 14 (Olfaction or olfactory or Dysosmia* or Parosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia*):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET 15 (smell* adj6 (disorder* or loss or distort* or alter* or dysfunction or impair* or abscen* or reduce* or different* or sensation* or abnormal* or perception* or change* or expected or decreas* or deficit*)):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET	1 MESH DESCRIPTOR COVID-19 EXPLODE ALL AND INREGISTER 2 MESH DESCRIPTOR SARS-CoV-2 EXPLODE ALL AND INREGISTER 3 (("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "novel corona virus" or "SARS CoV-2" or SARS-CoV2 or SARSCoV2 or "2019-novel CoV" or ncov19 or ncov-19 or nCov 2019 or COVID-19 or SARSCoV-2 or SARS-CoV-2)):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER 4 ((Wuhan and (coronavirus or "corona virus"))):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER 5 (((coronavirus or "corona virus" or COVID) adj3 "2019")):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER 6 ((wuhan adj2 (disease or virus))):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER 7 ((coronavirus or "corona virus" or COVID)):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER 8 MESH DESCRIPTOR Coronavirus AND INREGISTER 9 #7 or #8 AND INREGISTER 10 (2020 or 2021 or 2022):YR AND INREGISTER 11 #9 AND #10 AND INREGISTER 12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #11 AND INREGISTER	1 MESH DESCRIPTOR Olfaction Disorders EXPLODE ALL AND COVID19:INREGISTER 2 (Olfaction or olfactory or Dysosmia* or Parosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia*) AND COVID19:INREGISTER 3 (smell* adj6 (disorder* or loss or distort* or alter* or dysfunction or impair* or abscen* or reduce* or different* or sensation* or abnormal* or perception* or change* or expected or decreas* or deficit*)) AND COVID19:INREGISTER 4 smell* adj6 (prevent* or rehab* or recover* or therap* or train* or retrain*) AND COVID19:INREGISTER 5 #1 OR #2 OR #3 OR #4 6 (interventional):SY AND COVID19:INREGISTER 7 #5 AND #6	1 exp COVID-19/ 2 exp SARS-CoV-2/ 3 ("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "novel corona virus" or "SARS CoV-2" or SARS-CoV2 or SARSCoV2 or "2019-novel CoV" or ncov19 or ncov-19 or nCov 2019 or COVID-19 or SARSCoV-2 or SARS-CoV-2).ab,ti. 4 (Wuhan and (coronavirus or "corona virus")).ab,ti. 5 ((coronavirus or "corona virus" or COVID) adj3 "2019").ab,ti. 6 (wuhan adj2 (disease or virus)).ab,ti. 7 ("LAMP assay" or "COVID-19" or "COVID-19 drug treatment" or "COVID-19 diagnostic testing" or "COVID-19 serotherapy" or "COVID-19 vaccine" or "severe acute respiratory syndrome coronavirus 2" or "spike protein, SARS-CoV-2").os. 8 (coronavirus or "corona virus" or COVID).ab,ti. 9 Coronavirus/ 10 8 or 9 11 limit 10 to yr="2020 -Current" 12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 11 13 exp olfaction disorders/

(Continued)

16 (smell* adj6 (prevent* or rehab* or recover* or therap* or train* or retrain*)):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET

17 #13 OR #14 OR #15 OR #16 AND CENTRAL:TARGET

18 #17 AND #12 AND CENTRAL:TARGET

13 MESH DESCRIPTOR Olfaction Disorders EXPLODE ALL AND INREGISTER

14 (Olfaction or olfactory or Dysosmia* or Parosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia*):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER

15 (smell* adj6 (disorder* or loss or distort* or alter* or dysfunction or impair* or abscen* or reduce* or different* or sensation* or abnormal* or perception* or change* or expected or decreas* or deficit*)):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER

16 (smell* adj6 (prevent* or rehab* or recover* or therap* or train* or retrain*)):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER

17 #13 OR #14 OR #15 OR #16 AND INREGISTER

18 #17 AND #12 AND INREGISTER

19 * AND CENTRAL:TARGET

20 #18 NOT #19

14 (Olfaction or olfactory or Dysosmia* or Parosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia*).ab,ti.
15 (smell* adj6 (disorder* or loss or distort* or alter* or dysfunction or impair* or abscen* or reduce* or different* or sensation* or abnormal* or perception* or change* or expected or decreas* or deficit*)).ab,ti.
16 (smell* adj6 (prevent* or rehab* or recover* or therap* or train* or retrain*)).ab,ti.
17 13 or 14 or 15 or 16
18 12 and 17
19 randomized controlled trial.pt.
20 controlled clinical trial.pt.
21 randomized.ab.
22 placebo.ab.
23 drug therapy.fs.
24 randomly.ab.
25 trial.ab.
26 groups.ab.
27 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28 exp animals/ not humans.sh.
29 27 not 28
30 18 and 29

Embase (Ovid)	**Web of Science Core Collections (Web of Knowledge)**	**Trial registries (CRS)**	**Trail registries**
1 exp coronavirus disease 2019/ 2 exp severe acute respiratory syndrome coronavirus 2/ 3 ("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "novel corona virus" or "SARS CoV-2" or SARS-CoV2 or SARSCoV2 or "2019-novel CoV" or ncov19 or ncov-19 or nCov 2019 or COVID-19 or SARSCoV-2 or SARS-CoV-2).ab,ti.	# 13 #12 AND #11 Indexes=SCI-EXPANDED, CPCI-S Timespan=All years # 12 TS=((randomised OR randomized OR randomisation OR randomisation OR placebo* OR (random* AND (allocat* OR assign*)) OR (blind* AND (single OR double OR treble OR triple))))	1 (("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "novel corona virus" or "SARS CoV-2" or SARS-CoV2 or SARSCoV2 or "2019-novel	**ClinicalTrials.gov** (COVID-19 OR 2019-nCoV OR SARS-CoV-2 OR 2019 novel coronavirus OR severe acute respiratory syndrome coronavirus 2 OR Wuhan coronavirus OR coronavirus) AND (anosmia OR

(Continued)

4 (Wuhan and (coronavirus or "corona virus")).ab,ti.

5 ((coronavirus or "corona virus" or COVID) adj3 "2019").ab,ti.

6 (wuhan adj2 (disease or virus)).ab,ti.

7 (coronavir* or "corona virus" or COVID).ab,ti.

8 coronaviridae/ or coronavirinae/ or Coronaviridae infection/ or Coronavirus infection/ or exp sars-related coronavirus/

9 7 or 8

10 limit 9 to yr="2020 -Current"

11 1 or 2 or 3 or 4 or 5 or 6 or 10

12 exp smelling disorder/

13 (Olfaction or olfactory or Dysosmia* or Parosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia*).ab,ti.

14 (smell* adj6 (disorder* or loss or distort* or alter* or dysfunction or impair* or abscen* or reduce* or different* or sensation* or abnormal* or perception* or change* or expected or decreas* or deficit*)).ab,ti.

15 (smell* adj6 (prevent* or rehab* or recover* or therap* or train* or retrain*)).ab,ti.

16 12 or 13 or 14 or 15

17 11 and 16

18 Randomized controlled trial/

19 Controlled clinical study/

20 Random$.ti,ab.

21 randomization/

22 intermethod comparison/

23 placebo.ti,ab.

24 (compare or compared or comparison).ti.

25 ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab.

26 (open adj label).ti,ab.

27 ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab.

28 double blind procedure/

29 parallel group$1.ti,ab.

Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 11 #10 AND #6
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 10 #9 OR #8 OR #7
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 9 TS=(smell* NEAR/6 (prevent* or rehab* or recover* or therap* or train* or retrain*))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 8 TS=(smell* NEAR/6 (disorder* or loss or distort* or alter* or dysfunction or impair* or abscen* or reduce* or different* or sensation* or abnormal* or perception* or change* or expected or decreas* or deficit*))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 7 TS=(Olfaction or olfactory or Dysosmia* or Parosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia*)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 6 #5 OR #4 OR #3 OR #2 OR #1
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 5 TS=(coronavirus or "corona virus" or COVID)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 4 TOPIC: (wuhan NEAR/2 (disease or virus))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 3 TS=(((coronavirus or "corona virus" or COVID) NEAR/3 "2019"))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 2 TS=(Wuhan and (coronavirus or "corona virus"))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 1 TS=("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "novel corona virus" or "SARS CoV-2" or SARS-CoV2 or SARSCoV2 or "2019-novel CoV" or ncov19 or ncov-19 or nCov 2019 or COVID-19 or SARSCoV-2 or SARS-CoV-2)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years

CoV" or ncov19 or ncov-19 or nCov 2019 or COVID-19 or SARSCoV-2 or SARS-CoV-2)) AND CENTRAL:TARGET
2 ((Wuhan and (coronavirus or "corona virus"))) AND CENTRAL:TARGET
3 (((coronavirus or "corona virus" or COVID) adj3 "2019")) AND CENTRAL:TARGET
4 ((wuhan adj2 (disease or virus))) AND CENTRAL:TARGET
5 (coronavirus or "corona virus" or COVID) AND CENTRAL:TARGET
6 (2020 or 2021 or 2022):YR AND CENTRAL:TARGET
7 #5 AND #6 AND CENTRAL:TARGET
8 #1 OR #2 OR #3 OR #4 OR #7 AND CENTRAL:TARGET
9 (Olfaction or olfactory or Dysosmia* or Parosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia* or smell*) AND CENTRAL:TARGET
10 #8 AND #9 AND CENTRAL:TARGET
11 http*:SO AND CENTRAL:TARGET
12 (NCT0* or ACTRN* or ChiCTR* or DRKS* or EUCTR* or eudract* or IRCT* or ISRCTN* or JapicCTI* or JPRN* or NTR0* or NTR1* or NTR2* or NTR3* or NTR4* or NTR5* or NTR6* or NTR7* or NTR8* or NTR9* or SRCTN* or UMIN0*):AU AND CENTRAL:TARGET
13 #12 OR #11 AND CENTRAL:TARGET

smell OR Olfaction or olfactory) | Interventional Studies

ICTRP

(covid* OR 2019-nCoV OR SARS-CoV-2) AND (anosmia OR smell OR Olfaction OR olfactory OR Dysosmia* OR Paraosmia* OR Anosmia* OR hyposmia* OR phantosmia* OR Cacosmia* OR microsmia*)

(Continued)

30	(crossover or cross over).ti,ab.
31	((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or participant$1)).ti,ab.
32	(assigned or allocated).ti,ab.
33	(controlled adj7 (study or design or trial)).ti,ab.
34	(volunteer or volunteers).ti,ab.
35	human experiment/
36	trial.ti.
37	18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38	(random$ adj sampl$ adj7 ("cross section$" or questionnaire$1 or survey$ or database$1)).ti,ab.
39	comparative study/ or controlled study/
40	randomi?ed controlled.ti,ab.
41	randomly assigned.ti,ab.
42	39 or 40 or 41
43	38 not 42
44	Cross-sectional study/
45	randomized controlled trial/ or controlled clinical study/ or controlled study/
46	(randomi?ed controlled or control group $1).ti,ab.
47	45 or 46
48	44 not 47
49	(((case adj control$) and random$) not randomi?ed controlled).ti,ab.
50	(Systematic review not (trial or study)).ti.
51	(nonrandom$ not random$).ti,ab.
52	Random field$.ti,ab.
53	(random cluster adj3 sampl$).ti,ab.
54	(review.ab. and review.pt.) not trial.ti.
55	we searched.ab.
56	review.ti. or review.pt.
57	55 and 56
58	update review.ab.
14	#10 AND #13 AND CENTRAL:TARGET

(Continued)

59 (databases adj4 searched).ab.

60 (rat or rats or mouse or mice or swine or porcine or murine or sheep or lambs or pigs or piglets or rabbit or rabbits or cat or cats or dog or dogs or cattle or bovine or monkey or monkeys or trout or marmoset$1).ti. and animal experiment/

61 43 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 57 or 58 or 59

62 37 not 61

63 17 and 62

Appendix 3. Search strategies (December 2020 to June 2021)

CENTRAL (CRS)

1 (("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "novel corona virus" or "SARS CoV-2" or SARS-CoV2 or SARSCoV2 or "2019-novel CoV" or ncov19 or ncov-19 or nCov 2019 or COVID-19 or SARSCoV-2 or SARS-CoV-2)):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET

2 ((Wuhan and (coronavirus or "corona virus"))):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET

3 (((coronavirus or "corona virus" or COVID) adj3 "2019")):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET

4 ((wuhan adj2 (disease or virus))):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET

5 ((coronavirus or "corona virus" or COVID)):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET

6 (2020 or 2021):YR AND CENTRAL:TARGET

7 #5 AND #6 AND CENTRAL:TARGET

8 #1 OR #2 OR #3 OR #4 OR #7 AND CENTRAL:TARGET

9 MESH DESCRIPTOR Olfaction Disorders EXPLODE ALL AND CENTRAL:TARGET

10 (Olfaction or olfactory or Dysosmia* or Paraosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia*):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET

11 (smell* adj6 (disorder* or loss or distort* or alter* or dsyfunction or impair* or abscen* or reduce* or different* or sensation* or abnormal* or perception* or change* or expected or decreas* or deficit*)):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET

12 (smell* adj6 (prevent* or rehab* or recover* or therap* or train* or retrain*)):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET

13 #9 OR #10 OR #11 OR #12 AND CENTRAL:TARGET

14 #13 AND #8 AND CENTRAL:TARGET

MEDLINE (Ovid)

1 ("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "novel corona virus" or "SARS CoV-2" or SARS-CoV2 or SARSCoV2 or "2019-novel CoV" or ncov19 or ncov-19 or nCov 2019 or COVID-19 or SARSCoV-2 or SARS-CoV-2).ab,ti.

2 (Wuhan and (coronavirus or "corona virus")).ab,ti.

3 (coronavirus or "corona virus" or COVID) adj3 "2019").ab,ti.

4 (wuhan adj2 (disease or virus)).ab,ti.

5 ("LAMP assay" or "COVID-19" or "COVID-19 drug treatment" or "COVID-19 diagnostic testing" or "COVID-19 serotherapy" or "COVID-19 vaccine" or "severe acute respiratory syndrome coronavirus 2" or "spike protein, SARS-CoV-2").os.

6 (coronavirus or "corona virus" or COVID).ab,ti.

7 limit 6 to yr="2020 -Current"

8 1 or 2 or 3 or 4 or 5 or 7

9 exp olfaction disorders/

10 (Olfaction or olfactory or Dysosmia* or Paraosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia*).ab,ti.

11 (smell* adj6 (disorder* or loss or distort* or alter* or dsyfunction or impair* or abscen* or reduce* or different* or sensation* or abnormal* or perception* or change* or expected or decreas* or deficit*)).ab,ti.

12 (smell* adj6 (prevent* or rehab* or recover* or therap* or train* or retrain*)).ab,ti.

13 9 or 10 or 11 or 12

14 8 and 13

15 randomized controlled trial.pt.

16 controlled clinical trial.pt.

17 randomized.ab.

18 placebo.ab.

19 drug therapy.fs.

20 randomly.ab.

21 trial.ab.

22 groups.ab.

23 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22

24 exp animals/ not humans.sh.

25 23 not 24

26 14 and 25

Cochrane COVID-19 Study Register (CRS)

1 MESH DESCRIPTOR Olfaction Disorders EXPLODE ALL AND COVID19:INREGISTER

2 (Olfaction or olfactory or Dysosmia* or Paraosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia*) AND COVID19:INREGISTER

3 (smell* adj6 (disorder* or loss or distort* or alter* or dsyfunction or impair* or abscen* or reduce* or different* or sensation* or abnormal* or perception* or change* or expected or decreas* or deficit*)) AND COVID19:INREGISTER

4 (smell* adj6 (prevent* or rehab* or recover* or therap* or train* or retrain*)) AND COVID19:INREGISTER

5 #1 OR #2 OR #3 OR #4

6 (interventional):SY AND COVID19:INREGISTER

7 #6 AND #5

Cochrane ENT Register (CRS)

1 (("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "novel corona virus" or "SARS CoV-2" or SARS-CoV2 or SARSCoV2 or "2019-novel CoV" or ncov19 or ncov-19 or nCov 2019 or COVID-19 or SARSCoV-2 or SARS-CoV-2)):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER

2 ((Wuhan and (coronavirus or "corona virus"))):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER

3 (((coronavirus or "corona virus" or COVID) adj3 "2019")):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER

4 ((wuhan adj2 (disease or virus))):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER

5 ((coronavirus or "corona virus" or COVID)):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER

6 (2020 or 2021):YR AND INREGISTER

7 #5 AND #6 AND INREGISTER

8 #1 OR #2 OR #3 OR #4 OR #7 AND INREGISTER

9 MESH DESCRIPTOR Olfaction Disorders EXPLODE ALL AND INREGISTER

10 (Olfaction or olfactory or Dysosmia* or Paraosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia*):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER

11 (smell* adj6 (disorder* or loss or distort* or alter* or dsyfunction or impair* or abscen* or reduce* or different* or sensation* or abnormal* or perception* or change* or expected or decreas* or deficit*)):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER

12 (smell* adj6 (prevent* or rehab* or recover* or therap* or train* or retrain*)):AB,EH,KW,KY,MC,MH,TI,TO AND INREGISTER

13 #9 OR #10 OR #11 OR #12 AND INREGISTER

14 #13 AND #8 AND INREGISTER

Embase (Ovid)

1 ("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "novel corona virus" or "SARS CoV-2" or SARS-CoV2 or SARSCoV2 or "2019-novel CoV" or ncov19 or ncov-19 or nCov 2019 or COVID-19 or SARSCoV-2 or SARS-CoV-2).ab,ti.

2 (Wuhan and (coronavirus or "corona virus")).ab,ti.

3 ((coronavirus or "corona virus" or COVID) adj3 "2019").ab,ti.

4 (wuhan adj2 (disease or virus)).ab,ti.

5 (coronavirus or "corona virus" or COVID).ab,ti.

6 limit 5 to yr="2020 -Current"

7 1 or 2 or 3 or 4 or 6

8 exp smelling disorder/

9 (Olfaction or olfactory or Dysosmia* or Paraosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia*).ab,ti.

10 (smell* adj6 (disorder* or loss or distort* or alter* or dsyfunction or impair* or abscen* or reduce* or different* or sensation* or abnormal* or perception* or change* or expected or decreas* or deficit*)).ab,ti.

11 (smell* adj6 (prevent* or rehab* or recover* or therap* or train* or retrain*)).ab,ti.

12 8 or 9 or 10 or 11

13 7 and 12

14 Randomized controlled trial/

15 Controlled clinical study/

16 Random$.ti,ab.

17 randomization/

18 intermethod comparison/

19 placebo.ti,ab.

20 (compare or compared or comparison).ti.

21 ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab.

22 (open adj label).ti,ab.

23 ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab.

24 double blind procedure/

25 parallel group$1.ti,ab.

26 (crossover or cross over).ti,ab.

27 ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or participant $1)).ti,ab.

28 (assigned or allocated).ti,ab.

29 (controlled adj7 (study or design or trial)).ti,ab.

30 (volunteer or volunteers).ti,ab.

31 human experiment/

32 trial.ti.

33 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32

34 (random$ adj sampl$ adj7 ("cross section$" or questionnaire$1 or survey$ or database$1)).ti,ab.

35 comparative study/ or controlled study/

36 randomi?ed controlled.ti,ab.

37 randomly assigned.ti,ab.

38 35 or 36 or 37

39 34 not 38

40 Cross-sectional study/

41 randomized controlled trial/ or controlled clinical study/ or controlled study/

42 (randomi?ed controlled or control group$1).ti,ab.

43 41 or 42

44 40 not 43

45 (((case adj control$) and random$) not randomi?ed controlled).ti,ab.

46 (Systematic review not (trial or study)).ti.

47 (nonrandom$ not random$).ti,ab.

48 "Random field$".ti,ab.

49 (random cluster adj3 sampl$).ti,ab.

50 (review.ab. and review.pt.) not trial.ti.

51 "we searched".ab.

52 review.ti. or review.pt.

53 51 and 52

54 "update review".ab.

55 (databases adj4 searched).ab.

56 (rat or rats or mouse or mice or swine or porcine or murine or sheep or lambs or pigs or piglets or rabbit or rabbits or cat or cats or dog or dogs or cattle or bovine or monkey or monkeys or trout or marmoset$1).ti. and animal experiment/

57 39 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 53 or 54 or 55

58 33 not 57

59 13 and 58

Web of Science (Web of Knowledge)

#1 TS=("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "novel corona virus" or "SARS CoV-2" or SARS-CoV2 or SARSCoV2 or "2019-novel CoV" or ncov19 or ncov-19 or nCov 2019 or COVID-19 or SARSCoV-2 or SARS-CoV-2)

#2 TS=(Wuhan and (coronavirus or "corona virus"))

#3 TS=(((coronavirus or "corona virus" or COVID) NEAR/3 "2019"))

#4 TOPIC: (wuhan NEAR/2 (disease or virus))

#5 TS=(coronavirus or "corona virus" or COVID)

#6 #5 OR #4 OR #3 OR #2 OR #1

#7 TS=(Olfaction or olfactory or Dysosmia* or Paraosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia*)

#8 TS=(smell* NEAR/6 (disorder* or loss or distort* or alter* or dsyfunction or impair* or abscen* or reduce* or different* or sensation* or abnormal* or perception* or change* or expected or decreas* or deficit*))

#9 TS=(smell* NEAR/6 (prevent* or rehab* or recover* or therap* or train* or retrain*))

#10 #9 OR #8 OR #7

#11 #10 AND #6

#12 TS=((randomised OR randomized OR randomisation OR randomisation OR placebo* OR (random* AND (allocat* OR assign*)) OR (blind* AND (single OR double OR treble OR triple))))

#13 #12 AND #11

World Health Organization (WHO) COVID-19 'Global literature on coronavirus disease'

(ti:(olfaction OR olfactory OR dysosmia* OR paraosmia* OR anosmia* OR hyposmia* OR phantosmia* OR cacosmia* OR microsmia* OR smell*)) OR (mh:(olfato OR l'olfaction OR cacosmia OR paraosmia OR anosmia))

Trial Registry Records (CENTRAL via CRS)

1 (("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "novel corona virus" or "SARS CoV-2" or SARS-CoV2 or SARSCoV2 or "2019-novel CoV" or ncov19 or ncov-19 or nCov 2019 or COVID-19 or SARSCoV-2 or SARS-CoV-2)) AND CENTRAL:TARGET

2 ((Wuhan and (coronavirus or "corona virus"))) AND CENTRAL:TARGET

3 (((coronavirus or "corona virus" or COVID) adj3 "2019")) AND CENTRAL:TARGET

4 ((wuhan adj2 (disease or virus))) AND CENTRAL:TARGET

5 (coronavirus or "corona virus" or COVID) AND CENTRAL:TARGET

6 (2020 or 2021):YR AND CENTRAL:TARGET

7 #5 AND #6

8 #1 OR #2 OR #3 OR #4 OR #7

9 (Olfaction or olfactory or Dysosmia* or Paraosmia* or Anosmia* or hyposmia* or phantosmia* or Cacosmia* or microsmia* or smell*) AND CENTRAL:TARGET

10 #8 AND #9

11 http*:SO AND CENTRAL:TARGET

12 (NCT0* or ACTRN* or ChiCTR* or DRKS* or EUCTR* or eudract* or IRCT* or ISRCTN* or JapicCTI* or JPRN* or NTR0* or NTR1* or NTR2* or NTR3* or NTR4* or NTR5* or NTR6* or NTR7* or NTR8* or NTR9* or SRCTN* or UMIN0*):AU AND CENTRAL:TARGET

13 #11 OR #12

14 #10 AND #13

ICTRP (WHO Portal)

covid* AND anomsia OR covid* AND smell OR covid* AND olfact* OR coronavirus AND anomsia OR coronavirus AND smell OR coronavirus AND olfact* OR SARS-CoV* AND anomsia OR SARS-CoV* AND smell OR SARS-CoV* AND olfact*

ClinicalTrials.gov

(COVID-19 OR 2019-nCoV OR SARS-CoV-2 OR 2019 novel coronavirus OR severe acute respiratory syndrome coronavirus 2 OR Wuhan coronavirus OR coronavirus) AND (anosmia OR smell OR Olfaction or olfactory)

AND Interventional

WHAT'S NEW

Date	Event	Description
4 August 2022	New citation required but conclusions have not changed	This updated version of the review includes one additional study (D'Ascanio 2021), which considers palmitoylethanolamide (PEA) and luteolin compared to no intervention, bringing the total number of included studies to two. We have also identified a number of additional ongoing trials, which are listed in the Characteristics of ongoing studies.
28 February 2022	New search has been performed	This is a living systematic review. Latest searches conducted October 2021.

HISTORY

Protocol first published: Issue 2, 2021
Review first published: Issue 7, 2021

CONTRIBUTIONS OF AUTHORS

Lisa O'Byrne: sifted studies, carried out data extraction and risk of bias assessment, performed analyses and GRADE assessment for included studies, drafted and revised the review.

Katie Webster: scoped, designed and drafted the protocol with the help of the other authors. Sifted studies, carried out data extraction, risk of bias and GRADE assessment.

Samuel MacKeith: clinical guidance at all stages of project scoping and protocol development; commented on and edited the draft review, and agreed the final version.

Carl Philpott: clinical guidance at all stages of project scoping and protocol development; commented on and edited the draft review, and agreed the final version.

Claire Hopkins: clinical guidance at all stages of project scoping and protocol development; commented on and edited the draft review, and agreed the final version.

Martin Burton: clinical guidance at all stages of project scoping and protocol development; commented on and edited the draft review, and agreed the final version.

DECLARATIONS OF INTEREST

Lisa O' Byrne: none known.

Katie Webster: none known.

Samuel MacKeith: Samuel MacKeith is Assistant Co-ordinating Editor of Cochrane ENT, but had no role in the editorial process for this review.

Carl Philpott: Professor Carl Philpott sees and treats patients with COVID-19 related smell loss. He has written various online publications on the topic and conducted interviews and webinars internationally. He is a Trustee for the charity Fifth Sense. He is the senior author on the Clinical Olfactory Working Group consensus document on the management of post-infectious olfactory dysfunction and the consensus document on the use of systemic corticosteroids in COVID-19 related olfactory dysfunction.

Claire Hopkins: Professor Claire Hopkins sees and treats patients with COVID-19 related smell loss. She has spoken on the association between COVID and smell loss in multiple media outlets. She is senior author of the British Rhinological Society position paper on management of COVID-19 related smell loss.

Martin Burton: Professor Martin Burton is Co-ordinating Editor of Cochrane ENT, but had no role in the editorial process for this review.

SOURCES OF SUPPORT

Internal sources

- No sources of support provided

External sources

- National Institute for Health Research, UK

  Infrastructure funding for Cochrane ENT
- National Institute for Health Research (NIHR) COVID-19: Recovery and Learning programme, UK

  Award NIHR132103

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We planned to search the following sources on a quarterly basis, but after assessment of the original searches these were deemed to be unnecessary, and were therefore dropped from the sources to search:

- World Health Organization (WHO) COVID-19 'Global literature on coronavirus disease' https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov (search to date);
- COAP COVID-19 Living Evidence, Institute of Social and Preventive Medicine (ISPM), University of Bern https://zika.ispm.unibe.ch/assets/data/pub/search_beta/ (search to date).

In the protocol for this review we stated that we would impute any missing standard deviations (SDs) using methods outlined in the *Cochrane Handbook for Systematic Reviews of Interventions*. However, we were able to confirm some missing SDs for change in sense of smell scores from D'Ascanio 2021 during correspondence with the author of this paper, therefore imputation was not required.

When preparing the protocol for this review we intended to present the following outcomes in the summary of findings table:

- recovery of sense of smell (as reported by the participants);
- disease-related quality of life, as assessed by the Olfactory Disorders Questionnaire (or another validated questionnaire);
- serious adverse effects;
- change in sense of smell (as identified by psychophysical testing);
- overall, generic quality of life, as assessed by validated methods (e.g. EQ-5D);
- presence of parosmia;
- other adverse effects (including nosebleeds/bloody discharge).

No participant-reported data were available for the outcome "Recovery of sense of smell". However, we did find data for this outcome that had been identified by psychophysical testing, therefore these data were included in the summary of findings table.

We planned to include a summary of findings table for the following comparison(s):

- intranasal steroid drops/rinses versus no treatment/placebo;

- intranasal steroid sprays versus no treatment/placebo;
- olfactory training versus no treatment/placebo;
- intranasal vitamin A versus no treatment/placebo.

However, at present there are only two comparisons in this review: systemic corticosteroids plus intranasal steroid/mucolytic/decongestant solution compared to no intervention, and palmitoylethanolamide and luteolin compared to no intervention. We therefore present a summary of findings table for each of these comparisons.

INDEX TERMS

Medical Subject Headings (MeSH)

Adrenal Cortex Hormones; Anosmia; *COVID-19 [complications]; Expectorants; Luteolin; Nasal Decongestants; Randomized Controlled Trials as Topic; Smell

MeSH check words

Humans